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Summary
Staphylococcus aureus is a major cause of hospital-acquired infections that are becoming 
increasingly difficult to treat because of the organism’s ability to acquire resistance to current 
antimicrobial agents. Particular attention has been focussed on the evolution of methicillin-resistant S. 
aureus (MRSA) -  strains of S. aureus that are, in some cases, resistant to almost all known antibiotic 
classes. One method used to control the spread of MRSA has been the use of topical washes that 
include triclosan, a potent antimicrobial with particular activity against Gram-positive organisms. 
Triclosan has traditionally been classed as a biocide and is also used in a broad spectrum of consumer 
healthcare products, including toothpastes and deodorants. It has also been used to prevent bacterial 
growth through incorporation into plastics used during food preparation or sutures used to close 
wounds following surgery. However, in 1991 resistance to triclosan was reported and was described to 
transfer in association with mupirocin resistance. This was followed by reports that resistance was 
present in 7.5% of S. aureus isolates and that MRSA was less susceptible to triclosan than methicillin- 
sensitive S. aureus (MSSA). It later emerged that, contrary to previous thinking, triclosan targets a 
specific bacterial protein, Fabl. We aimed to characterize the development of reduced susceptibility to 
triclosan in MSSA and MRSA and to identify whether triclosan does have a single, specific target. We 
also set out to elucidate the potential for triclosan resistance to be disseminated by horizontal gene 
transfer (HGT). By using extensive microbiological and genetic techniques we found that S. aureus can 
evolve reduced susceptibility to triclosan through spontaneous mutation. MICs of 1-4 mg/L were 
achieved by a C284T mutation offabl, compared to wild-type MICs of -0.03 mg/L. However, reduced 
susceptibility was also observed in non -fabl mutants, implying that other mechanisms of resistance are 
available (and that triclosan has targets other than Fabl). We have shown that triclosan induces the 
leakage of potassium ions from cells, an indication that triclosan targets the cytoplasmic membrane. 
However, whilst reduced susceptibility to triclosan did confer reduced susceptibility to the lethal effects 
of 7.5 mg/L triclosan, this effect was ameliorated by higher concentrations of triclosan. Indeed, in-use 
concentrations of the commercial preparation of triclosan, Irgacide LP10, are equally active against 
reduced susceptibility S. aureus and wild-type. Therefore, the evolution of reduced-susceptibility to 
triclosan is of ambiguous clinical significance. We found that spontaneous mutation to reduced 
susceptibility was not associated with a significant fitness cost, augmenting its potential for emergence 
in nature. Evolution of reduced susceptibility did not confer co-resistance to other antimicrobials and 
MRSA and MSSA strains were equally susceptible. An assessment of commensal S. aureus carried 
amongst the student population of Cardiff revealed that reduced susceptibility to triclosan is rare in this 
population. However, coagulase-negative staphylococci (CoNS) showed consistently higher MICs for 
triclosan and may represent an amenable reservoir of resistance. There was no indication that 
mupirocin and triclosan resistance have co-transferred in the past. Indeed, there appeared to be no 
relationship between resistance to either of these compounds in S. aureus. Reduced susceptibility to 
triclosan could not be disseminated amongst S. aureus, or related Gram-positive bacteria by 
transduction, conjugation or transformation. Importantly, during the course of this work we discovered 
that triclosan could select for S. aureus small-colony variants (SCVs) that were coincidently resistant to 
gentamicin and penicillin. These were slow growing and illustrated the typical SCV phenotype. SCVs 
were more readily transformable than wild-type cells and may represent an enduring reservoir of 
resistance determinants.
In conclusion, we found that S. aureus could develop reduced susceptibility to triclosan by 
spontaneous mutation or the evolution of SCVs. However, the level of resistance is of ambiguous 
significance. We propose that triclosan does target Fabl, but also has other cellular targets, particularly 
at higher concentrations. Whilst the evolution of reduced susceptibility and the occurrence of SCVs 
should be monitored these should not preclude the use of triclosan as part of infection control 
procedures. However, to reduce the opportunities for resistance, infection control procedures should 
not rely upon a single antimicrobial to provide the panacea for nosocomial infections.
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Chapter 1 
Introduction
1
1.0 Introduction
Staphylococcus aureus is the leading cause of nosocomial infection in the United 
Kingdom (Griffiths et al., 2004) and United States (Pfaller et al., 1998). Infection 
with S. aureus is associated with substantial morbidity and mortality -  a trend that is 
increasing due to widespread dissemination of methicillin-resistant S. aureus (MRSA) 
(NNIS, 2004). The introduction and widespread use of antibiotics to treat these 
infections has led to increased resistance among bacteria, particularly in the clinical 
setting (Livermore, 2003). Recently antimicrobials other than antibiotics have also 
been implicated in bacterial resistance (Russell, 2002b). Such antimicrobials include 
disinfectants and antiseptics which, along with preservatives, are known as biocides. 
Biocides are an important group o f antimicrobials which are used extensively 
throughout both the clinical and community settings. Consequently, any development 
of resistance is of great importance to healthcare. S. aureus has proved adept at 
developing resistance to antimicrobials, and it is the evolution of biocide resistance in 
this organism that this report will concentrate on.
1.1 Phytogeny, structure and function of the staphylococci
The staphylococci are Gram-positive coccoid cells that divide in two planes, resulting 
in characteristic ‘grape-like’ clusters when stained and viewed by microscopy (Figure 
1.1). Pasteur and Koch were the first to observe and culture staphylococci, but the 
earliest detailed studies on staphylococci were performed by Alexander Ogston in 
1881 and Rosenbach in 1884 (Ogston, 1882; Cookson et al., 2003). Ogston coined the 
name Staphylococcus to describe grape-like clusters of bacteria he observed in pus 
from human abscesses and by 1884 a scientist named Rosenbach was able to isolate 
and grow these microorganisms in pure culture. He described two pigmented colony 
types of staphylococci and proposed the appropriate nomenclature: Staphylococcus 
aureus (golden) and Staphylococcus albus (white) (Kloos & Schleifer, 1986). The 
latter species is now known as Staphylococcus epidermidis. Although nineteen 
species of Staphylococcus are described in Bergey's Manual, (Holt et al., 1994) only 
S. aureus and S. epidermidis have been thought of as significant in their interactions 
with humans, but this appears to be changing with other coagulase-negative 
staphylococci (CoNS) species becoming increasingly prominent (Tan et al., 2006).
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Figure 1.1. The coccoid ceils of S. aureus divide in two planes causing the cells to form clusters 
resembling grapes, (a) Light microscopy can resolve this characteristic feature and is a simple way to 
distinguish staphylococcal cells from those of streptococci, which divide in a single plane and as a 
result form chains of cells, (b) Scanning and (c) transmission electron microscopy provide higher 
resolution images of S. aureus cells, enabling visualization of the polysaccharide capsule, cell wall and 
intracellular moieties.
(a)
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Humans are a natural reservoir of S. aureus. Although figures vary, about ten to 
twenty percent of the healthy adult population are intermittent carriers and twenty five 
to forty percent are persistently colonized (VandenBergh et al., 1999; Bishop et al., 
2006). S. aureus colonizes mainly the moist squamous epithelium of the anterior nares 
(Lowy, 1998; Massey et a l , 2006) and throat (Nilsson & Ripa, 2006), but it may be 
found in most other anatomical locales (Cookson et al., 2003). S. epidermidis is a 
ubiquitous colonizer of human and animal skin (Tan et al., 2006). Staphylococci are 
facultative anaerobes that grow by aerobic respiration or by fermentation that yields 
principally lactic acid. The bacteria are also catalase-positive and oxidase-negative. S. 
aureus can grow at temperatures ranging from 15 to 45 °C and are characteristically 
tolerant of salt, being able to grow when exposed to sodium chloride concentrations as 
high as 15% (w/v). Nearly all strains of S. aureus produce the enzyme coagulase, 
hence the presence of extracellular coagulase is a commonly used diagnostic test for 
the differentiation of S. aureus from other, non-coagulase producing, staphylococci.
The differentiation of S. aureus from CoNS is important in the clinic, since S. aureus 
is substantially more pathogenic (Gill et al., 2005b). Indeed coagulase is itself a 
virulence factor; it is an adhesin that reacts with prothrombin in the blood. The 
resulting complex is called staphylothrombin, which helps blood to clot by converting 
fibrinogen to fibrin (Kawabata et a l,  1985). Some coagulase is tightly bound to the 
surface of the bacteria and so S. aureus coats itself with fibrin upon contact with 
blood. Fibrin-coated staphylococci resist phagocytosis making the bacteria more 
virulent (Lowy, 1998).
CoNS include S. epidermidis, S. haemolyticus, S. saprophyticus, S. lugdunensis and a 
number of other species. Most are normal skin commensals and all are much less 
pathogenic than S. aureus. However, they have recently gained a role as pathogens as 
advances in other fields of medicine have provided an increasing supply of debilitated 
patients, highly prone to infection (von Eiff et al., 2002). CoNS are important causes 
of line- and device-associated infections in the immunosuppressed and account for 
about 7-9% of bacteraemias reported to the Public Health Laboratory Service 
(Reacher et a l,  2000). They are important also as causes of prosthetic valve 
endocarditis (Livermore, 2001) and are the major causative microorganisms in 
neonatal nosocomial sepsis (Krediet et al., 2004).
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Taxonomically, the genus Staphylococcus is in the bacterial family Bacillaceae, 
although the staphylococci are distantly related phylogenetically to other genera in the 
family. A variety of genetic criteria specify that the genus Staphylococcus forms a 
coherent and well-defined natural group that is broadly divergent from others within 
the family. On the basis of 16s RNA analysis, the genus Staphylococcus belongs to 
the broad Bacillus-Lactobacillus-Streptococcus cluster. The closest relatives of 
staphylococci are the enterococci and bacilli (Cole et al., 2003).
1.1.1 Genomic and genetic background of S. aureus.
Phylogenetic classification indicated that over 50% of predicted proteins encoded by 
the S. aureus genome are most similar to those in Bacillus subtilis and Bacillus 
halodurans (Kuroda et a l,  2001). These typically contain house-keeping genes that 
perform essential functions such as absorption of nutrients from the environment, 
synthesis of metabolic intermediates and bacterial multiplication. A Basic Local 
Alignment Search Tool (BLAST) homology search for the most closely related 
orthologues indicates that the genetic background of S. aureus has been vertically 
transmitted from a common ancestor that subsequently diverged to Bacillus and 
Staphylococcus species. With this perspective, it can be predicted that the 
corresponding domain of the chromosome will also be well conserved in other 
staphylococcal species, such as S. epidermidis (Ito et a l,  2003).
Whole genome sequences are now available for nine S. aureus strains and four CoNS 
strains (Table 1.1). The genomes of the MRSA strains have low G+C content (32.8- 
32.9%). Three sequenced MRSA strains possess high nucleotide sequence identities 
(Table 1.2). Table 1.3 displays some general features of seven MRSA genomes, 
including mobile genetic elements (MGE). Indeed, the majority of the nucleotide 
sequence disparity is due to the insertion of DNA regions that consist of putative 
exogenous genes. These regions are judged to be exogenous due to the absence of 
homologues in different S. aureus strains. Further nucleotide sequence differences are 
reported as a consequence of different preferences in codon usage and different G+C 
content within the ORFs (Kuroda et a l,  2001). This points towards a belief that the S. 
aureus chromosome is composed of two categories of DNA: background DNA,
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Table 1.1. Description of staphylococcal genomes that have been sequenced to date.
rain Refseq
Genome
_ Gft*oin Referenceol
size (bp) G+C (%)
k j l i a l l l  J c a t u r C S
s. aureus RF122 NC 007622 2742531 32 Associated with bovine mastitis (Herron et al., 2002)
s. aureus COL NC 002951 2809422 32 Early methicillin-resistant isolate (Gill et al., 2005a)
s. aureus MRSA252 NC 002952 2902619 32 Epidemic MRSA-16 clone (Holden et al., 2004)
s. aureus MSSA476 NC 002953 2799802 32 Invasive MSSA clone (Holden et al., 2004)
s. aureus MW2 NC 003923 2820462 32 Community-acquired MRSA strain isolated in mid-west USA (Baba et al., 2002)
s. aureus Mu50 NC 002758 2878529 32 Nosocomial MRSA strain, also shows intermediate vancomycin 
resistance
(Kuroda et al., 2001)
s. aureus N315 NC 002745 2814816 32 Nosocomial MRSA (Kuroda et al., 2001)
s. aureus NCTC 8325 NC 007795 2821361 32 Typical laboratory strain (Gillaspy et al., 2006)
s. aureus USA300 FPR3757 NC 007793 2872769 32 Epidemic clone of community-acquired MRSA (Diep et al., 2006)
s. epidermidis ATCC 12228 NC 004461 2499279 32 Non-biofilm forming, non-infection associated strain (Zhang et al., 2003)
s. epidermidis RP62A NC 002976 2616530 32 Biofilm-producing methicillin-resistant S. epidermidis (Gill et al., 2005a)
s. haemolyticus JCSC1435 NC 007168 2685015 32 Opportunistic pathogen with a highly antibiotic-resistant phenotype (Takeuchi et al., 2005)
s. saprophyticus ATCC 15305 NC 007350 2516575 33 Uropathogenic CoNS (Kuroda et al., 2005)
Table U .  Nucleotide sequence homology between genome sequenced strains of MRSA. Data 
taken from Baba et al., (2002).
Strain Mu50 N315
Mu50 - -
N315 99.7% -
MW2 94.7% 94.8%
Table 1.3. General features of seven staphylococcal genomes. Data collected from (Baba et al., 2002; Gill et al., 2005a; Diep et al., 2006).
Feature
5. aureus S. epidermidis
MW2 N315 Mu50 COL MRSA300 RP62A ATCC12228
Chromosome
Genome size (bp) 2820462 2814816 2878040 280942 2872769 2616530i 2499279
G+C content (%) 32.8 32.8 32.9 32.8 32.8 32.1 32.1
Open reading frames 2849 2797 3028 2721 2560 2553 2381
Percentage coding (%) 83.5 83.4 83.8 82 81 82 83
Ribosomal RNAs
16S 6 5 5 6 5 6 6
23S 6 5 5 6 5 6 6
5S 7 6 6 7 6 7 7
Insertion Sequences
IS/757 0 8 10 2 - 0 0
IS 1181 (degenerate) 0 0 0 1 - 0 0
\S43I (on SCCmec) 1 1 1 1 - 1 0
\S431 0 1 1 0 - 4 3
IS 431 (degenerate) 0 0 0 0 - 5 0
IS200 1 0 0 1 - 2 3
IS200 (degenerate) 0 0 0 1 - 1 1
IS256 0 0 0 0 - 5 0
IS3 0 0 0 1 - 0 0
I Sep/ 0 0 0 0 - 11 15
ISep/ (degenerate) 0 0 0 0 - 2 0
IS 12 72 (on SCC mec) 1 0 0 1 - 0 0
IS/272 1 0 0 0 - 0 1
IS/272-related (degenerate) 6 5 3 9 - 26 34
Transposons
Tn 554 0 4 2 0 - 3 0
Tn4001 0 0 0 0 - 1 0
TN5801 (conjugative) 1 0 1 0 - 0 0
Transposases 3 6 6 0 2 3 6
Degenerate transposases 1 6 9 1 - 5 0
Table 1.3. General features of seven staphylococcal genomes, continued.
Feature
S. aureus S. epidermidis
MW2 N315 Mu50 COL MRSA300 RP62A ATCC12228
Genomic islands
Prophage 2 1 2 1 2 1 0
SCC mec (type) 1 (IVa) 1 (II) 1(11) 1(1) 1 (IVa) 1(H) 0
SSCpbp4 0 0 0 0 0 0 1
vSa islands 5 4 5 5 3 0 0
vSe islands 0 0 0 0 0 2 3
ACME (type) 0 0 0 0 1(1) 0 0
Plasmids
Length (bp) 20654 24653 25107 4440 3125-37136 28080 4439-243708
G+C content 28.3 28.7 28.9 30.0 - 32 28-35.6
Open reading frames - 35 - 3 - 35 3-22
Percentage coding 75.6 78.0 80.9 - - - -
a Contains 6 plasmids 
b Contains 3 plasmids
transmitted from ancestral bacteria closely related to Bacillus species and MGE, 
which originated from other bacteria and were acquired by horizontal genetic transfer.
The paradigm of bacterial genomes is increasingly being viewed as having a core of 
essential genes (or housekeeping genes) that are accessorized with the acquisition or 
loss of dispensable genetic elements (Frost et al., 2005). Whilst this is a truism it fails 
to take in to account the different evolutionary processes employed by bacterial 
species. Evolution is believed to involve the movement of MGE, homologous 
recombination and the gradual accumulation of point mutations. Whilst bacterial 
species utilize these, they tend to show bias. For example the divergence of 
Escherichia coli and Salmonella enterica has been driven predominantly by the 
acquisition of horizontally transferred genes (Lawrence & Ochman, 1998). 
Examination of S. aureus using multilocus sequence typing (MLST) shows that point 
mutations give rise to new alleles at least fifteen-fold more frequently than does 
recombination. This contrasts with the naturally transformable species Neisseria 
meningitidis and Streptococcus pneumoniae, in which alleles change between five- 
and ten-fold more frequently by recombination than by mutation (Feil et al., 2003). 
However, phylogenetic analysis suggests that gene transfer does contribute toward the 
evolution of S. aureus over the long term (Feil et al., 2001) and Robinson & Enright 
(2004) described how two large recombinatorial events founded two lineages of S. 
aureus. So we see that the evolution of this species is a combination of macro- and 
microevolution, providing both the constancy that is required for the preservation of 
essential functions and the plasticity that is necessary for rapid phenotypic changes 
and the consequent ability to exploitation of new niches.
The clinical significance and global spread of MRS A has resulted in the evolution and 
epidemiology of this organism being the subject of much scrutiny. Interestingly, 
MLST analysis, along with SCCmec typing, has established that there are relatively 
few major epidemic MRS A (EMRSA) clones (Enright et al., 2002). Our present state 
of knowledge indicates that, rather than a single historical transfer of the genetic 
determinant for methicillin resistance (SCCmec) into S. aureus as suggested 
previously (Kreiswirth et al., 1993), this event has occurred several times (Enright et 
al., 2002). Furthermore, the emergence of major MRSA clones has come from the 
transfer of SCCmec into epidemic methicillin-sensitive S. aureus (MSSA) strains
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(Enright et al., 2002). This finding suggests the evolution of MRSA involved S. 
aureus strains that are well adapted to transmission within hospitals repeatedly 
receiving the mec determinant after the introduction of methicillin and then becoming 
the successful EMRSA clones within hospitals that we see today. As discussed in 
section 1.2.1, these same successful EMRSA clones are now proving their genetic 
resourcefulness by responding to the increasing use of vancomycin by becoming less 
susceptible to glycopeptides.
1.1.2 Colonization and infection with S. aureus.
S. aureus is a common coloniser of nasal passages and skin, and in this role the 
bacterium is commensal and exhibits no virulence. However, S. aureus is an 
opportunistic pathogen and can, in certain circumstances, initiate an infection. For this 
reason persons colonized with S. aureus are at an increased risk for subsequent 
infections (Wenzel & Perl, 1995). Rates of staphylococcal colonization are high 
among patients with type 1 diabetes (Tuazon et al., 1975), patients undergoing 
haemodialysis (Kirmani et al., 1978), surgical patients (Kluytmans et al., 1995; 
Herwaldt et al., 2004), intravenous drug users (Tuazon & Sheagren, 1974) and 
patients with acquired immunodeficiency syndrome (Weinke et al., 1992).
Analysis of the transmission properties of staphylococcal species reveals a number of 
factors suggesting that S. epidermidis is more efficient at transferring between hosts 
than S. aureus. Firstly, there are no known host barriers preventing colonization by S. 
epidermidis; current research indicates that all humans are colonized by this organism 
whilst only a sub-population of humans are colonized by S. aureus (Kluytmans et al., 
1997). Secondly, the staphylococcal mode of transmission between healthy hosts is by 
direct contact (Bauer et al., 1990). Since S. epidermidis resides on the skin, direct 
transfer between two hosts can be considered as a relatively simple process and is 
more likely to occur on a regular basis. In contrast, transmission of S. aureus requires 
the transfer of the microorganism from the nose to skin, subsequent transfer to the 
skin of a new host and, finally, colonization of the anterior nares of the new host. This 
extra degree of complexity is likely to make each transmission event less probable 
compared with the mechanism used by S. epidermidis (Massey et al., 2006).
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Studies on the phenomenon of Agr interference between genetically diverse S. aureus 
strains have revealed a third factor that contributes to S. epidermidis being more 
transmissible than S. aureus. Agr is a two-component signal-transduction system in 
staphylococci that uses a secreted octapeptide (autoinducing peptide; AIP) to 
communicate information on population density (Ji et al., 1997). In S. aureus four 
different Agr groups have been identified and interference between the strains 
expressing these different Agr groups has been demonstrated (Ji et al., 1997). 
Consequently, when a host is colonized by S. aureus of one Agr type, the competitive 
nature o f Agr interference will inhibit the colonization of any newly transmitted 
strains with a different Agr type (Massey et al., 2006). However, whilst studies on the 
Agr locus in S. epidermidis have revealed sequence diversity, no interference has been 
demonstrated between different Agr sequence types in this species (Dufour et al., 
2002; Lina et al., 2003). So these three factors indicate that S. epidermidis is more 
readily transmissible than S. aureus. Interestingly, this has been argued as one reason 
for the greater virulence of S. aureus’, virulence has evolved to overcome the complex 
transmission pathway (Massey et al., 2006).
S. aureus can cause a wide variety of infections including cutaneous infections, e.g., 
furunculosis, impetigo and abscesses, organ infections, e.g., osteomyelitis, 
endocarditis and arthritis and the toxinoses such as food poisoning, bacteraemia, 
scalded skin syndrome and toxic shock syndrome. S. aureus is also commonly 
isolated from the sputum of cystic fibrosis patients (Besier et al., 2007) and has a 
significant role in veterinary medicine, including the commercially important bovine 
mastitis (Tavema et al., 2007). S. aureus is able to invoke the associated symptoms of 
infection by the production of a variety of extracellular proteins, some cell-bound, 
others secreted, which participate in the initiation and establishment of an infection 
and by these criteria are defined as virulence factors (Novick et al., 2001).
1.1.2.1 Pathogenicity S. aureus.
S. aureus possesses many virulence factors which it is able to utilize to initiate an 
infection. S. aureus infections generally occur in those who are immunodeficient and 
have provided a means of entry into the body, i.e. a cut or wound (Lowy, 1998). It is
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for this reason that S. aureus is highly prevalent within post-operative infections. 
Some of the diverse virulence factors of S. aureus are shown in Table 1.4.
S. aureus infections are complex and require intricate combinations of the factors 
shown in Table 1.4, hence no single virulence determinate will lead to pathogenicity. 
Some global regulatory genes that coordinate the expression of various groups of S. 
aureus virulence genes have been identified (Peng et al., 1988; Dufour et al., 2002; 
Novick, 2003b; Lindsay et al., 2006). Of these the most extensively studied is Agr, 
which induces the expression of extracellular protein whilst suppressing the 
expression of surface protein. Agr and the other regulators appear to coordinate the 
pathogenesis of staphylococcal infections a sequential nature; surface proteins are 
predominantly synthesized during the exponential growth phase and secreted proteins 
during the stationary phase. So it seems that different stages of infection require 
different selections of virulence determinants, a hypothesis that is supported by 
evidence that the expression of surface proteins that bind extra-cellular-matrix 
molecules aids colonization of host tissues whereas subsequent synthesis of 
extracellular proteins favours the spread to adjacent tissues (Lowy, 1998).
Antimicrobial resistance is an important feature in S. aureus. Indeed, S. aureus has 
proven very successful at developing antimicrobial resistance and these antimicrobial- 
resistant strains are now causing considerable problems in both the clinical and 
community settings.
1.2 Antimicrobial resistance in S. aureus
Drug-resistant S. aureus strains have appeared following the introduction of new 
antimicrobials. At the time of introduction of penicillin for therapeutic use in the early 
1940s less than 1% of S. aureus isolates showed resistance to the antibiotic. However, 
a few years later the incidence of penicillin resistance in S. aureus had increased such 
that by 1946 approximately 60% of UK hospital isolates were penicillin resistant 
(Barber & Rozwadowska-Dowzendo, 1948). Levels of penicillin-resistant S. aureus 
continued to rise, Figure 1.2, and owing to the high incidence of penicillin-resistance 
it was necessary to introduce other antibiotics to control the infections.
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Table 1.4. Virulence factors of S. aureus. The genes encoding S. aureus pathogenicity are located in a 
variety of chromosomal locations, often associated with genomic islands and other mobile genetic 
elements.
Virulence Factor Role Examples
Adhesins Surface proteins that promote 
attachment to host proteins such as 
laminin and fibronectin.
Coagulase (Moreillon et al., 1995) and 
fibronectin-binding proteins (Menzies, 
2003).
Invasins Enable invasion by damage of host 
membranes.
Promote bacterial spread by 
dissolution of fibrin clots.
Enhance survival through nutrient 
provision.
a-toxin, P-toxin, 5-toxin, y-toxin 
(Novick, 2003a) and leukocidin (Gillet 
etal., 2002).
Staphylokinase (Collen, 1998)
Proteases, lipases, haemolysins and 
deoxyribonucleases (Urban et al., 2006)
Avoidance of host 
defences
Prevention of opsonization and 
phagocytosis by immunological 
disguise.
Enhance survival in phagocytes.
Capsule polysaccharide (O'Riordan & 
Lee, 2004), protein A (Peterson et al., 
1977) and leukocidin.
Carotenoids, catalase production.
Exotoxins Disrupt host membranes or otherwise 
promote symptoms of disease.
Toxic shock syndrome toxin (TSST-1), 
enterotoxins A-M and other superantigen 
toxins (Novick et al., 2001).
Intrinsic and 
acquired 
antimicrobial 
resistance
Prevent infection control by 
chemotherapeutics.
{3-lactamses, penicillin binding protein 2a 
(PBP2a) (Matsuhashi et al., 1986) or drug 
efflux (Kaatz et al., 2005; Ojo et al., 
2006).
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Figure 1.2. The accumulation of penicillin-resistance in S. aureus. Adapted from Livermore (2001).
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Antibiotics such as streptomycin, tetracycline, chloramphenicol, and erythromycin 
were introduced but these were similarly followed by the emergence of resistant 
strains (Shanson, 1981). Throughout the 1950s the introduction of new antibiotics 
lead to the development of multi-drug resistant S. aureus. In 1959 the P-lactamase 
stable agent methicillin was made available for treatment of these multi-drug resistant 
strains, however by 1960 the first methicillin-resistant S. aureus was reported (Jevons, 
1961; Jevons et al., 1963). An increasing number of MRS A strains were subsequently 
isolated and by the mid 1980s MRS A had become common in many parts of the 
world (al-Masaudi et al., 1991a). The mechanisms of resistance to several key 
antibiotics in S. aureus are shown in Table 1.5.
1.2.1 The Emergence of MRSA
After first appearing in the early 1960s, MRSA was able to spread to such an extent 
that by 1970-71 it accounted for nearly 10% of S. aureus at a major general hospital in 
Birmingham and for 15% of S. aureus from infective sources in Denmark (Livermore, 
2001). Interestingly however, their prevalence fell to almost zero later that decade and 
into the early 1980s. This decline has been attributed to the combination of several 
factors; strain displacement, the use of gentamicin and better infection control 
(Ayliffe, 1997). Unfortunately, this decline did not continue indefinitely and 
gentamicin resistance began to emerge in S. aureus, including MRSA, in the late 
1970s and early 1980s. Gentamicin-resistant MRSA became a problem by the mid- 
1980s and a strain designated epidemic MRSA 1 (EMRSA 1) achieved wide 
occurrence in the United Kingdom, the Irish Republic, and Australia (Ayliffe, 1997). 
EMRSA 1 was followed by further ‘epidemic’ MRSA strains, defined as those that 
had spread to two or more patients at two or more hospitals. Molecular 
epidemiological studies conducted in several countries since the late 1980s plainly 
indicate that a key factor for the huge geographic spread of MRSA is the 
dissemination of a relatively few highly epidemic clones (Crisostomo et al., 2001). In 
the late 1980s EMRSA 3 became prominent in the UK and was followed in the mid- 
1990s by EMRSA 15 and 16. These latter strains have achieved major spread and are 
often associated with severe infections. MRSA continues to increase in prevalence 
and cause severe clinical complications. Bacteraemia data for England and Wales 
demonstrate that the proportion of MRSA among S. aureus bacteraemia increased
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Table 1.5. Mechanism of resistance to several key antibiotics and there associated genetic location in S. aureus. Adapted from al Masaudi et al. (1991a).
Antibiotic Main resistance mechanism
Genetic location o f resistance 
Chromosome Plasmid Transposon
Comments
(3-lactam 
(penicillins & 
cephalosporins)
Enzymatic hydrolysis o f (3-lactam ring. MRSA Common Tn552 
Tn4002 
Tn3852 
Tn4201
Always linked with other antimicrobial determinants.
Methicillin Production o f new PBP (PBP2’ or 2a) with 
reduced affinity to P-lactams.
Exclusively Not found Probably MRSA always show resistance to other P-lactam 
antibiotics.
Mupirocin Alteration to or acquisition o f novel isoleucyl- Low-level resistance High-level Chromosomal high-level resistance may be due to
tRNA synthetase (M upA) (common) high-level 
resistance (rare)
resistance
(common)
integration o f a mupirocin resistance plasmid (Udo et 
al., 2003).
Glycopeptides 
(vancomycin & 
teicoplanin)
Intermediate resistance is not fully understood, 
but thickened cell wall and decreased 
peptidoglycan cross-linking are implicated. High- 
level resistance is via alteration in cell wall 
precursors with low affinity for 
vancomycin/teicoplanin.
Probably Yes lr\1546 Resistance is still fairly rare. No universal genetic 
marker for intermediate glycopeptide resistance has 
been discovered. High-level resistance is likely to 
have come from vancomycin-resistant enterococci 
(Howe e ta l.,  1998; Smith e ta l., 1999; M cC allum e/ 
al., 2006; Weigel et al., 2007)
Streptomycin Alterations in the structure o f the ribosome. 
Sometimes resistance can be through enzymatic 
modification o f streptomycin.
Common Infrequently
Erythromycin Target modification by adenine methylation o f 
domain V o f the 23 S rRNA conferred by erm 
gene.
Infrequently Common The product o f erm, adenine-N6- 
methyltransferase, also confers resistance to other 
macrolides and also lincosamides (Smith, 2004).
Table 1.5. Mechanism of resistance to several key antibiotics and there associated genetic location in S. aureus continued.
Antibiotic Main resistance mechanism
Genetic location o f resistance
Comments
Chromosome Plasmid Transposon
Gentamicin Enzymatic modification o f the antibiotic 
frequently by the enzymes AAC(6’) and 
APH(2”).
Often Frequently 7>i400l 
7>j3851 
7>i420 1
Plasmids often encode resistance to other antimicrobial 
agents and may be conjugative. Small colony variants 
(SCV) o f S. aureus are often gentamicin resistant (Proctor 
et al., 2006).
Tetracycline Efflux; ribosomal protection proteins. Infrequent Common Several incl. 
Tn916 &
T n1545
Conjugative transposons have been implicated in the 
dissemination o f tetracycline resistance (Roberts, 2005).
Chloramphenicol Chloramphenicol acetyl-transferase. Not found Exclusively Not found
Fusidic acid Decreased affinity o f the G factor for the 
antibiotic; decreased permeability.
Common Often Penicillin/ fusidic acid plasmid, aminoglycoside/ fusidic 
acid.
Rifampicin DNA polymerase with reduced affinity. Exclusively Not found Not found
Fluoroquinolones Modification o f type II and IV topoisomerases; Often Efflux is mediated by the NorA system, which is expressed
(ciprofloxacin & efflux. weakly in wild-type strains, but mutations leading to over­
levofloxacin) expression can confer resistance (Ohshita et al., 1990).
Sulphonamide Increased production o f />aminobenzoic acid. Common Infrequent Second mechanism o f resistance through the synthesis o f 
dihydropteroate synthase (DHPS) with reduced affinity.
Trimethoprim Overproduction o f or mutation in host 
dihydrofolate reductase.
Linezolid Mutation in the central loop domain V o f the 
component 23S rRNA subunit.
Exclusively A G2576T mutation o f the 23S rRNA has been described 
in three linezolid-resistant MRSA isolates (Tsiodras et al., 
2001).
Daptomycin Mechanism o f resistance is currently under 
investigation but may involve mutations 
affecting lysylphosphatidylglycerol synthetase, 
histidine kinase YycG and RNA polymerase
Exclusively Although resistance is low-level, treatment failure can 
result due to poor tissue penetration (Hayden et al., 2005).
from under 2% in 1990 to around 40% in 2004 (Readier et al., 2000; Department of 
Health, 2004). The number of deaths for which the underlying cause of death was 
reported as MRSA increased from 15 in 1993, to 360 in 2004 (Griffiths et al., 2004; 
Office for National Statistics, 2006). Rates for deaths involving MRSA in males 
increased by 66 per cent from 12.2 per million population in 2000 to 20.2 in 2004. In 
females, rates increased by 51 per cent, from 5.9 to 9.0 per million population, over 
the same period (Office for National Statistics, 2006). Further to this, laboratory 
reports of bacteraemia caused by MRSA also increased from 210 in 1993 to 5,309 in 
2002 (Griffiths et al., 2004).
Current therapies of choice for MRSA infections are the glycopeptides vancomycin 
and teicoplanin. Patients unable to tolerate vancomycin have been treated with 
fluoroquinolones, trimethoprim-sulfamethoxasole or clindamycin, which although 
effective, are not as popular as vancomycin because they have less antistaphylococcal 
activity or because resistance develops during therapy (Lowy, 1998). Fusidic acid and 
rifampicin are also used, but only in combination either with each other or with a 
glycopeptide due to the risk of selecting resistant mutants. More recently, two new 
drugs with anti-MRSA activity have been developed, the oxazolidinone antimicrobial, 
linezolid (Swaney et al., 1998) and the cyclic lipopeptide antimicrobial, daptomycin 
(Jeu & Fung, 2004).
However, S. aureus with reduced susceptibility to glycopeptides have been reported. 
These are known as glycopeptide-intermediate S. aureus (GISA) (Hiramatsu et al., 
1997) and fears that high-level resistance could be acquired from vancomycin- 
resistant enterococci (VRE) appear to have been fulfilled (Gonzalez-Zom & 
Courvalin, 2003; Weigel et a l, 2003; Tenover et al., 2004; Mater et al., 2005; Weigel 
et al., 2007). Low-level resistance to daptomycin and linezolid leading to treatment 
failure has also been described in MRSA strains (Tsiodras et al., 2001; Hayden et al., 
2005). GISA, high-level vancomycin resistant strains and MRSA resistant to new 
therapies represent a major gap in antimicrobial chemotherapeutics.
Efforts to control MRSA infection rates have also focussed upon reducing 
transmission of the organism from person to person. The key mechanism for 
transmission of MRSA is by skin to skin contact between a carrier and a new host
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(Massey et al., 2006), where they are available to initiate a new infection or be passed 
on to another host. Hence, targeting transient and asymptomatic carriage of MRSA is 
theorized to reduce infection rates by reducing the number of infection sources. 
Techniques for the decolonization of non-sterile skin sites are centred on alcohol 
based handwashes, washing with antimicrobial preparations (see section 1.4.1.1) and 
the use of topical antibiotics to remove colonization of the nose (see section 1.4.2).
The isolation of MRSA infected or colonised patients by means of single rooms or 
cohort isolation systems is also used to reduce spread. However the value of isolation 
has been the subject of much discussion; Verhoef et al. (1999) strongly favoured the 
use of isolation, whilst Cooper et al. (2004) found there was a paucity of well 
designed studies to allow the role of isolation measures alone to be assessed, but that 
there is evidence that concerted efforts that include isolation can reduce MRSA. 
However, Cepeda et al. (2005) have since found that moving MRSA-positive patients 
into single rooms or cohorted bays does not reduce cross-infection. Gloves and other 
personal protective equipment are also used as barriers to transmission.
Whilst the above are the main procedures used in healthcare facilities, the public, 
particularly in the UK, has focused on cleaning up “dirty” hospitals. It has been 
proposed that an increase in order and cleanliness does probably foster an increase in 
overall attention to detail within an organisation, but house-keeping programmes are 
unlikely to have a substantial impact on MRSA transmission (Huskins & Goldmann, 
2005; Eaton, 2005; Green et al., 2006).
Hence, the challenge for healthcare professionals is to develop a multifaceted 
approach to MRSA control, involving the skilled choice of antibiotic therapy in 
combination with efforts to reduce transmission.
1.2.2 Mechanism of methicillin resistance in S. aureus
MSSA utilize three penicillin-binding proteins (PBPs), known as PBP1, 2, and 3, to 
catalyse cross-linking of peptidoglycan. As discussed in the previous section (1.2.1) S’. 
aureus has evolved following several successful MSSA strains acquiring an additional 
component, PBP 2' or 2a, which has low affinity for P-lactams. As a consequence
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MRSA are resistant to all P-lactams. The genetic determinant of methicillin resistance, 
mec, has long been known to be localized on the chromosome of S. aureus (Sjostrom 
et al., 1975). mec was mapped to a locus between the genes encoding the virulence 
factor protein A {spa) and a purine biosynthesis protein {purA) (Kuhl et al., 1978). 
PBP 2' or 2a is encoded by the mec A gene which has the regulatory genes mecl and 
often mecRl all of which have been cloned and their nucleotide sequences determined 
(Ito et al., 2003). Comparative genomics of MRSA strains in the 1980s revealed that a 
substantial length of the chromosomal DNA segment (greater than 30 kb) carrying 
mec had no allelic equivalence in methicillin-susceptible S. aureus strains, therefore 
the segment was called additional DNA or mecDNA (Beck et al., 1986). Subsequent 
work showed this region to be a genomic island that acted as a specific structure for 
the genetic trait of methicillin resistance. Further to this it was later shown that the 
entire island was precisely excised from S. aureus N315 chromosome by the function 
of two site-specific recombinases (ccrA and ccrB) encoded by the island. This led to 
naming the island staphylococcal cassette chromosome mec or SCCmec (Ito et al., 
1999). Direct and inverted repeat sequences are found at the boundary of SCC mec. 
One of which is present on the S. aureus chromosome and the other inside SCCmec. 
SCC mec is present at a fixed site on the chromosome inside orjX (with unknown 
function) located near the origin of replication, which is 10 kb downstream of pur A 
and 66-89 kb upstream of the spa gene (Ito et al., 1999). So SCCmec consists of 
mecA and intact or truncated sets of regulatory genes, mecRl and mecl, the ccr gene 
complex and also ‘junkyard’ or J regions (JI, J2, and J3) that are located between and 
around the mec and ccr complexes and include a variety of genes or pseudogenes 
which, in general, do not appear to be essential or useful for the bacterial cell, 
although noteworthy exceptions include plasmid- or transposon-mediated resistance 
genes fornon-p-lactam antibiotics or heavy metals (Zhang et al., 2005).
Several types of SCCmec elements have been described. These are classified as types 
I-VI on the basis of the mec and ccr gene complexes they contain and are further 
classified into subtypes according to their junkyard region DNA segments. Thus far, 
there are three classes (A, B, and C) of mec complex and five allotypes (1 to 5) of ccr 
complex. Different combinations of these complex classes and allotypes generate the 
various SCCmec types (Table 1.6). SCCmec types have their own epidemiology.
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Table 1.6. Classification o f current SCC m ec types found in MRSA.
SCCmec type8 mec complex1* ccr allotype0 Original strain Reference
I Class B Type 1 NCTC10442 (Ito et al., 2001)
II Class A Type 2 N315 (Ito e ta l, 2001)
III Class A Type 3 85/2082 (Ito et a l, 2001)
IVa ClassB Type 2 CA05 (M ae/a l, 2002)
IVb Class B Type 2 8/6-3P (Ma et al., 2002)
IVc Class B Type 2 MR108 (Ito et a l, 2003)
IVd Class B Type 2 JCSC4469 (Ma et al., 2006)
V Class C Type 5 WIS [WBG8318]-JCSC3624 (Ito et al., 2004)
VI Class B Type 4 HDE288 (Oliveira et a l, 2006)
8 Subtypes of SCCmec TV differ based on junkyard (J) region DNA.
b Class A mec contains the complete mec complex (mecl-mecRl-mecA) and classes B and C have the 
mecA regulatory genes disrupted due to the presence of insertion sequences (x¥lS1272-AmecRl- mecA 
and \S431-AmecRl-mecA, respectively).
c ccr type 1 contains ccrBl-ccrAl, type 2 contains ccrB2-ccrA2, type 3 contains ccrB3-ccrA3, type 4 is 
a sporadic allotypes that contains ccrB4-ccrA4 and type 5 contains ccrC.
For example, SCCmec types IV or V are associated with newly emerging community- 
acquired MRSA (CA-MRSA) strains. These SCC mec types possess novel, small, 
mobile SCCmec genetic elements which contain the mecA gene with or without 
additional antibiotic resistance genes and are more easily transferred to other strains of 
S. aureus than larger SCCmec (types I, II, and III) elements (O'Brien et al., 2004).
Interestingly, mec A -determined resistance to p-lactams has been found to be present 
in up to 50% of CoNS isolates and resistance to other antibiotics, including 
aminoglycosides, quinolones, macrolides and tetracyclines is widespread amongst 
these species. The mechanisms responsible for resistance are identical to those 
prevalent in S. aureus indicating a role for horizontal gene transfer in the 
dissemination of methicillin resistance. Indeed, it has been proposed that SCCmec has 
been dispersed amongst staphylococci by transduction; mecA has never been found on 
mobile DNA but has spread among several S. aureus lineages and among different 
coagulase-negative species (Livermore, 2001).
1.2.3 Development of reduced susceptibility to antimicrobials
Two main categories exist for the development of antimicrobial resistance in S. 
aureus: intra-cellular diversification i.e. mutation or recombination within an already 
present bacterial gene, and inter-cellular diversification, mediated by the acquisition 
of a resistance gene from other organisms by some form of genetic exchange 
(horizontal gene transfer). Mutations can be caused by chemically- or physically- 
induced DNA damage, or by polymerase error during DNA replication, Figure 1.3(a). 
Consequently, in vitro spontaneous mutants resistant to agents generally arise at a
jC . o
frequency of between 10 and 10' per bacterium per generation (al-Masaudi et al., 
1991a). This value is inline with bacterial basal mutation rate. Recombination can also 
create new combinations of genes, as outlined in Figure 1.3(b).
Resistance to certain antimicrobials can be achieved through mutation including 
streptomycin, fusidic acid, rifampicin and novobiocin. Resistance to rifampicin, for 
example, is conferred by a mutation in RNA polymerase (rpoB) gene (Aubry-Damon 
et al., 1998). Mutations confer resistance often by changing the amino acid sequence
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Figure 1.3(a). Processes that generate intra-cellular diversity: mutagenesis. Mutagenesis and DNA repair are intimately related. Native DNA can be subjected to 
endogenous and exogenous sources of DNA damage. The nature of the damage determines the repair pathways activated to counteract these lesions. Failure to 
accurately restore the wild-type sequence has potentially lethal consequences, but may also bring about a phenotypic change that facilitates the colonization of a 
new niche. Adapted from Battista & Earl (2004). AER, alternative excision repair; BER, Base-excision repair; MMR, methyl-directed mismatch repair; NER, 
Nucleotide-excision repair.
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Figure 1.3(b). Processes that generate intra-cellular diversity: recombination. Diversity can also be created by the process of recombination. Two different types of DNA 
substrates could be formed as a result of a replication fork running into a nick (formation of a double-strand end; also the substrate generated during processes of conjugation 
and transduction) or a non-coding lesion (lesion square on the DNA) to form a gap. The genes and the particular stage of recombination at which their products are predicted 
to function are indicated. Adapted from Sandler & Niisslein (2004).
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of the target protein, resulting in a protein with altered properties, such as reduced 
binding affinity to the antimicrobial. This is frequently conferred by mutations within 
the active site of the protein. Alternatively, mutations can affect the expression of a 
gene; up-regulation or over expression of a target gene will reduce the potency of an 
antimicrobial (Fan et al., 2002). However, it seems unlikely that these would be an 
overly common occurrence in vivo since chromosomal mutations conferring antibiotic 
resistance can cause loss of fitness in the mutant organisms (Andersson & Levin,
1999).
Nonetheless, this is not always the case, for example low-level mupirocin resistance 
conferred by a V588F substitution in isoleucyl-tRNA synthetase has been shown not 
to be associated with a loss in fitness (Hurdle et al., 2004). Furthermore, it is possible 
that the original fitness costs can be ameliorated by subsequent evolution (Andersson 
& Levin, 1999). The acquisition of resistance genes has little or no effect on the 
fitness of the recipient and would therefore be expected to have a raised prevalence 
amongst S. aureus in the natural environment. Indeed it is now generally accepted that 
horizontal gene transfer plays a major role in the mediation and accumulation of 
antimicrobial resistance among the staphylococcal population (al-Masaudi et al., 
1991a).
Several mobile genetic elements carrying antimicrobial resistance genes in 
staphylococci have been discussed in depth (Novick, 1989; Novick et al., 2001). 
Exogenous resistance genes are found on various mobile genetic elements (plasmids, 
insertion sequences (IS), transposons, bacteriophages (phages) and genomic islands). 
These mobile genetic elements can be transferred between staphylococci by several 
methods, facilitating the dissemination of resistance and virulence genes.
1.3 Gene transfer systems in staphylococci
There are three fundamental mechanisms for the transfer of resistance genes between 
staphylococci. These are conjugation, transduction and transformation, Figure 1.4.
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Figure 1.4. Transfer of DNA between bacterial cells. Transduction (1). The DNA genome 
(yellow) of a temperate phage inserts into the chromosome (dark blue) as a prophage; it later replicates, 
occasionally packaging host DNA alone (generalized transduction) or with its own DNA (specialized 
transduction), lyses the cell, and infects a naive recipient cell in which the novel DNA recombines into 
the recipient host cell chromosome (red). Conjugation (2). Large, low copy number conjugative 
plasmids (orange) use a protein structure to establish contact with a recipient cell and to transfer 
themselves to the recipient cell. Alternatively, a copy of a small, multicopy plasmid or defective 
genomic island or a copy of the entire bacterial chromosome can be transferred to a naive cell, in which 
these genetic elements either insert into the chromosome or replicate independently if compatible with 
the resident plasmids (light green). Transposition (3). Transposons (pink) integrate into new sites on 
the chromosome or plasmids by non-homologous recombination. Integrons (dark green) use similar 
mechanisms to exchange single gene cassettes (brown). Adapted from Frost et al., 2005.
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1.3.1 Conjugation
Bacterial conjugation is a highly specific process whereby DNA (plasmid) is 
transferred from donor to recipient bacteria by a specialized multi-protein complex, 
named the conjugation apparatus. A key prerequisite for conjugative transfer is an 
intimate association between the cell surfaces of the donor and recipient cells. In 
Gram-negative bacteria, this physical contact is established by complex extracellular 
filaments, the sex pili. For the majority of Gram-positive bacteria, the means to 
achieve this intimate cell to cell contact have not yet been fully identified, but a strong 
level of homology has been found with type IV secretion systems (Grohmann et al., 
2003).
Staphylococcal conjugation was first described in 1982 with the description of the 
transfer of class III plasmids carrying gentamicin resistance (Jaffe et al., 1982). These 
plasmids occur very commonly in S. epidermidis and may well be responsible for the 
spread of gentamicin resistance to S. aureus (Novick, 1989). Until recently most 
conjugative staphylococcal plasmids isolated carried resistance to gentamicin and 
other aminoglycosides, ethidium bromide and quaternary ammonium compounds. 
Some of these plasmids were also found to encode resistance to penicillin. Conjugal 
plasmids have also been shown to mobilize smaller non-self-transmissible plasmids 
(Grohmann et al., 2003). In addition a self-transmissible gentamicin resistance 
plasmid was able to mediate its own transfer over a wide range of pH values and 
temperatures (al-Masaudi et al., 1991b).
The view of the role plasmids take in bacterial resistance to biocides has changed 
significantly since research started in the early 1980s. It was initially thought that, 
whilst plasmid-encoded resistance to anions and cations (such as mercurial and silver 
compounds) existed, plasmids were not normally responsible for high levels of 
biocide resistance (Russell, 1997). Since then, there have been frequent reports 
linking the presence of plasmids with resistance to biocides such as chlorhexidine 
gluconate (CHX) (Cookson et al., 1986; al-Masaudi et al., 1988; Cookson et a l , 
1991a) and quaternary ammonium compounds (QACs) (Paulsen et al., 1996a; 
Bjorland et al., 2001; Chapman, 2003; Noguchi et al., 2005). These findings show
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that conjugation systems are probably of significant importance in the dissemination 
of antimicrobial resistance genes among the Staphylococcus genus.
In addition to plasmids, S. aureus strains are also known to possess conjugative 
transposons. Conjugative transposons are mobile DNA elements that encode all the 
necessary functions for intracellular transposition and intercellular conjugation. The 
first identified was an 18 kb Tn916 transposon from E.faecalis (Jaworski & Clewell, 
1995). Tn916 and the closely related element Tnl545 from S. pneumoniae form the 
foundation of a family of conjugative transposons with an extremely broad host range. 
Members of the Tn9J6-Tnl545 family have been found naturally in, or have been 
introduced into, more than 50 different species and more than 20 genera of bacteria 
including S. aureus. All members of the family encode a tetracycline determinant of 
the TetM type and many also carry genes encoding resistance to further antimicrobial 
agents (Salyers et al., 1995).
1.3.2 Transduction
Phages are widely distributed in staphylococcal populations. Moreover, most clinical 
isolates harbour at least one prophage, illustrated by the genome sequences of S. 
aureus strains, Table 1.3. It appears probable that transduction is the mechanism by 
which the mecA determinant has spread amongst staphylococci; mecA has never been 
found on mobile DNA but has spread among several S. aureus lineages and among 
different coagulase-negative species (Livermore, 2001). Phage-mediated transduction 
has also been postulated to be the primary mechanism by which (3-lactamase genes 
have spread among staphylococci. Supportive of this mechanism is the fact that most 
staphylococcal class I, p-lactamase-producing plasmids are 35-40 kb in size, roughly 
the size of a phage genome. As such, the mistaken incorporation of the plasmid into 
the phage head (generalized transduction) can be facilitated (Novick, 1989; Rice,
2000). DNA mobilized by specialized transduction arises from illegitimate 
recombination during excision of a prophage from the host genome, leading to the 
packaging of a phage ‘genome’ lacking some phage genes but gaining some host 
traits. The fate of the transferred DNA is independent of the transduction process and 
depends on the recipient cell’s mechanisms of recombination and DNA stabilisation 
(Miller, 2004). However, the requirement for the death of the donor cell, the need to
29
protect the recipient from destruction by normal phage particles in addition to the 
artificial conditions needed for the transduction process in vitro raises doubts as to 
whether transduction could be a significant process in nature (al-Masaudi et al., 
1991a). To this end, transfer of other resistance determinants by transduction is not 
well documented, although is has been implicated as a mechanism for the 
dissemination of virulence determinants (Rice, 2000).
1.3.3 Transformation
The ability to absorb free DNA from the environment is relatively rare in species of 
Gram-positive bacteria. However S. aureus, under specific conditions, is able to take 
up ‘naked’ DNA from the environment. The natural competence system of S. aureus 
is induced only in very early exponential growth (Novick, 1989). Either chromosomal 
or plasmid DNA can be transformed into S. aureus, although competence requires 
high calcium concentrations (0.1 M). Indeed, the requirement for a non-physiological 
calcium concentration and a short period of competence (when nucleases are absent) 
are reported to dramatically reduce the likelihood of transformation in nature (Lacey, 
1984). There are several stages to the process of taking up DNA from the 
environment. Firstly, potential recipients must encounter a DNA molecule, and this 
must be positioned immediately adjacent to uptake sites on the cell surface. Molecules 
may drift to the organism, if it is attached in an aquatic environment, or unlike S. 
aureus the organism might have motility and locate/interact with a DNA source. 
Secondly, the fragment must be of the right size and conformation to be recognized by 
the cell. DNA must be double stranded and, ideally, have a size greater than five kb 
(Bacillus subtilis and S. pneumoniae most efficiently bind duplex DNA of about 10 to 
18 kb). Once a DNA fragment has been recognized it can be transported in to the cell. 
This process requires several genes and slightly different pathways are adopted by 
Gram-positive and Gram-negative bacteria. Due to the complexity and thickness of 
the Gram-positive cell wall an intricate collection of transport and accessory proteins 
are required to achieve successful DNA transport. In Gram-positive bacteria DNA 
binds rapidly to cell surface uptake sites, where an ordered process appears to take 
place; the DNA is reduced enzymatically into fragments of a predetermined optimal 
size for translocation (averaging 15 to 18 kb). The newly generated ends are adjacent 
to uptake sites, and uptake can start. In B. subtilis and S. pneumoniae a nuclease
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(EndA) degrades one strand (5' to 3'), allowing the 3' end of a single-stranded 
molecule to travel into the cytoplasm (Day, 2004). Finally, once in the cell the DNA 
molecule is reliant upon the host organism’s recombination (generally recA), 
stabilization and expression systems to be assimilated into the host genome and, 
ultimately, expressed.
1.4 Antimicrobial agents
Antibiotics are used as chemotherapeutic drugs whilst biocides are chemicals used as 
antiseptics, disinfectants and preservatives. Biocides have a range of uses such as 
disinfection of surfaces (disinfectants), control/prevention of infection (antiseptics and 
topical antimicrobials) or incorporated into pharmaceutical, cosmetic, consumer 
healthcare or other types of product to prevent microbial contamination 
(preservatives), Table 1.7.
No single antimicrobial agent is ideal for use in all situations. When selecting an 
antimicrobial for use in a particular setting several factors are taken into consideration 
including the active ingredient, concentration, user acceptability, rapidity of action, 
persistence, cost, inactivation, safety and toxicity (Rutala & Weber, 2001). Some 
characteristics of topical antimicrobial agents are discussed in Table 1.9. Biocide 
activity is affected by several factors, notably concentration, period of contact, pH, 
temperature, presence of inactivants and the nature, numbers, location and condition 
of the microorganisms (Russell, 2006). Biocide concentration is of prime importance. 
The effect of concentration, or dilution, on the activity of a biocide is measured by the 
concentration exponent (n or r|). Biocides with high revalues, such as phenolics and 
alcohols, rapidly lose activity upon dilution. QACs, chlorhexidine, glutaraldehyde and 
triclosan have a low revalue and hence retain much of their activity upon dilution 
(Russell, 2003b). Many biocides also have an optimum pH range. Glutaraldehyde and 
cationic biocides, such as chlorhexidine and QACs, are most active at high pH whilst 
the potency of hypochlorites and phenolics is increased at low pH. Generally the 
activity of biocides increases with increased temperature, although this is of little 
practical use. Inactivation readily reduces the efficacy of biocides. Inactivation can 
occur through interaction with organic matter (blood, serum, pus, dirt) and non-ionic
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Table 1.7. Clinical and other uses o f biocides. Adapted from Russell (2003).
Biocide type Example(s) General examples of use(s)
Alcohol Ethanol Hand sanitising
Aldehyde Formaldehyde
Formaldehyde-releasing agents 
Glutaraldehyde
Virucidal agent 
Topically; irrigation solutions 
Endoscope disinfection
Biguanide Chlorhexidine 
PHMB (polymeric)
Antiseptic, disinfectant, 
pharmaceutical preservative 
Swimming pool disinfection, contact 
lens solutions
CRA NaCIO, NaDCC industrial Disinfection of blood spillages; 
sanitisation compounds
Isothiazolon Chloromethyl and methyl derivatives Cosmetic and pharmaceutical 
preservatives
Peroxygen Hydrogen peroxide 
Peracetic acid
Antiseptic, disinfectant, deodorant 
Endoscope disinfection
Phenylether Triclosan Preoperative disinfection, body 
washes, dental hygiene, consumer 
healthcare
Phenol and cresol Preservatives, disinfectants
QAC BZK, CPC, CTAB Skin disinfection, preoperative 
disinfection, antiseptics, 
pharmaceutical preservatives
Vapour phase Ethylene oxide Low-temperature sterilisation of 
non-thermostable materials
PHMB, polyhexamethylenebiguanide; NaCIO, sodium hypochlorite; NaDCC, sodium
dichlorocyanurate; BZK, benzalkonium chloride; CPC, cetylpyridinium chloride; CTAB, 
cetyltrimethylammonium bromide; CRA, Chlorine-releasing agent
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surfactants, and also through adsorption to containers. Microorganisms show 
substantial differences in their response to biocidal treatment, for example the 
differences between Gram-positive and Gram-negative bacteria, Table 1.8. The 
condition of the microorganisms, such as biofilm cells, also has a marked outcome on 
biocide susceptibility (Russell, 2003b). There are several similarities and differences 
between biocide and antibiotic action. Antibiotics inhibit a specific target in a 
biosynthetic process, such as peptidoglycan synthesis. By contrast biocides have 
multiple, concentration-dependent targets, with subtle effects occurring at low 
concentration and more damaging effects at higher concentrations. However, some 
similarities do also exist, including cellular penetration of cationic agents, both 
antibiotic and biocide. Some biocides and antibiotics also share membrane-damaging 
effects and morphological changes induced (Russell, 2003a). There is also a shared 
target site between one biocide (triclosan) and an antibiotic (isoniazid) in some 
mycobacteria (McMurry et al., 1999).
1.4.1 Triclosan
Triclosan (2,4,4’-trichloro-2’-hydroxyphenyl ether, Irgasan® DP300, Irgacare® MP 
and Irgacide® LP10) is a broad spectrum biocide that has been in use for more than 35 
years. It was developed in the 1960s by J.R. Geigy AG (Basel, Switzerland) and is 
now manufactured predominantly by Ciba Speciality Chemicals GmbH (Grenzach- 
Wyhlen, Germany). Usage was increasing, but has now stabilized, with about 350 
tonnes of triclosan being used within countries of the European Union every year. Of 
this, the UK is estimated to use 60-90 tonnes (Environment Agency, 2004).
Triclosan is the most potent of the bis-phenol class of antimicrobials and, as with all 
biocides of this class, possesses the hydroxy-halogenated derivatives of two phenolic 
groups connected by a bridge, Figure 1.5. It is an off-white, tasteless and odourless, 
crystalline powder with a molecular weight of 289.5. Triclosan is practically insoluble 
in water, but moderately soluble in alkaline solutions and readily soluble in most non­
polar organic solvents. The thermal stability of triclosan powder is relatively good up 
to 150°C or even up to 200°C, if not heated for more than 2 hours (Bhargava & 
Leonard, 1996).
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Table 1.8. Characteristics of topical antimicrobial agents. Adapted from Rutala & Weber (2001).
Alcohols CHX Iodophores PCMX Triclosan
Gram-positive bacteria Excellent Excellent Excellent Good Good
Gram-negative bacteria Excellent Good Good Fair Good
M. tuberculosis Excellent Fan- Good Fair Fan-
Fungi Good Fair Good Fan- Poor
Viruses Good Good Good Fair Unknown
Rapidity of action Most rapid Intermediate Intermediate Intermediate Intermediate
Residual activity None Excellent Minimal Good Excellent
Concentration (%) 70-92 4, 2; 0.5 in 10, 7.5, 2, 0.5 0.5-.3.75 0.3-2.0
alcohol
Inactivation No data Minimal Yes Minimal Minimal
Safety Drying, Ototoxicity, Skin irritation Need data Skin and eye
volatile keratitis irritant
M. tuberculosis, Mycobacterium tuberculosis', CHX, Chlorhexidine gluconate; PCMX, 
parachlorometaxylene.
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Figure 1.5. The chemical structure of triclosan. The synthetic bisphenol consists of hydroxy- 
halogenated derivatives of two phenolic groups connected by a bridge.
OH C l
C l C l
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Triclosan is a broad spectrum antimicrobial, but exhibits particular activity against 
Gram-positive bacteria. However, efflux systems and a non-susceptible enoyl 
reductase in Pseudomonas aeruginosa confer an innate resistance (Heath et al., 2001; 
Levy, 2002; Chuanchuen et al., 2003). The susceptibilities of some Gram-positive and 
Gram-negative bacteria, including several antibiotic resistant strains, are described in 
Table 1.9. Susceptibility of Gram-negative bacteria and yeasts can be significantly 
enhanced by formulation effects. For example, triclosan in combination with EDTA 
caused increased permeability of the outer membrane (Leive, 1974). Indeed, during 
clinical or domestic use, triclosan is delivered typically as part of complex 
formulations containing various combinations of surfactants, detergents, chelating 
agents and wetting agents, which affect the antimicrobial activity of triclosan and 
ultimately affect the susceptibility of microorganisms exposed to it.
Depending on the type and concentrations of constituents in the formulation, triclosan 
products with the same levels of antimicrobial may demonstrate varying levels of 
effectiveness; efficacy may be affected by pH, detergent base, emollients and 
humectants, ionic nature of the formulation and type of surfactants (Larson, 1995). 
Triclosan exhibits minimal pH sensitivity and interference from skin conditioners 
(Jones et al., 2000). It is also non-ionic, as a consequence of this it would be unlikely 
that the inclusion of lotions or moisturizers would affect the effectiveness of triclosan 
formulations, unlike products containing cationic biocides, such as chlorhexidine, 
which are readily inactivated by anionic lotions. However, the activity of triclosan is 
influenced by the amount and type of surfactant in the formulation, a key ingredient in 
handwash products (Jones et al., 2000). Surfactants are surface active agents that 
lower surface tension (allowing the cleanser to wet the skin), emulsify soils and 
remove transient microorganisms. Their interaction with triclosan starts when 
surfactant molecules aggregate in water to form micelle structures. These structures 
are important to the emulsification process but can also lead to an unwanted 
consequence; molecules of triclosan can be sequestered in these micelles and thus 
become less bioavailable. Recently this problem has been avoided by optimizing the 
ratios of certain surfactants and other common skin care ingredients, which can reduce 
the interaction between triclosan and the micelles. This technology is referred to as 
“de-blocking” or “activated triclosan” (Fuls & Fischler, 2004).
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Table 1.9. The susceptibilities of some Gram-positive and Gram-negative bacteria to triclosan.
The MICs were calculated by the agar dilution method. Data are taken from Vischer & Regos, (1973), 
Regos et al., (1979) and Bhargava & Leonard (1996).
Organism Strain Medium3 Triclosan MIC (mg/L)
Gram-positive bacteria
Bacillus subtilis NCTC 8236 NA 0.1
Bacillus megaterium NA 3
Bacillus cereus NA 3
Bacillus cereus var. mycoides NA 3
Clostridium botulinum NCTC 3805 BHIA 3
Clostridium tetani NCTC 9571 BHIA 3
Corynebacterium diphtheriae ATCC 6917 BHIA 3
Corynebacterium diphtheriae NCTC 3984 BHIA 3
Corynebacterium diphtheriae BHIA 3
Corynebacterium minutissimum ATCC 6501 BHIA 5
Diplococcus pneumoniae NCTC 7465 BHIA 3
Lactobacillus arabinosus CITM 706 MACA 33
Lactobacillus arabinosus ATCC 8014 MACA 33
Lactobacillus fermenti CITM 707 MACA 33
Listeria monocytogenes ATCC 15313 1
Mycobacterium tuberculosis YA
Mycobacterium smegmatis NCTC 8152 BHIA 1
Mycobacterium phlei BHIA 0.3
Propionibacterium acnes ATCC 6919 BHIA 3
Sarcina lutea NCTC 196 BHIA 3
Sarcina ureae ATCC 6473 BHIA 0.1
Staphylococcus aureus NCTC 6571 NA 0.03
Staphylococcus aureus NCTC 7447 NA 0.01
Staphylococcus aureus NCTC 6966 NA 0.1
Staphylococcus aureus NCIMB 9518 NA 0.03
Staphylococcus aureus (MRSA) MRSA 11 NA 0.075
Staphylococcus aureus (MRSA) MRSA 11777 NA 0.5
Staphylococcus aureus (MRSA) MRSA 9543 NA 1
Staphylococcus epidermidis NA 0.03
Streptococcus agalactiae NCTC 8181 BHIA 33
Streptococcus mutans NCTC 10832 BHIA 21
Streptococcus pyogenes NCTC 8322 BHIA 3
Streptococcus sanguis NCTC 7863 BHIA 2.6
Streptococcus oralis NCTC 11427 BHIA 5.2
Enterococcus faecalis ATCC 8619 BHIA 10
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Table 1.9. The susceptibilities o f some Gram-positive and Gram-negative bacteria to triclosan
continued.
Organism Strain Medium Triclosan MIC (mg/L)
Gram-negative bacteria 
Aerobacter aerogenes CITM 413 NA 1
Alcaligenes faecalis ATCC 8750 MHA 0.5
Bacteroides denticola ATCC 33185 NA 3.1
Bacteroides intermedius ATCC 25612 1.6
Burkholderia mallei NCTC 9674 NA 0.3
Burkholderia pseudomallei NCIMB 10230 NA 1
Burkholderia cepacia NA 256
Brucella intermedia BrAA 0.1
Brucella melitensis BA 1
Brucella suis BrAA 0.03
Enterobacter cloacae ATCC 13047 MHA 0.5
Escherichia coli NCTC 86 NA 0.1
Escherichia coli NCTC 8196 NA 0.03
Escherichia coli NCTC 8739 MHA 0.2
Escherichia coli (serotype 0157) ATCC 35150 MHA 0.2
Escherichia coli (serotype 0157) ATCC 43888 MHA 0.1
Escherichia coli (serotype 0157) ATCC 43894 MHA 0.2
Haemophilus influenzae ATCC 33391 MHA 2
Klebsiella pneumoniae ATCC 11296 MHA 0.3
Klebsiella pneumoniae ATCC 4352 BHIA 0.06
Legionella pneumophila ATCC 33152 1
Moraxella catarrhalis NCTC 3622 BA 33
Morganella morganii NA 10
Pasteurella septica NCTC 948 NA 0.1
Porphyromonas gingivalis WCA 2.5
Prevotella oralis ATCC 33573 6.3
Proteus vulgaris NCTC 8313 NA 0.1
Proteus vulgaris NCTC 4175 NA 0.01
Proteus mirabilis NCTC 8309 NA 0.3
Proteus mirabilis ATCC 14153 MHA 0.5
Pseudomonas aeruginosa NCTC 1999 NA >100
Pseudomonas aeruginosa ATCC 12055 NA >1000
Pseudomonas aeruginosa NCTC 8060 NA >1000
Pseudomonas fluorescens NCTC 4755 NA >100
Pseudomonas oleovorans ATCC 8062 BHIA 0.5
Pseudomonas stutzeri ATCC 17588 MHA 1
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Table 1.9. The susceptibilities of some Gram-positive and Gram-negative bacteria to triclosan 
continued.
Organism Strain Medium Triclosan MIC (mg/L)
Gram-negative bacteria continued
Salmonella enteritidis NA 0.3
Salmonella paratyphi A NCTC 5322 NA 0.3
Salmonella paratyphi B NCTC 5704 NA 0.1
Serratia marcescens ATCC 14756 MHA >512
Serratia marcescens ATCC 13880 BHIA >1000
Shigella dysenteriae NCTC 2249 NA 0.1
Shigella flexineri NCTC 8192 NA 0.3
Shigella sonnei NCTC 7240 NA 0.1
Vibrio cholerae NA 10
Vibrio eltor NCTC 8457 NA 10
Fungi and yeasts
Aspergillus niger ATCC 6275 M 30
Aspergillus fumigas ATCC 9197 SMA 10
Candida albicans NA 3
Candida albicans ATCC 10259 M 3
Epidermophyton floccosum ATCC 10227 SMA 1-10
Trichophyton ajelloi SMA 10
Trichophyton mentagrophytes ATCC 9533 SMA 1
Trichophyton rubrum SMA 10
Trichophyton tonsurans SMA 10
a BA, blood agar; BHLA, Brain-heart infusion agar; BrAA, Brucella agar albimi; M, mycophil agar; 
MACA, microassay culture agar; MHA, Mueller-Hinton agar; NA, nutrient agar; SMA, Sabouraud 
maltose agar; WCA, Wilkins-Chalgren-Bouillon agar; YA, Youman’s agar.
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1.4.1.1 Clinical and domestic use of triclosan
For many years triclosan has been included in products such as hand soaps, lotions, 
toothpastes, deodorants and oral rinses (Russell, 2004). It has also been incorporated 
into a range of items including tea towels, chopping boards and toys (Levy, 2001). 
These applications have been used to prevent the development and/or spread of 
infection and microorganism-associated odours in the community setting. However, 
triclosan has an important role in infection control within the clinical setting (Jones et 
al., 2000).
Although the efficacy of triclosan in surgical scrub studies has been limited, it has 
shown effectiveness against transient bacteria in health care personnel handwash 
studies (Jones et al., 2000). The efficacy of various triclosan formulations, in 
comparison with 4% chlorhexidine formulations, was demonstrated in a healthcare 
personnel handwash test (Jampani et al., 1998). Additionally, Bartzokas et al. (1983) 
demonstrated the effectiveness of several variations of triclosan detergents and 60% 
isopropyl alcohol on E. coli. In two similar studies the effectiveness of triclosan 
formulations were demonstrated against E. coli and Pseudomonas fluorescens mixed 
in a ground beef slurry to reproduce conditions found in meat and poultry processing 
facilities (Sheena & Stiles, 1983; Stiles & Sheena, 1987). The aforementioned studies 
confirm the efficacy of various triclosan formulations to remove transient microbial 
flora that may be acquired by medical staff in the health care environment and in food 
handling or preparation settings.
Importantly, in 1987 triclosan was successfully used to control on outbreak of MRSA 
(Tuffiiell et al., 1987) and more recently it was used successfully to control MRSA 
outbreaks in a neonatal nursery (Zafar et al., 1995), a cardiothoracic surgical unit 
(Brady et al., 1990) and one outbreak of a strain also resistant to mupirocin (Irish et 
al., 1998). Subsequently, in 1998 it was recommended for the control of nosocomial 
MRSA (Ayliffe et al., 1998) and 2% triclosan baths are now one of the recommended 
rationales for skin decolonisation of MRSA carriers (Coia et al., 2006).
Another benefit of using triclosan in the regimen of decolonising hospital patients is 
that it has long been thought of as a non-specific biocide (Chuanchuen et a l, 2001)
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and as a consequence the development of resistance was seen as highly unlikely 
(Russell, 2004). Recently this previous dogma has been challenged by evidence that 
triclosan may act on a specific cellular target, much like an antibiotic.
1.4.1.2 Triclosan: biocide or antibiotic?
Biocides are generally broad-spectrum antimicrobials which act by many non-specific 
means, targeting numerous intracellular, cytoplasmic and cell wall sites. Meanwhile, 
antibiotics have single and specific cellular targets. Triclosan was previously seen as a 
biocide, but a growing amount of research challenges this point of view. Evidence 
now indicates that triclosan may act on a specific target, the highly conserved enzyme 
enoyl-ACP reductase, which is also known as FabI (Heath et a l , 1998; McMurry et 
al., 1998; Heath et al., 1999; Heath & Rock, 2000; Fan et al., 2002). The enoyl 
reductase, InhA, in Mycobacterium smegmatis was also found to be a target for 
triclosan action (McMurry et a l , 1999). However the question still remains whether 
inhibition of a single enzyme by triclosan is indeed responsible for all its inhibitory 
and lethal actions (Russell, 2003b).
1.4.1.3 Reduced susceptibility to triclosan in S. aureus
Following the introduction of triclosan into clinical practice there has been an 
increased interest in reduced susceptibility of microorganisms to the antimicrobial. 
Several reports now describe the isolation of reduced susceptibility S. aureus strains. 
In 1991 S. aureus strains with minimum inhibitory concentrations (MICs) of 2-4 mg/L 
were isolated from patients treated with daily triclosan baths (Cookson et al., 1991b). 
The MICs of sensitive S. aureus are 0.01-0.1 mg/L (Table 1.10). Furthermore in 1997 
7.5% of S. aureus clinical isolates were found to have triclosan MICs of at least 1 
mg/L, although they did not find any differences between MRSA and MSSA strains 
(Bamber & Neal, 1999). However, Al-Doori et al maintain that there has not been a 
significant increase in reduced triclosan susceptibility amongst nosocomial MRSA in 
Scotland (Al-Doori et a l, 2003).
As mentioned in section 1.4.1.1 triclosan has been reported to achieve its growth- 
inhibitory activities by blocking bacterial fatty-acid synthesis and more specifically by
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explicitly inhibiting an NADH-dependent enoyl-acyl carrier protein (ACP) reductase, 
encoded by the fab l gene, Figure 1.6.
Triclosan has been shown to bind strongly to, and inhibit, S. aureus Fabl (Ward et al., 
1999; Fan et a l , 2002; Sivaraman et al., 2004). Consequently, Fabl has been 
scrutinised for its role in reduced triclosan susceptibility and two main mechanisms of 
Fabl mediated resistance have been proposed. Comparison of fab l sequences from 
susceptible and reduced susceptibility S. aureus strains indicated that a mutation 
within fab l resulting in a F204C alteration in the Fabl protein conferred greatly 
reduced triclosan susceptibility (1-4 mg/L; Figure 1.7) (Fan et a l, 2002).
Since the first description offab l mutations several more predicted alterations to the 
Fabl amino acid sequence that confer reduced triclosan susceptibility have been 
described (Brenwald & Fraise, 2003). It is also proposed that a moderate reduction in 
susceptibility in S. aureus can be conferred by the over production of Fabl (Fan et a l, 
2002).
However, some authors maintain that triclosan has cellular targets other than Fabl. 
Brenwald and Fraise (2003) did not find mutations in the fab l gene of three clinical S. 
aureus isolates with triclosan MICs of 4.0 mg/L. This lack of fab l mutations suggests 
that genetic loci other than fab l are also involved in triclosan resistance. Indeed, other 
targets, principally in the cytoplasmic membrane, have been suggested for triclosan 
(McDonnell & Pretzer, 1998). Additionally triclosan has been shown to intercalate 
into the cell wall causing it to become destabilised and compromising its functional 
integrity (Villalain et a l, 2001; Guillen et a l, 2004). Triclosan resistance in other 
genera is conferred by alternative enoyl-ACP reductase enzymes and/or drug efflux. 
Efflux has been reported as the sole source of high-level triclosan resistance in P. 
aeruginosa (Chuanchuen et a l, 2003).
In practice triclosan is normally utilized at concentrations much greater than the MICs 
associated with reduced triclosan susceptibility, see section 1.1.2. At such 
concentrations triclosan is rapidly bactericidal. This level of lethality has been shown 
to extend to ‘triclosan-resistant’ strains of E. coli (McDonnell & Pretzer, 1998) and S. 
aureus (Suller & Russell, 2000). Membrane damage has been shown to occur at
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Figure 1.6. Reactions in type II bacterial fatty acid biosynthesis. Key enzymes are shown but the
distribution of particular components varies in a species-specific manner. For example, FabA occurs 
only in proteobacteria, whereas FabZ is ubiquitous. Both function interchangeably in elongation cycles 
up to 10 carbons and both function in the synthesis of saturated fatty acids. FabB and FabF both occur 
in proteobacteria whereas only a FabF synthase occurs in pathogenic Gram-positive bacteria. Three 
different enoyl-ACP reductase enzymes have been discovered in different pathogens, Fabl (S. aureus) 
and FabK (Heath & Rock, 2000) and FabL (Heath et a l, 2000). Adapted from Payne et al. (2001).
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Figure 1.7. Structural consequences of mutations within fab l conferring a F204C alteration in the 
Fabl protein, (a) X-ray crystal structure of triclosan bound to wild-type E. coli Fabl and (b) model of 
triclosan bound to F204C E. coli Fabl. The side-chain atoms of F204 and C204 are highlighted in cyan. 
Adapted from Fan et al., 2002.
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bactericidal levels by triclosan-induced potassium ion leakage and other membrane- 
destabilizing effects have also been demonstrated during exposure to high level 
triclosan (Russell, 2004). Triclosan demonstrates a Z-pattem type of adsorption, 
which is indicative of the breakdown of a structure, presumably the membrane, and 
the generation of new adsorbing sites (Denyer & Maillard, 2002). Therefore, whilst 
low concentrations of triclosan may target Fabl, at in use concentrations triclosan 
possesses multiple modes of action.
1.4.1.4 Transfer of reduced triclosan susceptibility amongst MRSA strains
As mentioned in the previous section in 1991 Cookson et al. isolated several MRSA 
strains with reduced susceptibility to triclosan (MICs between 2-4 mg/L). These 
strains were isolated from patients who had undergone 2 weeks of treatment with 
nasal mupirocin and daily triclosan baths. In addition to the reduced triclosan 
susceptibility the isolates showed high-level mupirocin resistance with MICs of >512 
mg/L. The authors also report that the reduced triclosan susceptibility could be cured 
by incubation at 42°C and could be transferred to sensitive S. aureus recipients on 
filters or in mixed culture. This transfer was always found to include mupirocin 
resistance. These transfer events have never been observed by others. The description 
of development of and co-transfer of triclosan and mupirocin resistance would be of 
great significance with regards the dissemination of triclosan resistance determinants 
within MRSA.
1.4.2 Mupirocin
Mupirocin is a topical antibiotic with no systemic formulation (it is rapidly 
hydrolyzed to an inactive form by blood plasma). It is a natural product of 
Pseudomonas fluorescens and has a novel structure that classifies it as member of the 
pseudomonic acid family, Figure 1.8. Mupirocin is not readily classified with any 
known group of antibiotics and has a unique mode of action. It was first introduced to 
clinical practice in the UK in 1985 and has since proved effective in the treatment of 
skin infections and in particular the elimination of nasal MSS A and MRSA carriage 
(Hurdle et al., 2005). Consequently, it is the world’s most widely used topical 
antibiotic for the control of MRSA (Boyce, 2001).
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Figure 1.8. Mupirocin is a member of the pseudomonic acid family, (a) It consists of a short fatty 
acid (non-anoic acid) ester linked to monic acid, (b) The tail portion closely resembles the isoleucyl 
moiety of the isoleucyl-adenylate reaction intermediate required for polypeptide synthesis (Hurdle et 
al., 2005).
(a)
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Mupirocin is bacteriostatic, but at lower pH (approximating that of parts of the skin) 
appears to be bactericidal. Mupirocin is in part an analogue of isoluecine and exerts an 
antimicrobial effect by irreversibly and specifically binding bacterial isoleucyl-tRNA 
synthetase (IleS) causing the interruption of polypeptide chain elongation and the 
abolition of protein synthesis (Hughes & Mellows, 1980; Yanagisawa et al., 1994). 
This is followed by a response that results in the biosynthesis of guanosine tetra- and 
pentapeptides. These in turn inhibit the activity of RNA polymerase and down- 
regulate several key processes, including the biosynthesis of stable RNA, DNA, 
protein, and peptidoglycan. So by perturbing several metabolically important 
processes, the action of mupirocin leads to the cessation of bacterial growth and the 
attenuation of virulence in vivo (Hurdle et al., 2005).
1.4.2.1 Emergence of mupirocin resistance
The definitions of mupirocin resistance have varied, but with an increasing number of 
resistant strains having been investigated, it appears that there are 2 resistant 
populations; those showing low-level resistance (MIC = 8-256 mg/L) and those 
showing high-level resistance (MIC >256 mg/L). The former is of tentative clinical 
significance whilst high-level resistance has been implicated in treatment failure 
(Cookson, 1998).
High-level resistance was described shortly after mupirocin was introduced into 
clinical practice (Rahman et al., 1987) and is mediated by the mupA gene, which is 
almost always located on plasmids that vary in size, restriction pattern and ability to 
transfer by conjugation (Thomas et al., 1999; Udo et al., 2001). mupA encodes a 
second, novel staphylococcal IleS and was in existence before the introduction of 
mupirocin (Rahman et al., 1990). This second IleS has a 50% inhibitory concentration 
( I C 5 0 )  of 7000-10,000 jug/L in comparison to 0.9-2.5 |ig/L for the sensitive enzyme 
(Gilbart et al., 1993). Whilst it is well established that mupA encodes plasmid-borne 
high-level resistance a recent report discusses the identification of a chromosomal 
location for mupA. It is surmised that this chromosomal mupA has resulted from the 
integration of a mupirocin resistance plasmid into the S. aureus chromosome (Udo et 
al, 2003).
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Low-level mupirocin resistance is more common than high-level and arises from point 
mutations within the chromosomal isoleucyl-tRNA gene (IleS) of staphylococci. 
Comparison of ileS nucleotide sequences from S. aureus strains expressing mupirocin 
sensitivity and low-level mupirocin resistance has identified mutations correlated with 
low-level resistance. Mutations conferring valine to phenylalanine alterations at either 
residue 588 or 631 were found to impart low-level mupirocin resistance (Antonio et 
al., 2002). Low-level mupirocin resistance has not been found to be transferable 
amongst staphylococci.
1.4.3 Cationic biocides
The broad grouping of cationic biocides include the widely used chlorhexidine (CHX) 
compounds and cetylpyridinium chloride (CPC). The chemical structures of these two 
biocides are quite different with CHX being a bisbiguanide and CPC a quaternary 
ammonium compound (QAC). Both show substantial bactericidal effects against S. 
aureus.
CHX is probably the most widely used biocide in antiseptic products, in particular in 
handwashing and oral products. It is bactericidal and has a broad spectrum of activity. 
CHX damages outer cell wall layers, crosses the cell wall and subsequently attacks 
the cytoplasmic membrane, resulting in cell death (El-Moug et al., 1986). 
Importantly, CHX activity is highly pH dependent and is greatly reduced in the 
presence of organic matter, which precludes its use in some preparations.
Antiseptics and disinfectants based on QACs are used extensively in hospitals and 
other health care settings, as well as in the food industry and consumer healthcare 
products (McDonnell & Russell, 1999; Bjorland et al., 2001). CPC has long been 
known to be a membrane-active agent, with the target site predominantly the 
cytoplasmic membrane (Hugo & Frier, 1969). The cytoplasmic membrane is essential 
many key cellular processes, hence the disruption of the structural organization and 
integrity of the membrane by CPC causes cell death.
Plasmid-encoded resistance to QACs has been found in staphylococci. Resistance to 
QAC among S. aureus and CoNS was first studied and reported in human clinical
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isolates in which three QAC resistance genes have been characterized: qacA, qacB, 
and smr (formerly qacC) (Paulsen et al., 1996a; Paulsen et al., 1996b; Bjorland et al., 
2001). Additionally, plasmid encoded resistance to CPC has been found in S. aureus 
(Thomas & Archer, 1989). CHX shares similarities in mode of action with CPC and 
there is often cross resistance between the compounds. Resistance to CHX has also 
been linked with nucleic acid binding proteins that are frequently plasmid encoded 
(Cookson et a l, 1991a; Russell, 1997).
1.5 S, aureus capsule polysaccharide
Microorganisms that cause invasive disease frequently produce extracellular capsular 
polysaccharides. Capsule production in S. aureus was first described in 1931 (Gilbert, 
1931) although this was restricted to the large, mucoid capsules. S. aureus 
microcapsules (non-mucoid) and the current capsular polysaccharide typing scheme 
were described some 50 years later (Karakawa & Vann, 1982). Since the introduction 
of this scheme approximately 90% of Staphylococcus aureus isolates have been 
shown to produce one of 11 serotypes of capsular polysaccharides. Serotypes CP5 and 
CP8 account for approximately 25% and 50%, respectively, of isolates recovered 
from humans, offering support for their pathogenic significance (O'Riordan & Lee, 
2004). CP5 and CP8 serotypes are considered as microcapsules because they are 
much smaller than those produced by the mucoid serotypes 1 and 2. The 
microcapsules of CP5 and CP8 are extracellular, uronic acid-containing 
polysaccharides that are too small to be visualized by negative staining with India ink, 
Figure 1.9. These two capsules are very similar and differ only in the position of O- 
acetyl groups and the linkages between the amino sugars. The function of CP5 and 
CP8 in S. aureus virulence has been investigated in great depth especially with regard 
their role they take in impeding phagocytosis. Consequently S. aureus capsules have 
been at the centre of research aimed at developing a S. aureus vaccine (Fattom et al.,
2004). In addition to their role in avoiding host defence one author has also reported 
upon the potential for the capsule polysaccharide of mucoid S. aureus to provide a 
level of protection from chemotherapeutic treatments by posing a permeability barrier 
to antimicrobial agents (Kolawole, 1984).
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Figure 1.9. S. aureus microcapsules are too small to be viewed by negative staining, (a) Hence 
transmission electron microscopy (TEM) is used to view the capsule polysaccharide, (i) CP5 
microcapsule and (ii) acapsular S. aureus. Adapted from O'Riordan and Lee (2004) (b) The structures 
of S. aureus capsule polysaccharide types 5 and 8.
(a)
(b)
CP5; —►4)-P-D-MaiV7NAcA3Ac(1^4)-a-L-Fuc/7NAc-(l-^3)-p-D-FucpNAc-(l 
CP8; —>3)-p-D-Man^NAcA4Ac(l—►3)-a-L-Fuc/?NAc-(l—>3)-p-D-FucpNAc-(l
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1.6 Small colony variants of S'. aureus
The first description of a bacterial small colony variant (SCV) was in 1910, when an 
abnormal form of Eberthella typhosa (now known as Salmonella enterica) was 
reported (Jacobsen, 1910). Subsequently, SCVs have been described for a broad 
variety of genera and species, including the 1957 description of an S. aureus SCV 
(Jensen, 1957). Since their discovery S. aureus SCVs have been associated with 
persistent, recurrent and antibiotic resistant infections. In particular isolates from these 
unusually tenacious infections have harboured mutations in genes responsible for 
biosynthesis of thymidine and electron transport chain (ETC) electron carriers.
1.6.1 Characteristics of S. aureus small colony variants
S. aureus SCVs appear during exposure to antimicrobial compounds, most commonly 
the aminoglycosides. They are slow growing and appear as small colonies on tryptic 
soy or Mueller Hinton agar. The characteristic small colonies are approximately one 
tenth the size of wild type strains. Although many alterations in bacterial metabolism 
cause slow growth, only a limited number of defects are found in SCVs from clinical 
specimens, with two groups of SCVs being consistently recovered: SCVs that are 
deficient in electron transport and SCVs that are deficient in thymidine biosynthesis 
(Proctor et a l , 2006). Electron transport-deficient SCVs are menaquinone or haemin 
auxotrophs. Menaquinone and the prosthetic group haemin are essential components 
of staphylococcal ETC; menaquinone is the first electron acceptor, accepting electrons 
from FADH2 or the NADH oxidase complex, whilst haemin is the component of 
cytochromes that receive electrons from menaquinone. Menaquinone and heme are 
synthesized using enzymes encoded by the men and heme operons, respectively (Tien 
& White, 1968).
Thymidine-auxotrophic SCVs are less well understood. Their phenotype is very 
similar to ETC-deficient SCVs, yet the link between genotype and phenotype is less 
explicit. It is possible that thymidine-auxotrophs are double mutants, because they can 
be recovered from pus, which is a plentiful source of thymidine for S. aureus. The 
mechanisms of thymidine-dependent SCVs persistence have not been elucidated fully,
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however they have been reported to show altered tricarboxylic acid cycle and acetic 
acid metabolism (Chatterjee et al., 2007).
A typical pleiotropic phenotype is associated with SCVs, including slow growth rate, 
absence of pigmentation, reduced range of carbohydrate utilization and a lack of 
exoenzyme production (including virulence factors). In ETC-defective SCVs this 
phenotype can be directly related to the interruption of electron transport (McNamara 
& Proctor, 2000), Figure 1.10. Without oxidative respiration the S. aureus cells can 
produce ATP only through fermentation. This process is significantly less efficient, 
resulting in a severe shortage in ATP. Biosynthesis of cell components essential for 
growth, such as cell wall teichoic acid, require ATP. In addition, ATP is required for 
many cellular functions such as uptake of amino acids and carbohydrates and in the 
structure and maintenance of nucleic acids. Therefore, a lower capacity to produce 
ATP slows growth and results in bacteria that produce small colonies. Interestingly 
anaerobic growth of S. aureus mimics the SCV phenotype, because under such 
conditions menaquinone is not synthesized. This is in contrast to E. coli which has 
two quinines, menaquinone for anaerobic conditions and ubiquinone which is used 
when oxygen is present, enabling wild-type growth under anaerobic conditions.
ATP is required for carotenoid biosynthesis, hence SCVs are non-pigmented 
(McNamara & Proctor, 2000). Alteration of carbohydrate utilization, including 
manitol, can also be related to defects in electron transport. S. aureus cells devoid of 
an ETC can generate ATP directly from glucose; however, the utilization of other 
sugars requires an intact tricarboxylic acid cycle. The interruption of electron 
transport results in down-regulation of the tricarboxylic acid cycle, blocking the 
uptake of complex carbohydrates. The reduction in cellular ATP levels indirectly 
blocks the first step of the phosphotransferase system inhibiting the use of manitol, 
xylose, lactose, sucrose, maltose, and glycerol (Reizer et al., 1988).
In general, interruption of electron transport alters bacterial virulence factor 
production. For example, staphylococcal SCVs show a consistent reduction in a-toxin 
production. Interestingly, this phenomenon occurs even though SCV cells are able to 
enter into stationary phase, a situation when agr (see section 1.1.2) is active and 
toxins are produced (von Eiff et al., 1997b). Furthermore, a hemB mutant of S. aureus
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Figure 1.10. Relationship between electron transport and the small colony variant phenotype in 
S. aureus. Defects in electron transport limit the amount of ATP that is used for is available for cell 
wall biosynthesis, which leads to a slower growth rate and, subsequently, smaller colonies. The dearth 
of energy also decreases pigment formation and reduces the membrane potential (A'F), which results in 
decreased uptake of cationic compounds. Reproduced from Proctor et al. (2006).
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(used as a model for studying ETC-deficient SCVs) displayed more fibrinogen 
binding sites than the parent strain. SCV internalization is mediated by fibronectin 
bridging between the bacterial fibronectin-binding proteins and the receptor aspi- 
integrin, which is present at the surface of eukaryotic cells. Importantly, the lack of a- 
toxin production can work in combination with the greater number of fibrinogen 
binding sites to enable SCVs to enter, rather than lyse, host cells (Dziewanowska et 
al., 1999; Sinha et al., 1999; Proctor et al., 2006). Survival within host cells shields 
the bacteria from host defence systems and antibiotics unable to cross eukaryotic cell 
membranes, providing conditions highly conducive for persistent colonization.
1.6.2 Antimicrobial resistance in SCVs
SCVs show resistance to a range of chemotherapeutics. However, resistance in SCVs 
does not follow the ‘classic’ mechanisms of resistance, as discussed in section 1.2.3. 
Rather, resistance is a direct consequence of defects in electron transport and ATP 
synthesis (Proctor, 1998). ETC disruption and attenuated ATP synthesis confer 
resistance in three main ways: decreased rate of cell wall biosynthesis, reduced uptake 
of positively charged compounds and internalization within host cells. As discussed in 
the previous section ATP is severely limited in SCV cells and as a result cell wall 
biosynthesis is greatly reduced. This reduced biosynthesis is associated with an 4-fold 
increase in MIC of cell wall specific antibiotics, such as penicillin (McNamara & 
Proctor, 2000).
In the absence of a functional ETC, glycolytic ATP production produces only 60-70% 
of the normal trans-membrane potential (A'F). Uptake of cationic antimicrobial 
compounds by S. aureus is enabled by the accumulation of the compounds on a 
negatively charged bacterial membrane. The diminished A'F of SCVs reduces this 
accumulation, and hence uptake, of positively charged antimicrobials. Reduced 
uptake by SCVs results in a 10-30 fold increase in MIC of aminoglycosides, 
lantibiotics, and cationic peptides (Kahl et al., 1996; Koo et al., 1996; McNamara & 
Proctor, 2000; Proctor et al., 2006). The potency of other antimicrobials may also be 
affect by changes in A'F, however this process affects only those compounds that 
require a large membrane electrochemical gradient for uptake.
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The survival of SCVs within host cells also reduces the efficacy of antimicrobial 
therapeutics through the limited ability of these compounds to cross eukaryotic 
membranes; the host cell acts as a barrier against the drug. Of further concern is the 
substantial decrease in susceptibility SCVs show when adhering to a surface. SCVs 
adhering to fibronectin covered surfaces were shown to exhibit a > 100-fold increase 
in MIC of oxacillin, vancomycin and fleroxacin. And when SCVs were both adhering 
to a surface and in stationary phase of growth, two conditions that reduce metabolic 
activity, they were found to be fully resistant to oxacillin and vancomycin, with 
fleroxacin exhibiting very limited effects (Chuard et al., 1997).
In addition to the widely studied aminoglycosides, a variety of other compounds can 
be used to select for S. aureus SCVs. These include inhibitors of cell-wall synthesis 
(vancomycin, cycloserine, and bacitracin), other antibiotics (e.g. chloramphenicol, 
trimethoprim-sulfamethoxazole, streptomycin), crystal violet, and barium chloride 
(Seligman, 2006).
1.6.3 Clinical complications of SCVs
It is postulated that SCVs are spontaneous mutants that are selected in vivo by 
antimicrobial exposure, their ability to survive within host cells and the low levels of 
free menaquinone and haemin. Patients infected with SCVs often have a history of 
long-term antibiotic treatment. S. aureus SCVs can cause tenacious infections. 
Individuals with SCV infections can experience prolonged disease-free periods that 
are punctuated by recurrences of normal colony morphology revertants, that are 
susceptible to previously used antimicrobial chemotherapeutics. Hence, patients can 
enter a prolonged cycle of infected and seemingly infection-free periods, Figure 1.11.
SCVs further complicate infection control and antibiotic prescribing practice by 
obscuring the aetiology of the infection and by their altered antibiogram. As discussed 
below, the altered phenotype of SCVs greatly complicates the bacterial isolation and 
identification procedures required to make a diagnosis and implement the appropriate 
therapy. Whilst the incidence of SCVs in clinical specimens has been found to range 
from 1% to more than 70% in different studies (Acar et a l, 1978; von Eiff et al.,
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Figure 1.11. The cycle of recurrent SCV infections. Following diagnosis of an S. aureus infection 
antibiotics are administered. Whilst the therapy appears to clear the infection, the antibiotic is actually 
selecting for the SCV form of the organism. Due to reduced expression of virulence factors SCV 
infections have few symptoms. Consequently, clinicians believe the infection has cleared and antibiotic 
therapy is stopped. This removes the selective pressure that maintains the S. aureus cells in their SCV 
form, and they are free to revert to wild-type. The symptoms recur and the cycle starts again.
Antibiotic therapy u
L □Selection for SCVs
Exotoxins Adhesins Internalization
Drug 
resistance
Rapid
growth
Invasins Slow
growth
[ Reversion to wild-type
Cessation of antibiotic therapy
56
1997a; Kahl et al., 2003), it is thought that SCVs are often overlooked or 
misidentified during routine clinical microbiology procedures. Although data 
concerning the virulence of SCVs are ambiguous, infections have proven fatal 
(Pelletier et al., 1979; Seifert et al., 1999; Jonsson et al., 2003). Hence, misdiagnosis 
may have severe repercussions.
Whilst S. aureus can initiate a variety of infections, it appears that the two main types 
of SCV (ETC-deficient and thymidine auxotrophic) are associated with particular 
types of infection. ETC-deficient SCVs are associated with osteomyelitis, sinusitis, 
muscle abscesses and device related infections (Proctor et al., 1995; Spanu et al.,
2005). Meanwhile, thymidine SCVs are seen commonly in cystic fibrosis patients 
(Kahl et al., 1998; Haussler et a l, 1999; Kahl et al., 2003; Kahl et al., 2005).
Interestingly, a recent study has shown that the presence of Ps. aeruginosa selects for 
the growth of S. aureus as SCVs (Hoffman et al., 2006). This has been supported by a 
12-month prospective study which found patients positive for S. aureus SCVs were 
significantly more commonly co-colonized with Ps. aeruginosa (Besier et al., 2007). 
Lower weight, advanced age and prior use of trimethoprim-sulfamethoxazole were 
also identified as independent risk factors for S. aureus SCV positivity in cystic 
fibrosis patients (Besier et al., 2007).
1.6.4 Practical complications of S. aureus small colony variants
SCVs pose several complications to practical work. Identification of the cells is 
complicated by numerous factors including atypical colony morphology, slow growth 
and aberrant biochemical tests. The standard biochemical tests for the identification of 
S. aureus are made obsolete by the change in antibiogram, carbon source utilization 
and virulence factors; SCVs show a very slow coagulase reaction and much reduced 
haemolytic activity -  two factors regularly used in S. aureus identification. As a result 
staphylococcal SCVs are difficult to recognize and are often misidentified as CoNS or 
varidans streptococci (McNamara & Proctor, 2000). Many selective agars and 
commercially available systems lack the reliability to identify and characterize S. 
aureus SCVs (Kipp et al., 2005; Seligman, 2006). Further ambiguity is provided by 
the instability of their phenotype. The doubling time of a reverted bacterium,
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depending on the growth medium, is six to nine times faster than that of SCVs, 
allowing revertants to out compete the SCVs during culture.
SCVs, depending on the mutation, revert to a wild type phenotype at various rates. 
For example, slow growing variants that follow penicillin treatment often revert on a 
single passage through fresh media. In contrast, streptomycin-induced SCVs are often 
stable through more than ten passages on fresh media (McNamara & Proctor, 2000).
The elucidation of antimicrobial susceptibility is also problematic with SCVs; slow 
growth often invalidates disc diffusion or automated methods. Currently, detection of 
the mecA gene by PCR and the MRSA-Screen latex agglutination test using higher 
colony numbers are the only methods shown to reliably and rapidly detect methicillin 
resistance in SCVs (Kipp et al., 2004).
1.7 Aims and objectives of this study
The information provided in this chapter demonstrates clearly that the subject of 
biocide resistance in bacteria is an area where much further research is required. 
Required areas of study are the development of resistance, mechanisms of biocide 
action and mechanisms of resistance (McDonnell & Russell, 1999; Russell, 1999; 
White & McDermott, 2001; Russell, 2002a). The possibility of linked biocide and 
antibiotic resistance remains contentious (Walsh et al., 2003; Braoudaki & Hilton, 
2004; Sattar, 2006; Yazdankhah et al., 2006), but given the scale of the problem with 
antibiotic resistance, it is clear that continued study in this area is also essential 
(Fraise, 2002).
The objective of this study, involving the important biocide triclosan and clinically 
significant organisms, was to investigate aspects of triclosan resistance and the 
potential role of horizontal gene transfer in S. aureus. This was achieved by the 
following aims:
• Investigate the role of clinically significant S. aureus capsule polysaccharides 
upon biocide susceptibility.
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• Characterize the development of reduced susceptibility to triclosan in S. 
aureus.
• Identify whether reduced susceptibility to triclosan involves a single 
mechanism and if this is associated with Darwinian fitness effects.
• Investigate the potential for a reduction in triclosan susceptibility affecting 
resistance to other antimicrobials.
• Assess the incedence of reduced triclosan susceptibility in the community.
• Identify whether triclosan susceptibility in S. aureus is typical of 
staphylococci, or if there are differences amongst these species.
• Identify if there is a relationship between mupirocin resistance and reduced 
susceptibility.
• If a relationship is identified, is the resistance transferable amongst S. aureus?
• Investigate how triclosan affects gene transfer in staphylococci.
Whilst completing the work necessary to achieve these aims we discovered an 
intriguing feature of S. aureus dining exposure to triclosan: the development of SCVs. 
Therefore, we also aimed to characterize this phenomenon as follows:
• Characterize the development of S. aureus SCVs in the presence of triclosan.
• Investigate the phenotypic and lifestyle properties of triclosan-induced SCVs.
• Identify the potential for SCVs to acquire and disseminate antimicrobial 
resistance by horizontal gene transfer.
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Chapter 2
Susceptibility of capsular Staphylococcus aureus strains to some 
antibiotics, triclosan and cationic biocides
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Sir,
Approximately 90% of Staphylococcus aureus isolates produce one of 11 serotypes of 
capsular polysaccharides. Serotypes CP5 and CP8 account for ~25% and 50%, 
respectively, of isolates recovered from humans, offering support for their pathogenic 
significance (O'Riordan & Lee, 2004). The importance and relevance of these capsule 
types is confirmed by the development of a conjugate vaccine, StaphVAX™ that 
includes type 5 and 8 capsule polysaccharides (Fattom et al., 2004). CP5 and CP8 
serotypes are considered as microcapsules because they are much smaller than those 
produced by the mucoid serotypes 1 and 2. The microcapsules of CP5 and CP8 are 
extracellular, uronic acid-containing polysaccharides that are too small to be 
visualized by negative stains such as India ink. These two capsules are very similar 
and differ only in the position of 0-acetyl groups and the linkages between the amino 
sugars. The function of CP5 and CP8 in S. aureus virulence has been investigated in 
great depth, especially with regard to their role in impeding phagocytosis (O'Riordan 
& Lee, 2004). However, few authors have reported upon the potential for a capsule 
polysaccharide to present a permeability barrier to antimicrobial agents. Gram- 
positive bacteria possess a cell wall that is usually permeable and does not limit the 
incursion of antimicrobials. However, resistance through reduced penetration has been 
shown to occur, for example vancomycin-intermediate resistant S. aureus (VISA) 
strains produce a distinctly thickened cell wall (Lambert, 2002). Furthermore, in 1984 
Kolawole discussed the effect of a mucoid capsule upon disinfectant and antiseptic 
susceptibility in S. aureus. He concluded that the thick capsule, as associated with 
serotypes CPI and CP2, does provide a permeability barrier to common biocides but 
fell short of testing the more common and clinically important serotypes. We wish to 
report how CP5 and CP8 microcapsules affect the susceptibility of S. aureus to 
several antibiotics and three widely used biocides: triclosan, chlorhexidine gluconate 
and cetylpyridinium chloride.
A range of 14 antibiotic discs were purchased from Oxoid (Basingstoke, UK) and 
used to analyse S. aureus Reynolds and two isogenic capsule mutants. Antibiotic 
susceptibility was established as per the BSAC standardized disc susceptibility testing 
methodology (Andrews, 2001a) (Table 1). The MICs of nine of these clinically 
relevant antibiotics were elucidated by Etest strips (AB Biodisk, Sweden) according 
to the manufacturer’s recommendations. MICs for the three biocides were calculated
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Table 1. Antibiotic susceptibility of the three S. aureus capsule strains alongside the control strain NCTC 6571 for which the antibiogram is known.
Strain Pen Oxa
Antibiotic susceptibility
Van Mup Chi Tet Ery Gen Fd Amp Cec Cro Rif Tec
CP5 R S S S S S S S S R R S S S
CP8 R s S S S S S S S R R S S S
CP- R s S S S S R s S R R S S S
6571 S s S S S S S s S S S s S S
R, resistant; S, susceptible; Pen, penicillin; Oxa, oxacillin; Van, vancomycin; Mup, mupirocin; Chi, chloramphenicol; Tet, tetracycline; Ery, erythromycin; 
Gen, gentamicin; Fd, fusidic acid; Amp, ampicillin; Cec, cefaclor; Cro, ceftriaxone; Rif, rifampicin; Tec, teicoplanin.
using Iso-Sensitest agar (Oxoid, Basingstoke, UK), multipoint inoculator (Denley; 
Mast Diagnostics, Bootle, UK) and incubation in air at 37°C for 18-20 h, in 
accordance with BSAC guidelines (Andrews, 2001b). Triclosan (Irgasan DP300) was 
a gift from Ciba Speciality Chemicals; chlorhexidine gluconate and cetylpyridinium 
chloride were purchased from ICN Biomedicals Inc. (Ohio, USA). Of the three S. 
aureus Reynolds strains, one was wild-type, expressing a serotype CP5 capsule, one a 
mutant expressing CP8 and the third a second mutant, lacking a capsule (CP-) 
(Nilsson et al., 1997). The acapsular Reynolds strain was constructed by replacing the 
serotype-specific capsule genes cap5HIJK on the bacterial chromosome with an 
erm{B) gene, conferring erythromycin resistance. S. aureus NCTC 6571 (Oxford) was 
included alongside the capsule strains as a control. The MICs were defined as the 
lowest concentration of antimicrobial with which there was no visible growth of the 
organism and are shown in Table 2, along with the Etest data. In addition, all strains 
were investigated for P-lactamase production by nitrocefin stick (Oxoid, Basingstoke, 
UK; Table 2).
The antibiogram for NCTC 6571, as deduced by antibiotic disc susceptibility testing, 
was as expected. No difference in antibiotic susceptibility was observed between the 
capsule strains other than for erythromycin, resistance to which was found in CP-. 
This was as expected due to the construction of the CP- strain by disruption of the 
serotype-specific capsule genes with an erm(B) gene. The nitrocefin test implies that 
penicillin and ampicillin resistance is conferred by p-lactamase production in S. 
aureus Reynolds. MICs for NCTC 6571 were within plus or minus one two-fold 
dilution of the expected MIC (Andrews, 2001b). The capsule strains all demonstrated 
MICs for each antimicrobial within plus or minus one two-fold dilution of each other. 
The only exception to this was—once again—erythromycin, confirming the results of 
the susceptibility disc test. From this we deduced that there is no significant difference 
between the antibiotic and biocide susceptibilities of the strains investigated herein. 
Consequently, we conclude that the capsule polysaccharide serotypes CP5 and CP8 
do not present a permeability barrier to the antibiotics used in this investigation, or to 
triclosan, chlorhexidine gluconate or cetylpyridinium chloride.
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Table 2. MICs for S. aureus Reynolds expressing either capsule serotype CPS, CP8 or C P - (acapsular).
MIC (mg/L)
Strain P-lactamase Pen8 Oxa8 Van8 Mup8 Chi8 Tet8 Ery8 Gen8 Fd8 Tricb CHXb CPi
CP5 + 16 0.75 1 0.125 6 0.28 0.38 0.25 0.064 0.13 2 2
CP8 + 16 0.75 1 0.125 6 0.38 0.38 0.25 0.064 0.13 2 2
CP- + 16 0.75 1 0.125 4 0.5 >256 0.19 0.064 0.13 2 2
6571 . 0.023 0.125 1 0.19 4 0.064 0.19 0.19 0.094 0.13 2 2
“Calculated by Etest (AB Biodisk, Sweden). 
b Calculated in accordance with BSAC guidelines.
Pen, penicillin; Oxa, oxacillin; Van, vancomycin; Mup, mupirocin; Chi, chloramphenicol; Tet, tetracycline; Ery, erythromycin; Gen, gentamicin; Fd, fusidic acid; 
Trie, triclosan; CHX, chlorhexidine gluconate; CPC, cetylpyridinium chloride.
These results indicate that whereas S. aureus capsule polysaccharides are implicated 
in virulence, they are not involved in conferring reduced antibiotic or biocide 
susceptibility. Clinical implications are pertinent through the choice of clinically 
relevant antibiotics and biocides regularly used in the hospital setting.
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Chapter 3
FabI mutations, drug resistance and fitness costs of reduced triclosan 
susceptibility in Staphylococcus aureus
Submitted for publication in the Journal of Antimicrobial Chemotherapy
Synopsis
Objectives: To evaluate the impact of mutations conferring reduced triclosan 
susceptibility upon antimicrobial susceptibility and fitness in Staphylococcus aureus. 
Methods: We evaluated the effects of mutation towards reduced triclosan 
susceptibility upon antimicrobial susceptibility and fitness in methicillin-susceptible 
and methicillin-resistant S. aureus. Logio reductions in viable cell numbers and 
potassium leakage were used to assess susceptibility to the bactericidal effects of 
triclosan. The fab l gene of reduced susceptibility mutants was sequenced and their 
fitness analyzed by investigating growth and relative competitive fitness.
Results: Several mutants with reduced susceptibility to triclosan (MIC of 1-2 mg/L) 
were isolated, most of which possessed a novel triclosan resistance mutation in the 
fabl gene, C284T. This mutation confers an alanine to valine substitution at the 95 
residue of the Fabl protein. A reduced susceptibility strain with an unaltered fab l gene 
was also isolated. These mutants showed reduced susceptibility to the lethal effects of 
triclosan at 7.5 mg/L, but were as susceptible as the wild type at >20 mg/L. These 
mutations did not significantly affect bacterial fitness and did not affect susceptibility 
to a range of antimicrobials.
Conclusions: A lack of fitness cost supports the potential for development of low- 
level triclosan resistance. However, this level of resistance is of ambiguous 
significance and does not affect susceptibility to other antimicrobials. The description 
of a reduced susceptibility mutant without an associated fab l mutation and evidence 
of triclosan-induced cytoplasmic membrane damage indicates that the fabl protein is 
not the sole target for triclosan, providing weight to the argument that whilst fabl is 
undoubtedly a target for low-level triclosan, it is also has other modes of action.
Introduction
The biocide triclosan (Irgasan DP300; 2,4,4'-trichloro-2'-hydroxydiphenyl ether) is an 
antimicrobial used broadly in personal care and household applications, mainly in bar 
soap, toothpastes and mouthwashes, but also in hand disinfectants and other consumer 
health care products. Additionally, triclosan has found some use in the home through 
incorporation in domestic plastics such as chopping boards. It has activity against a 
broad spectrum of Gram-negative and Gram-positive microorganisms, including the
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common nosocomial pathogens Escherichia coli, Staphylococcus aureus and 
Enterobacter spp. Following a successful application in 19871 and more recent 
reports, triclosan has been shown to be effective for the control of methicillin-resistant 
S. aureus (MRSA). ' Consequently, 2% triclosan baths are now one of the 
recommended rationales for skin decolonisation of MRSA carriers.6
Triclosan is an important antimicrobial and due to its classification as a biocide, it was 
with some furore that resistance to the compound was reported.7 MRSA strains were 
isolated with MICs of 2-4 mg/L from patients treated with daily triclosan baths; this 
compares with MICs of 0.001-0.1 mg/L for sensitive strains. Subsequently, 7.5% of S. 
aureus clinical strains were found to have triclosan MICs of at least 1 mg/L.8 In 1998 
McMurry et al.9 postulated that, in contradiction to the biocide dogma, triclosan acts 
on a specific cellular target; traditionally biocides have been viewed to act through 
multiple cytoplasmic and membranous targets.10 The lack of a discrete mechanism of 
action makes the acquisition of cellular resistance unlikely. However, it has now been 
shown that a mode of action of triclosan is via inhibition of enoyl-acyl carrier protein 
(ACP) reductase (Fabl) in organisms such as & aureus and E. coli that rely on this 
enzyme to execute the final step in the elongation cycle of bacterial fatty acid 
biosynthesis.9,11'13 In fact it appears that the mode of action of triclosan is 
concentration dependent;14'16 low-level triclosan targets Fabl but at bactericidal 
concentrations it appears to act upon multiple non-specific targets and has been shown 
to intercalate into the cell wall causing it to become destabilised, compromising its 
functional integrity.17,18
Two reduced triclosan susceptibility phenotypes are mediated by alterations to Fabl; 
MICs raised above 0.016 mg/L result from a three- to five-fold increase in the levels 
of Fabl production, whereas further reduced susceptibility (MIC = 1 to 2 mg/L) results 
from alteration of the native Fabl as a consequence of spontaneous mutations in the 
fab l gene in combination within increased enzyme production.19 A number of 
predicted alterations to the Fabl amino acid sequence that confer reduced triclosan 
susceptibility have been described.19'21 The significance of such increases in MIC is 
uncertain. These MICs are far below the in-use concentrations of triclosan in hand 
wash, bath formulations (0.1 to 0.3%, or 1000 to 3000 mg/L, respectively) and surface 
disinfectants (0.1 to 1%, or 1000 to 10,000 mg/L, respectively), for hospital wash
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applications for MRSA eradication even 2% (20,000 mg/L) triclosan is 
recommended.6 These in-use concentrations are magnitudes higher than the 
concentrations of triclosan needed to inhibit raised MIC isolates described to date. 
Additionally, during clinical or domestic use, triclosan is delivered typically as part of 
complex formulations containing various combinations of surfactants, detergents, 
chelating agents and wetting agents, which support the antimicrobial activity of 
triclosan and ultimately affect the susceptibility of microorganisms exposed to it. 
However, in nature bacteria often grow as complex biofilms and this can impact upon 
antibacterial susceptibility,22 residual levels of triclosan may be closer to the MICs of 
reduced susceptibility strains and the presence of triclosan provides a selection 
pressure for acquisition of resistance by horizontal transfer, if this is possible. More 
recently, low-level resistance to triclosan has been described in small colony variants 
(SCV) of S. aureus 23 The mode of reduced susceptibility to triclosan in SCVs is yet 
to be fully understood, however their fab l gene sequences were unchanged compared 
to their parent, implying that alterations in the Fabl protein were not involved.
Mutations in drug targets that confer resistance to antimicrobials can impose fitness 
costs on the organism.24 The occurrence of some fab l mutations in clinical 
staphylococcal isolates showing reduced triclosan susceptibility appears to reflect a 
low-cost of these mutations in terms of bacterial fitness. In contrast, other fabl 
mutations may impose fitness costs, precluding their appearance.
There is a paucity of data discussing the impact of reduced susceptibility upon the 
clinical efficacy of triclosan and to what extent resistant strains will impact upon 
healthcare. Herein we discuss the molecular basis of reduced triclosan susceptibility 
in S. aureus and investigate its associated fitness costs. Furthermore, we describe the 
lethal effects of triclosan upon wild type and reduced susceptibility S. aureus and 
discuss whether triclosan does truly have a single cytoplasmic target.
Materials and Methods
Unless otherwise stated, all concentrations are % weight/volume. All experiments 
were performed in triplicate (n-3) and unless otherwise stated results are presented as 
mean ± standard error of the mean (s.e.).
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S. aureus strains and growth conditions. Table 3.1 describes the 37 S. aureus strains 
used within this investigation. Prior to experimentation all strains were confirmed as 
S. aureus by streaking on Vogel-Johnson agar (VJA; Oxoid) and latex-agglutination 
test for extra-cellular coagulase (Staphylase test; Oxoid). Strains were stored in 50% 
glycerol at -80°C and, when required, maintained on either nutrient agar (NA; Oxoid), 
Iso-Sensitest agar (ISA; Oxoid) or Mueller Hinton agar (MHA; Oxoid). Over-night 
cultures were prepared by inoculation of 10 mL nutrient broth (NB; Oxoid) or Iso- 
Sensitest broth (ISB; Oxoid) with colonies from a streak plate and incubation in an 
orbital shaker at 37°C for 15 h.
S. aureus mutants with reduced susceptibility to triclosan were isolated by the growth 
of S. aureus strains to mid-log phase in 10 mL ISB at 37°C. At this point pre-warmed 
triclosan solution (100 mg/L) was added to achieve a final concentration of 0.01 
mg/L, further incubation was performed for 6 h at 37°C. Cells were harvested by 
centrifugation (5000 rev/min for 15 min), washed and resuspended in 10 mL quarter- 
strength Ringer’s solution (Oxoid). 100 pL volumes of 109 cells/mL were spread on to 
the surface of ISA plates containing 0-10 mg/L triclosan. Plates were incubated for 48 
h at 37°C. Suspected reduced triclosan susceptibility mutants were observed as 
pigmented colonies on plates containing triclosan and confirmed as S. aureus by 
streaking onto VJA, coagulase test and multiplex PCR, as described previously.25 
Such colonies were maintained on NA supplemented with 1 mg/L triclosan, from 
which over-night cultures prepared in NB or Mueller Hinton broth (MHB; Oxoid) 
with 1 mg/L triclosan were made when required. Stability of reduced triclosan 
susceptibility was examined by sub-culture in triclosan-free NB with sporadic testing 
for triclosan MIC. The phenotype was designated as stable if no reduction in MIC was 
seen following a course of 10 sub-cultures. Triclosan powder (Irgasan DP300) was a 
gift from Ciba Spezialitatenchemie Grenzach GmbH (Grenzach-Wyhlen, Germany) 
and was dissolved in sterile dimethylsulphoxide (DMSO). DMSO concentrations 
were maintained below 1% in growth media and DMSO controls were run alongside 
experiments where required.
Biocide and antibiotic susceptibility. MICs for three biocides, triclosan, chlorhexidine 
gluconate (CHX; ICN Biomedicals Inc., USA) and cetylpyridinium chloride (CPC;
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Table 3.1. S. aureus strains used during this investigation.
S. aureus strain Description Reference/Source
NCTC6571 Oxford strain, isolated in 1940. Highly susceptible to many antimicrobials NCTC
Mu50 Genome sequenced VISA strain 60
NCIMB9518 Triclosan susceptible industrial strain 61
9518T1 Low-level reduced triclosan susceptibility mutant o f  NCIMB9518 61
9518T2 Low-level reduced triclosan susceptibility mutant o f  NCIMB9518 61
9518T3 Low-level reduced triclosan susceptibility mutant o f  NCIMB9518 61
9518T4 Low-level reduced triclosan susceptibility mutant o f  NCIMB9518 This study
9518Rif Rifampicin resistant mutant o f  NCIMB9518 This study
F89 High-level mupirocin resistant strain 62
F89T1 Low-level reduced triclosan susceptibility mutant o f  F89 This study
24500 Clinical MRSA isolate UHW, Cardiff
24500T1 Low-level reduced triclosan susceptibility mutant o f  24500 This study
27343 Clinical MRSA isolate UHW, Cardiff
27343T1 Low-level reduced triclosan susceptibility mutant o f  27343 This study
24532 Clinical MRSA isolate UHW, Cardiff
27393 Clinical MRSA isolate UHW, Cardiff
27368 Clinical MRSA isolate UHW, Cardiff
24497 Clinical MRSA isolate UHW, Cardiff
24467 Clinical MRSA isolate UHW, Cardiff
22373 Clinical MRSA isolate SDGH, Swansea
223065 Clinical MRSA isolate SDGH, Swansea
223021 Clinical MRSA isolate SDGH, Swansea
224035 Clinical MRSA isolate SDGH, Swansea
224005 Clinical MRSA isolate SDGH, Swansea
223232 Clinical MRSA isolate SDGH, Swansea
223278 Clinical MRSA isolate SDGH, Swansea
223058 Clinical MRSA isolate SDGH, Swansea
269263 Clinical MRSA isolate with low-level mupirocin resistance UHW, Cardiff
260379 Clinical MRSA isolate with low-level mupirocin resistance UHW, Cardiff
266261 Clinical MRSA isolate with low-level mupirocin resistance UHW, Cardiff
260556 Clinical MRSA isolate with low-level mupirocin resistance UHW, Cardiff
247378 Clinical MRSA isolate with high-level mupirocin resistance UHW, Cardiff
259658 Clinical MRSA isolate with high-level mupirocin resistance UHW, Cardiff
260711 Clinical MRSA isolate with high-level mupirocin resistance UHW, Cardiff
260989 Clinical MRSA isolate with high-level mupirocin resistance UHW, Cardiff
269026 Clinical MRSA isolate with high-level mupirocin resistance UHW, Cardiff
B 17637 Clinical MRSA isolate with high-level mupirocin resistance UHW, Cardiff
UHW, University Hospital of Wales; SDGH, Singleton District General Hospital.
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ICN Biomedicals Inc., USA), were calculated following the guidelines of the British 
Society for Antimicrobial Chemotherapy (BSAC).26 Etest® strips (Bio-stat Ltd, UK) 
were utilized to attain the MIC for antibiotics, as per the manufacturer’s directions. 
Significant effect of mupirocin resistance upon triclosan MIC was analysed by 
Kruskal-Wallis test. Significant effect of mutation to reduced triclosan-susceptibility 
upon antimicrobial susceptibility was analysed by analysis of variance (ANOVA).
Calculation of mutation rate. The rate of mutation towards reduced triclosan 
susceptibility was assessed by growth of S. aureus strains to late-log phase in 10 mL 
NB at 37°C. At this point cells were harvested by centrifugation (5000 rev/min for 15 
min), washed, resuspended in quarter-strength Ringer’s solution and adjusted to 1010 
cells/mL. 100 jiL  volumes of 1010 cells/mL were spread on to the surface of NA agar 
plates containing 0.1, 0.5, 1.0, 2.0 and 10 mg/L triclosan. Additionally, dilutions of 
the cultures were plated onto NA in order to calculate the number of wild type CFU. 
Plates were incubated for 48 h at 37°C. Colonies that grew on triclosan plates were 
counted and a selection streaked on VJA and analysed for coagulase to confirm as S. 
aureus. Frequencies were expressed as numbers of mutants per CFU.
Sequencing o f the fab l gene. Chromosomal DNA was extracted as described 
previously27 and the fabl gene sequenced as per Seaman et alP  Sequence 
construction and analyses were performed using BioEdit version 7.0.5.3.
Bactericidal effects o f triclosan. The bactericidal effects of triclosan on wild-type S. 
aureus and their reduced susceptibility mutants were compared as previously 
reported except the inoculum was adjusted to 10 cfu/mL and sampling was 
continued up to 40 min. Log reduction was then calculated from logioNc - logioNt, 
where Nc and Nt represent the numbers of cfu/mL in the control and triclosan 
solutions, respectively. The same method was used when assessing the lethal effects 
of Irgacide LP10 except a stock solution of Irgacide LP10 (pH 5.5, 10% triclosan, 4% 
sodium lauryl sulphate; gift from Ciba Spezialitatenchemie Grenzach GmbH) was 
used to achieve final triclosan concentrations of 7.5><10'5, 2.0x1 O'4, 0.2 and 2.0%.
To investigate potassium ion leakage from cells during exposure to triclosan, cultures 
were grown on the surface of an NA plate at 37°C for 24 h. Cells were then emulsified
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in 5 mL of 0.9% NaCl (Sigma), washed three times by centrifugation and resuspended 
in 100 mL of 0.9% NaCl, with the appropriate concentration of triclosan, to give a 
bacterial concentration of 109 cfu/mL. At timed intervals, 10 mL was removed and 
filtered through a 0.2 pm cellulose nitrate filter to remove cellular material. The 
potassium concentration in the supernatant was then measured using an atomic 
absorption spectrophotometer (Varian Spectra AA100). As control experiments, cells 
were incubated in triclosan-free NaCl solution (negative control) and treated with 
lysostaphin 100 mg/L (Sigma) for 30 min at 30°C and heated at 100°C for 10 min 
(positive control). Significant effect of triclosan or Irgacide LP10 on the reduction in 
cell density and potassium leakage was tested with ANOVA.
Efficacy and toxicity o f triclosan neutralizing solution. The neutralizer used here 
was based on the British Standard EN 1499.30 The solution was made fresh in distilled 
water and contained 30 g/L Tween 80 (Sigma), 3 g/L lecithin from eggs (Sigma), 1 
g/L L-histidine (Sigma) and 5 g/L sodium thiosulphate (Fisher). Both the efficacy and 
the toxicity of the neutralizer were investigated prior to testing with methods 
described by Walsh et al. (1999)31 and Langsrud and Sundheim (1998)32 respectively. 
Briefly, 8 mL of neutralizer, 100 pL of triclosan (10 mg/mL) and 900 pL sterile de­
ionized water was inoculated with 1 mL of an 18 h culture of S. aureus NCIMB9518 
grown at 37°C. The viable cell count was enumerated after 5 min contact time at 
ambient temperature. As controls, sterile de-ionized water was added to the incubation 
mixture instead of the triclosan solution or the neutralizer. During exposure of the 
cells to triclosan without the neutralizer no viable cells were detected in the sample 
after the 5 min incubation period. There was no significant difference (P = 0.869) 
between the viable cell count of cultures exposed to triclosan and the neutralizer and 
where water was substituted for triclosan. This confirmed the ability of the neutralizer 
to quench bactericidal activity of triclosan at 100 mg/L. When examining the possible 
toxicity of the neutralizer, there was no significant difference (P = >0.05) between the 
viable cell counts of cultures exposed to sterile water and those exposed to the 
neutralizer for 15 min, confirming that the neutralizer was non-toxic to those strains 
under investigation.
Analysis o f fitness. Growth curves were attained by spectrophotometric analysis (580 
nm) of MHB cultures using a DYNEX Technologies MRX® Microplate Absorbance
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Reader with Revelation™ application programme. In each well of a sterile 96-well 
microtitre plate (Fisher Scientific, UK) 100 pL of ISB or ISB containing 2x final 
concentration of triclosan was inoculated with 100 pL of ISB culture, diluted with 
broth to 106 cells per mL. Plates were sealed with adhesive plate seals (ABgene, UK) 
and incubation was performed at 37°C with agitation for 48 h. Significant effect of 
mutation towards reduced triclosan susceptibility and effect of triclosan on bacterial 
growth was tested with ANOVA or Mann-Whitney test. All data are presented as the 
mean ± s.e.
The relative competitive fitness of reduced triclosan susceptibility mutants and 
parental strains was measured in pair-wise competition experiments. ISB was 
inoculated with a mixture of overnight cultures of triclosan-susceptible parental strain 
(trics) and reduced-susceptibility mutant (tricr) in a 1:1 ratio. The number of viable 
trics and tricr were determined by plating dilutions of the mixed cultures onto both 
non-selective ISA and selective ISA containing triclosan at a concentration of 4 x 
MIC for the parental strain at time 0 and after 24 h incubation at 37°C. A minimum of 
three independent cultures were used and the relative competitive fitness, W, was 
calculated according to Lenski (1988):33
where ao and aj are the cell density of the parent strain at time 0 and 1 day, 
respectively. Likewise for bo and bj, but representing the cell density of the mutant 
strain. A control culture of just the parent strain was run alongside and plated on the 
selective ISA to control against spontaneous tricr mutants of NCIMB9518.
To assess the fitness of the strains during exposure to triclosan the experiment was 
repeated with the presence of 0.5 mg/L triclosan in the growth media. Due to the 
exposure to triclosan the number of viable parent cells was expected to diminish 
during the course of the mixed infection. Hence, to enumerate this shrinking 
population it was necessary to use rifampicin resistant (Rif*1) mutants of the parent 
strain and to adjust the selective media accordingly (ISA containing 10 mg/L 
rifampicin and ISA containing triclosan at a concentration of 0.5 mg/L). Rif*1 mutants 
were isolated34 and investigated for affect upon fitness as described previously.35 This
\n(bjb0)/day
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ensured bacterial fitness was not affected by Rif*. Under conditions of antimicrobial 
stress it was preferable to express the performance of the strains in terms of selection 
rates, r:33
r _ ln(a,/ao)-ln(V&e) 
day
where, ao and ai are the cell density of the mutant strain at time 0 and 1 day, 
respectively. Likewise for bo and bj, but representing the cell density of the parent 
strain.
Results
Triclosan resistance in S. aureus and reduced susceptibility mutants
Triclosan MICs ranged between 0.03 and 0.06 mg/L for clinical isolates and lab 
strains, whilst mutants selected for reduced triclosan susceptibility showed MICs of 1- 
2 mg/L, Table 3.2.
Reduced triclosan susceptibility was stable in all mutants selected for culturing. 
Reduced susceptibility mutants were isolated at rates of between 3.5><10'9± 1.05x10'10 
and ~1.0x10’n per CFU (level of detection) (Figure 3.1). There was no significant 
difference between the rates of mutation in MRSA and MSSA or between mupirocin- 
resistant (MupRSA) and mupirocin-susceptible (MupSSA) strains (P -  0.754 and 
0.917, respectively). However, rate of mutation was dependent upon the concentration 
of triclosan used for selection. The rate of selection for mutants was similar on 0.1, 
0.5 and 1.0 mg/L triclosan (P -  0.122), but was significantly reduced when the 
selection medium contained 2 or 10 mg/L triclosan (P = 0.001 and <0.001, 
respectively).
Antibiotic and biocide resistance in reduced-triclosan susceptible S. aureus.
The MICs of several antibiotics and biocides before and after mutation to reduced- 
triclosan susceptibility are shown in Table 3.3. No significant difference was found 
between triclosan MICs of mupirocin-susceptible and mupirocin-resistant S. aureus
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Table 3.2. MICs of triclosan and antibiotic resistance profiles for S. aureus strains.
S. aureus strain Antibiotic resistance profile Triclosan MIC (mg/L)
NCTC6571 - 0.03
Mu50 Pen, Oxa, Van"11, Tet, Ery, Cip, Amp, Cec, Cro, R if 0.06
NCIMB9518 - 0.03
9518T1 - 1.0
9518T2 - 2.0
9518T3 - 2.0
9518T4 - 1.0
9518Rif R if 0.03
F89 Pen, MupH, Tec, Amp, Cec 0.03
F89T1 Pen, MupH, Tec, Amp, Cec 1.0
24500 Pen, Oxa, Cip, Amp, Cec, Cro 0.03
24500T1 Pen, Oxa, Cip, Amp, Cec, Cro 1.5
27343 Pen, Oxa, Cip, Amp, Cec, Cro 0.06
27343T1 Pen, Oxa, Cip, Amp, Cec, Cro 1.0
24532 Pen, Oxa, Ery, Tec, Cip, Amp, Cec, Cro 0.03
27393 Pen, Oxa, Ery, C ip ,, Amp, Cec, Cro 0.03
27368 Pen, Oxa, Ery, Cip, Amp, Cec, Cro 0.06
24497 Pen, Oxa, Ery, C ip ,, Amp, Cec, Cro 0.03
24467 Pen, Oxa, Cip, Amp, Cec, Cro 0.06
22373 Pen, Oxa, Cip, Amp 0.06
223065 Pen, Oxa, Cip, Amp 0.03
223021 Pen, Oxa, Ery, Cip, Amp 0.13
224035 Pen, Oxa, Ery, Cip, Amp 0.03
224005 Pen, Oxa, Cip, Amp 0.06
223232 Pen, Oxa, Ery, Cip, Amp 0.03
223278 Pen, Oxa, Cip, Amp 0.06
223058 Pen, Oxa, Cip, Amp 0.13
269263 Pen, Oxa, Gen, Cip, Amp 0.03
260379 Pen, Oxa, MupL, Ery, Cip, Amp, Cec, Cro, R if 0.06
266261 Pen, Oxa, MupL, Ery, Cip, Amp, Cec, Cro 0.06
260556 Pen, Oxa, M upL, Ery, Cip, Amp, Cec, Cro 0.13
247378 Pen, Oxa, MupH, Ery, Cip, Amp, Cec, Cro 0.03
259658 Pen, MupH, Ery, Amp, Cec, Cro 0.06
260711 Pen, MupH, Ery, Amp, Cec, Cro, R if 0.06
260989 Pen, MupH, Ery, Amp, Cec, Cro, R if 0.03
269026 Pen, MupH, Amp, Cec, Cro, R if 0.13
B17637 Pen, MupH, Ery, Amp, Cec, Cro, R if 0.03
Pen, Penicillin; Oxa, Oxacillin; Vanmt, Intermediate-Vancomycin; MupL, Low-level Mupirocin; MupH, 
High-level Mupirocin; TET, Tetracycline; ERY, Erythromycin; GEN, Gentamicin; TEC, Teicoplanin; 
CIP, Ciprofloxacin; Amp, Ampicillin; Cec, Ceflacor; Cro, Ceftriaxone; Rif, Rifampicin.
Figure 3.1. Affect of genetic background upon rate of mutation to triclosan resistance. There was 
no significant difference between the mean rate of mutation to reduced triclosan susceptibility for 
MSSA (filled squares), MRSA (filled triangles) and MupRSA (filled circles) strains (P -  >0.05). Points 
represent mean ± s.e.
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Table 3.3. Antibiotic and biocide MICs before and after mutation to reduced triclosan susceptibility.
Strain
Minimum Inhibitory Concentration (mg/L)
PEN* OXA* VAN* MUP* CHL/ TETt ERY* GEN* LZD* TEC1 CIP1 Trie* CHX* CPC*
NC1MB9518 <0.016 0.125 1 0.19 8 0.19 0.38 0.19 0.5 0.38 0.19 0.03 1 1
9518T1 0.023 0.125 1 0.38 8 0.5 0.38 <0.064 0.5 0.38 0.19 1 1 1
9518T2 0.023 0.125 1.5 0.19 6 0.25 0.5 0.125 0.5 0.38 0.19 2 1 1
9518T3 0.023 0.125 1.5 0.125 6 0.25 0.38 0.125 0.5 0.38 0.19 2 1 1
9518T4 0.023 0.125 1 0.19 8 0.25 0.38 0.125 0.5 0.38 0.19 1 1 1
F89 1 0.75 1.5 >1024 4 0.5 >256 0.19 0.5 0.75 0.38 0.03 1 1
F89T1 1 0.38 1.5 >1024 4 0.5 >256 0.25 0.5 0.75 0.19 1 1 1
24500 48 64 1.5 0.25 4 0.5 0.38 0.19 0.5 0.25 >32 0.063 3 3
24500T1 48 48 1 0.38 4 0.5 0.5 0.125 0.5 0.25 >32 1.5 3 3
27343 32 >256 1 0.38 8 0.5 0.38 0.19 0.38 0.5 >32 0.063 2 2
27343T1 48 >256 1 0.38 8 0.25 0.38 0.19 0.5 0.5 >32 1 2 2
Calculated by Etest (AB Biodisk, Sweden). Calculated in accordance with BSAC guidelines. PEN, Penicillin; OXA, Oxacillin; VAN, Vancomycin; MUP, Mupirocin; 
CHL, Chloramphenicol; TET, Tetracycline; ERY, Erythromycin; GEN, Gentamicin; LZD, Linezolid; TEC, Teicoplanin; CIP, Ciprofloxacin; Trie, triclosan; CHX, 
chlorhexidine gluconate; CPC, cetylpyridinium chloride.
(P -  0.712). Mutation to reduced triclosan susceptibility was not shown to affect 
susceptibility to another antimicrobial, including mupirocin, which has previously
n  #
been associated with low-level triclosan resistance. MRSA and MSSA strams were 
equally susceptible to triclosan.
Bactericidal effects o f triclosan
We investigated the effect of a raised triclosan MIC upon the bactericidal effects of 
this biocide. Lethality of triclosan at 7.5 and 20 mg/L was examined on reduced 
susceptibility strains and their progenitor. In an effort to model the effects of triclosan 
in a complex formulation, as employed in the clinic, this experiment was repeated 
with 7.5x1 O'4, 2.0x1 O'3, 2 and 20 % Irgacide LP10 (equivalent to 7.5, 20, 2000 and 
20,000 mg/L triclosan respectively). Our results show that, contrary to previous 
reports, reduced susceptibility to triclosan does affect the bactericidal effects of 7.5 
mg/L triclosan (Figure 3.2). However, all mutants were as susceptible as their parent 
strain to the lethal effects of triclosan at 20 mg/L. 2 and 20% Irgacide LP10 exhibited 
very high bactericidal efficacy; both reduced cultures by 7 Logs within 0.5 min and 
there was no significant difference between the killing of wild type or reduced 
susceptibility strains (data not shown). At much lower concentrations of Irgacide 
LP10 the killing was not so rapid and comparable to that of standard triclosan (Figure 
3.2). We found no significant difference between the bactericidal effects of triclosan 
or Irgacide LP10 in exponentially growing cells, stationary phase cells and non­
growing cells (P -  >0.05; data not shown).
The leakage of potassium from cells is an indication of cytoplasmic membrane 
damage and consequently cell death. We measured triclosan-induced potassium 
leakage in NCIMB9518 and reduced susceptibility mutants to identify if there was a 
correlation between MIC and susceptibility to the cytoplasmic effects of triclosan. 
Triclosan caused significant potassium leakage in all strains and at all concentrations 
(Figure 3.3). However, 7.5 mg/L triclosan and 7.5X10-4 % Irgacide LP10 induced 
significantly less membrane damage than higher concentrations (P = <0.05) and this 
was dependent upon triclosan MIC; potassium leakage was less in mutants with 
reduced susceptibility to triclosan. However, this correlation between MIC and
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Figure 3.2. The bactericidal effects of triclosan or Irgacide LP10 on S. aureus NCIMB9518 (solid 
line) and four mutants with reduced susceptibility to triclosan (dashed lines; T l, filled diamond; 
T2, filled triangle; T3, filled circle ; T4, cross), (a) Treatment with 7.5 mg/L triclosan or (b) equivalent 
Irgacide LP10 produced a kill rate dependent upon strain MIC. At these concentrations the lethal effect 
of triclosan is significantly different between wild type and mutants (P= <0.05). The times for a five 
logio reduction in cell density were increased from 13 min for wild type S. aureus to 20 min for C284T 
mutant strain 9518T1, 34 and 33 for double mutants (C284T and T-108G) 9518T2 and T3 respectively 
and 36 min for 9518T4. However, at higher concentrations of triclosan, (c) 20 mg/L triclosan and (d) 
2.0x10'3% Irgacide LP10, no significant difference was observed between the lethal effect upon wild 
type and mutants (P = >0.05). Data are the mean of three measurements ± s.e.
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Figure 33. Estimation of cytoplasmic membrane damage by measurement of extracellular 
potassium concentration, (a) The leakage of potassium from NCIMB9518 (solid line) and reduced 
susceptibility mutants (dashed lines; T l, filled diamond; T2, filled triangle; T3, filled circle ; T4, cross) 
was assessed when exposed to 7.5 mg/L triclosan and (b) 7.5 xlO'4% Irgacide LP10. (c) and (d) There 
was no significant difference in triclosan-induced cytoplasmic membrane damage between wild type 
and mutants at 20 mg/L triclosan or equivalent Irgacide LP10 (P = >0.05).
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potassium leakage was not statistically significant, unlike when assessing cell death 
described above (Figure 3.4).
Fabl mutation detection
The fab l genes of all triclosan mutants and their progenitor strains were amplified and 
sequenced, including the putative promoter region (see appendix 9.1). The sequence 
was highly conserved amongst all strains. F89 showed the greatest sequence diversity, 
with a total of 5 base pairs difference, none of which altered the amino acid sequence. 
Most triclosan mutants (9518T1, 9518T2, 9518T3, 24500T1 and 27343T1) had a 
previously un-described C284T mutation, conferring an alanine to valine substitution 
at the 95th residue. Furthermore, 9518T2 and 9518T3, mutants with the highest MICs, 
also possessed a mutation in the putative promoter region (T-108G). 9518T4 showed 
no change in its fab l gene sequence.
Fitness costs o f fabl mutation
Fitness of reduced susceptibility mutants was compared to that of their parent strain 
by analysis of their growth curves and in competitive fitness experiments. There was 
no significant difference between the doubling times of C284T mutants and their 
parent strain (P -  0.47) or between those carrying both the C284T and T-108G 
mutation (P = 0.48) whilst under conditions free from triclosan, Table 3.4. The 
mutations also had no significant effect upon the competitive fitness of the strains (P 
-  0.867). The results showed a significant difference between the doubling time and 
competitive fitness of mutants and their parent strain in the presence of 0.5 mg/L 
triclosan (P = 0.014). Parent strains were unable to grow in triclosan media and as a 
result were vastly out competed by mutant strains that were unaffected by the 
presence or absence of 0.5 mg/L triclosan (P -  0.848).
Discussion
Triclosan resistance and antimicrobial susceptibility. Wild type S. aureus strains were 
highly susceptible to triclosan, exhibiting MICs far below the concentrations expected 
to be encountered in situ. In congruence with some reports, MRSA and MSS A strains
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Figure 3.4. Correlation between susceptibility to bactericidal effects and triclosan MIC. (a) The
rate of kill when exposed to 7.5 mg/L triclosan (filled triangles) or 7.5><1 O'5 % Irgacide LP10 (open 
triangles) was significantly effected by triclosan MIC. (b) This was not true for concentrations >20 
mg/L or 2.0x10"3% or when measuring potassium leakage. Filled squares represent 20 mg/L triclosan; 
open squares represents 2.0X10"3% Irgacide LP10; Open circles represent 2.0% Irgacide LP10; crosses 
represent 20% Irgacide LP10.
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Table 3.4. Mutations associated with reduced triclosan susceptibility and their effects on bacterial
growth and fitness with and without exposure to triclosan.
MHB* MHB with 0.5 mg/L triclosan1 Substitutions
Strain
Triclosan MIC 
(mg/L)
Doubling 
time (min)
Competitive 
Fitness, W
Doubling 
time (min)
Selection rate, r 
(/day)b
Nucleotide substitutions 
in fa b l region0
Amino acid 
substitution in Fabl
NCIMB9518 0.03 39.6 ± 0.26 1.00 0.03 ± 0.003 d NA NA
9518T1 1 51.4 ±1.02 1.38 ±0.02 59.3 ±1.12 15.73 ±0.56 C284T A95V
9518T2 2 38.4 ±0.30 0.98 ± 0.01 37.2 ± 0.45 14.92 ±0.44 C284T, T-108G A95V
9518T3 2 37.9 ± 0.86 1.09 ±0.02 36.8 ± 0.77 17.83 ±0.49 C284T, T-108G A95V
9518T4 1 40.2 ± 0.68 1.02 ±0.01 38.7 ± 0.39 15.27 ±0.16 None detected None detected
F89 0.03 37.3 ±0.21 1.00 0.98 ±  0.002 d NA NA
F89T1 1 38.6 ± 0.44 1.03 ±0.01 40.2 ± 0.52 16.74 ±0.23 C284T A95V
24500 0.063 44.7 ±0.71 1.00 0.05 ± 0.003 d NA NA
24500T1 1.5 42.8 ± 0.48 0.96 ± 0.01 44.5 ± 0.82 15.93 ±0.41 C284T A95V
27343 0.063 40.1 ±0.58 1.00 0.02 ± 0.006 d NA NA
27343T1
a \ i . _
1
b t
40.9 ± 0.90 0.94 ± 0.01 39.4 ±1.06 15.66 ±0.73 C284T A95V
a Mean ± s.e. In the presence o f triclosan it was preferable to  express fitness in terms o f selection ra te s .0 Includes 
structural fa b l  gene and putative promoter region. d Value shows selection rate for wild type parent versus 
rifampicin resistant parent (in the absence o f  triclosan). NA, Not applicable.
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were equally susceptible to triclosan.8,36,37 If, as previously reported, triclosan 
resistance is transferable in association with mupirocin resistance7 then we would 
expect an association between these resistances in our strain collection. However, no 
correlation was found between resistance to mupirocin and resistance to triclosan, 
implying that no co-transfer of these resistances had occurred in the recent history of 
our collection. Several other authors have also expressed surprise at finding a lack of 
congruence between these resistances.8,20,38
However, we were able to isolate mutants with low-level resistance to triclosan. There 
was no evidence for mutation conferring co-resistance to other antimicrobials, a 
possibility discussed at length with regards triclosan.15,38'45 Nonetheless, this may 
remain a prospect, especially if resistance to triclosan can be conferred by alteration 
of other, yet undescribed, targets or processes, such as efflux. Indeed, it should be 
considered that the use of antimicrobials not only selects for the evolution of 
antimicrobial resistance. It also selects for the infrastructure required to develop 
resistance. Hence, although the mutation to reduced triclosan susceptibility described 
herein does not appear to confer resistance to any other antimicrobials, it may assist 
future evolution of drug resistance. Furthermore, low-level antimicrobial resistance in
S. aureus is often overlooked and may be associated with greater clinical risks than 
we might expect, such as increased mutation frequencies to higher resistance, 
increased virulence, improved in vivo fitness and resistance to unrelated compounds 46
The frequency of mutation was close to that expected from spontaneous mutation
Q
(-1.0x10'). This rate was not affected by the genetic background of the strain; there 
was no significant difference between the rates of mutation in MRSA, MSS A, 
MupRSA or MupSSA. However, the triclosan concentration did bias the selection of 
those strains with reduced susceptibility to triclosan. 1 mg/L triclosan biased towards 
the selection of those strains with either the single or double mutation, whilst 2 mg/L 
selected for the subset of these with the double mutation; reflecting the fact that 
resistance to triclosan concentrations of -1 mg/L requires a single point mutation, but 
progression to higher levels of resistance (2-4 mg/L) requires additional alterations.19
A previous report suggests that the multi-target nature of biocides detaches 
susceptibility as measured by MIC from bactericidal susceptibility, unlike antibiotics,
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which exhibit an explicit link between MIC and bactericidal susceptibility.38 Hence 
we aimed to establish whether there was or was not a link between triclosan MIC and 
susceptibility to their lethal effects in our collection. Our findings contradict this 
previous report, suggesting that at low concentrations of triclosan, reduced 
susceptibility mutants are more resistant to the lethal effects of triclosan. However, 
higher concentrations proved equally lethal. This provides further evidence that it is 
only at low concentrations that triclosan acts upon a discrete target. This is further 
supported by our evidence that the growth state of the cells does not affect the
- j o
bactericidal activity of triclosan; as proposed by Suller and Russell, if FabI is the 
sole target for triclosan, then should exponentially growing organisms be more 
susceptible to it?
During clinical or domestic use, triclosan is delivered typically as part of complex 
formulations containing various combinations of surfactants, detergents, chelating 
agents and wetting agents, all of which will affect their action, and ultimately, 
efficacy. Furthermore, typical in-use concentrations of triclosan in hand wash, bath 
formulations (0.1 to 0.3%) and surface disinfectants are 0.1 to 1%, for hospital wash 
applications for MRSA eradication up to 2% triclosan is recommended.6 Hence, in an 
attempt to better reflect in situ conditions, we also assessed the antimicrobial activity 
of Irgacide LP10, a commercial preparation of triclosan intended for clinical use. As 
with standard triclosan, reduced triclosan-susceptibility mutants did display an 
increased tolerance towards Irgacide LP10 at very low concentrations, however all 
strains were very rapidly killed by recommended in-use concentrations of Irgacide 
LP10.
Potassium ion leakage from cell suspensions, used to assess triclosan-induced 
cytoplasmic membrane damage, occurred at similar rates for all S. aureus strains, 
including reduced susceptibility mutants. Mutants do show some reduction in 
susceptibility to lethal effects when measured by potassium leakage, but less than 
when measured by viable counts. Hence, mutation of fab l does not offer any 
statistically significant reduction in susceptibility to triclosan induced cytoplasmic 
membrane damage. The correlation between MIC and insusceptibility to killing does 
not hold true for potassium leakage. We propose that Fabl mutation does confer a 
greater tolerance towards the lethal effects of triclosan, but only at low concentrations
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where there is insufficient triclosan available to bring about significant membrane, 
DNA, RNA or protein synthesis related effects. Hence we provide further evidence 
that triclosan causes a multitude of effects (including membrane perturbations) 
culminating in cell lysis, but this is concentration dependent.
Fitness costs o f fabl mutation. Sequencing the fab l gene and preceding promoter of 
triclosan mutants revealed two novel mutations conferring reduced triclosan 
susceptibility; C284T and T-108G. C284T confers an alanine to valine substitution at 
the 95th residue, although not previously described in S. aureus this is in close 
proximity to the previously reported G93V alteration described in E. coli by Heath et 
al. in 2000. Binding studies have demonstrated that triclosan inhibits Fabl via the 
formation of a stable triclosan-NAD+-FabI complex.19 Hence, we hypothesize that the 
location of the A95V substitution affects the formation of this complex, reducing the 
inhibitory effect of triclosan on the protein.
Triclosan MICs were increased further by development of a mutation in the putative 
promoter region, feasibly by conferring the over expression of the mutated Fabl, as 
suggested by Fan et al.19 Interestingly, we also isolated a mutant showing reduced 
susceptibility to triclosan without any sequence alterations within its fabl. Implying 
that some other target has been altered and hence Fabl is not the sole target for 
triclosan; genetic loci other than fab l may also be involved in triclosan resistance. 
Indeed a recent study has shown that in Streptococcus mutans, an organism that lacks 
triclosan-susceptible Fabl, triclosan is lethal by acting upon multiple targets including 
several enzymes of the glycolysis pathway.47
Evolution of reduced susceptibility to triclosan by mutation did not diminish the 
fitness of strains. Hence mutations such as these may be expected in situ, especially in 
locations exposed to triclosan where reduced susceptibility mutants may out-compete 
the wild type. However, current data have not indicated any explicit link between 
triclosan exposure and resistance in ex-situ isolates, microcosms, domiciliary 
environment or triclosan manufacturing site.48'52
Although the experiments reported here did not reveal a statistically significant 
difference in the in vitro fitness of strain 9518T1 there is, nevertheless, an indication
108
that the C284T mutation in 9518T1 is associated with decreased fitness when 
compared to the parental strain NCIMB9518. 9518T1, isolated after the first round of 
triclosan exposure showed a longer doubling time and was less able to compete with 
its parent than 9518T2 and T3, strains isolated from second and third serial exposures 
to triclosan. This indicates that in addition to reducing their susceptibility 9518T2 and 
T3 have restored their fitness, possibly through compensatory chromosomal 
mutations.
Triclosan remains an important and efficacious antimicrobial and bacterial fatty acid 
biosynthesis is a major target for development of novel antimicrobials, including the 
potential MRS A targeting platensimycin that inhibits FabF.19,53-59 However, we 
should be aware of the development of reduced susceptibility through mutation, 
altered gene expression and the development of SCVs. Using a combination of 
antimicrobials for control of microorganisms is a favourable way to reduce the 
chances of resistance and triclosan can be an important tool as part of this control.
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Abstract
We aimed to evaluate the level of antimicrobial resistance in staphylococci isolated 
from a representative of the student population of Cardiff. Microorganisms were 
recovered from a group of undergraduate students (n = 93) by nasal and skin swab. 
Identification was performed using selective agars, multiplex PCR and coagulase test. 
Isolated S. aureus and coagulase negative staphylococci (CoNS) where subsequently 
assessed for susceptibility to a selection of antibiotics, cationic biocides and triclosan. 
Students also completed a short questionnaire providing details of risk factors 
associated with S. aureus carriage. CoNS were isolated from 81 students (87.1%) 
whilst S. aureus was isolated from 30 (32.3%). CoNS were found to carry 
significantly more antimicrobial resistance traits than S. aureus, including methicillin, 
penicillin and triclosan resistance (P <0.05). One MRSA strain was isolated, the 
source of which was found to be a family member. In conclusion we find that CoNS 
represent an important reservoir of antimicrobial resistance genes, providing a 
resource for evolution of resistance to a broad spectrum of antimicrobial agents. 
Hence, the reduced susceptibility of CoNS should be considered when delivering 
antimicrobial therapies. We also discuss how familial transfer of MRSA may play a 
significant role in the spread of MRSA.
Introduction
Staphylococcus aureus is a major cause of hospital-acquired infection and the 
persistent increase in the numbers of methicillin-resistant S. aureus (MRSA) and 
methicillin-susceptible S. aureus (MSSA; Office for National Statistics, 2006) is 
causing considerable concern amongst healthcare professionals and general public. 
The emergence and spread of microorganisms with reduced susceptibility to 
antimicrobials in the community now presents a new challenge to public health. 
Increasing attention is being paid to community-associated MRSA (C-MRSA), for 
which infection rates are rising in many areas around the world (Lu et al., 2005). In 
contrast, whilst coagulase-negative staphylococci (CoNS) are frequently isolated in 
clinical microbiology laboratories and are becoming increasingly important causative 
agents of hospital-acquired infections (von Eiff et al., 2002) they attract little interest
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(Shittu et a l, 2006). CoNS have particular association with prosthetic devices and 
other invasive apparatus and regularly harbour multi-drug resistance (von Eiff et al., 
2002).
The relationship between the use of antibiotics and the development of antibiotic 
resistance has been discussed at length (Livermore, 2003). More recently the 
increased use of biocides as disinfectants, antiseptics and preservatives has also 
created discussion about their role in the development of resistance (Russell, 1999, 
Russell, 2000, Levy, 2001, Levy, 2002, Russell, 2002). Particular attention has been 
paid to the broad-spectrum antimicrobials triclosan (Irgasan DP300; 2,4,4'-trichloro- 
2’-hydroxydiphenyl ether), chlorhexidine gluconate (CHX) and cetylpyridium 
chloride (CPC). All are used widely in mouthwashes, hand disinfectants and also in 
surgical scrubs and during pre-operative skin preparation. Moreover, triclosan and 
CHX have been found to be useful for the control of MRSA (Webster, et al, 1994, 
Zafar, et a l, 1995, Wenisch, et a l, 2006, Simor, et a l, 2007) and are part of the 
recommended rationale for skin decolonisation of MRSA carriers in the United 
Kingdom (Coia et a l, 2006).
Resistance to biocides has traditionally been viewed as unlikely, principally due to 
their multiple mechanisms of action. However reduced susceptibility to all three of 
these biocides has been reported. Triclosan has been found to target enoyl-acyl carrier 
protein reductase, the product of the fab l gene which catalyzes the final elongation 
step during bacterial fatty acid biosynthesis (Heath & Rock, 2000; Fan et a l, 2002). 
Over expression or mutation of this gene can confer reduced susceptibility to 
triclosan, however triclosan has also been shown to have other targets and resistance 
is limited to low levels (MIC 1-4 mg L'1, compared to 0.01- 0.1 mg L'1 for susceptible 
strains; Russell, 2004; Seaman et a l, 2007b). Plasmid encoded resistance to CPC, a 
quaternary ammonium compound, has been found in S. aureus (Thomas & Archer, 
1989). Resistance to CHX, a bisbiguanide, has been linked with nucleic acid binding 
proteins that are often plasmid encoded (Cookson et a l, 1991; Russell, 1997).
Staphylococci are normal skin commensals and as such are often ignored when 
isolated from non-sterile sites (Tan et a l, 2006). However, commensal staphylococci 
may contain an important ‘pool’ of antimicrobial resistance genes, which could
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impact severely upon public health by being transferred to other, more virulent, 
species or strains or by a shift in the commensal to a more pathogenic existence. 
Therefore, it is important to quantify the resistance gene pool of both the CoNS and S. 
aureus flora of a unique community-based population, whilst considering the role of 
biocides in antimicrobial chemotherapy and resistance. We calculated the incidence of 
skin carriage of staphylococci among 93 university students. Isolates were 
investigated for their susceptibility to a selection of antibiotics, cationic biocides and 
triclosan, and this was collated along with data on risk factors for S. aureus and 
MRSA carriage.
Materials and Methods
Study population and sample collection
The samples were collected from undergraduate university students attending a series 
of practical classes at Cardiff University, Cardiff, Wales, in the period from 7th to 17th 
March 2005. Students were chosen at random and asked to participate in the study. 
Each subject underwent swabbing of the axilla and the anterior vestibule of both nares 
with a sterile swab. A questionnaire was also completed by each student to ascertain 
their exposure to known risk factors for MRSA carriage (Charlebois et al., 2004; Lu 
et a l , 2005) including age, visitation to a hospital within last 30 days, admission to a 
hospital for >two days in the last six months or living with a healthcare professional. 
A total of 93 (53 male, 40 female) students underwent the same swabbing procedure 
and completed the questionnaire as part of the study.
Each swab specimen was streaked on to a Vogel-Johnson agar plate (VJA; Oxoid, 
Basingstoke, UK) and two Mueller Hinton agar plates (MHA; Oxoid), one of which 
was supplemented with triclosan (0.5 mg L'1). Plates were incubated at 37°C for 48 h, 
after which morphological and Gram stain examinations were performed. Colonies of 
interest were streaked on MHA supplemented with 5% defibrinated sheep blood 
(Oxoid) and incubated at 37°C for 24 h.
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Bacterial strains and growth conditions
S. aureus NCTC6571, S. aureus NCIMB9518, MRSA Mu50 and S. epidermidis 
12228 were used as control strains during this investigation. All control and test 
organisms were confirmed as S. aureus or coagulase-negative staphylococci (CoNS) 
by streaking on VJA, latex-agglutination test for extra-cellular coagulase (Staphylase 
test; Oxoid) and multiplex PCR, as described previously (Zhang et a l , 2004; Seaman 
et al., 2007a; Table 4.1). Strains were stored in 50% glycerol at -80°C and, when 
required, maintained on either nutrient agar (NA; Oxoid ), Iso-Sensitest agar (ISA; 
Oxoid) or MHA. Over-night cultures were prepared by inoculation of 10 ml nutrient 
broth (NB; Oxoid) or Iso-Sensitest broth (ISB; Oxoid) with colonies from a streak 
plate and incubation in an orbital shaker at 37°C for 15 h. Triclosan-susceptible 
isolates were preliminarily identified by growth on MHA and the absence of growth 
on the plate supplemented with triclosan.
Biocide and antibiotic susceptibility
MICs for three biocides, triclosan (gift from Ciba Spezialitatenchemie Grenzach 
GmbH, Grenzach-Wyhlen, Germany), CHX (ICN Biomedicals Inc., Costa Mesa, 
USA) and CPC (ICN Biomedicals Inc.) were calculated for all organisms according to 
the guidelines of the British Society for Antimicrobial Chemotherapy (Andrews,
2001). Etest strips (Bio-stat Ltd, Stockport, UK) were utilized to attain the MIC for 
penicillin, oxacillin, mupirocin, vancomycin, teicoplanin, linezolid, ciprofloxacin, 
gentamicin, chloramphenicol, tetracycline and erythromycin. Isolates were 
categorized as either susceptible or resistant according to MIC breakpoints described 
previously (Andrews, 2004; Brown et al., 2005). Methicillin resistance, as indicated 
by oxacillin MIC, and high-level mupirocin resistance were confirmed by 
amplification of the mecA and mupA genes, respectively, as part of the multiplex PCR 
described above. In addition, all isolates were investigated for (3-lactamase production 
by nitrocefin stick (Oxoid).
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Table 4.1. Primers used during multiplex PCRs used in identifying S. aureus and CoNS and in 
typing of SCCmec elements. The concentration of each primer used in the reaction is given.
Primer Oligonucleotide sequence (5-3 ')
Final concentration 
(pM )
Target Reference
Staph756F aactctgttattagggaagaaca 0.24 Staphylococcus 16S rRNA
Staph750R ccaccttcctccggtttgtcacc 0.24 gene
N ucl gcgattgatggtgatacggtt 0.08
S. awrei/5-specific nuc gene
Nuc2 agccaagccttgacgaactaaagc 0.08
M upAl tatattatgcgatggaaggttgg 0.1 mupA (high-level
MupA2 aataaaatcagctggaaagtgttg 0.1 mupirocin resistance)
M ecAl gtagaaatgactgaacgtccgataa 0.24 mecA (methicillin
MecA2 ccaattccacattgtttcggtctaa 0.24 resistance)
Type I-F gctttaaagagtgtcgttacagg 0.048
SCCmec I
Type I-R gttctctcatagtatgacgtcc 0.048
Type U-F cgttgaagatgatgaagcg 0.032
SCCmec II
Type II-R cgaaatcaatggttaatggacc 0.032
Type III-F ccatattgtgtacgatgcg 0.04
SCCmec III
Type III-R ccttagttgtcgtaacagatcg 0.04
Type IVa-F gccttattcgaagaaaccg 0.104
SCCmec IVa
Type IVa-R ctactcttctgaaaagcgtcg 0.104
Type IVb-F tctggaattacttcagctgc 0.092
SCCmec IVb
Type IVb-R aaacaatattgctctccctc 0.092
Type IVc-F acaatatttgtattatcggagagc 0.078
SCC mec IVc
Type IVc-R ttggtatgaggtattgctgg 0.078
Type IVd-F5 ctcaaaatacggaccccaataca 0.28
SCCmec IVd
Type IVd-R6 tgctccagtaattgctaaag 0.28
Type V-F gaacattgttacttaaatgagcg 0.06
SCCmec V
Type V-R tgaaagttgtacccttgacacc 0.06
M ecAl 47-F gtgaagatataccaagtgatt 0.046
mecA
M ecAl 47-R atgcgctatagattgaaaggat 0.046
(Jaffe et al., 2000)
(Shortle, 1983)
(Anthony et al., 
1999)
(Ryffel et al., 1990) 
Zhang et al. (2005) 
Zhang et al. (2005) 
Zhang et al. (2005) 
Zhang et al. (2005) 
Zhang et al. (2005) 
Zhang et al. (2005) 
Zhang et al. (2005) 
Zhang et al. (2005) 
Zhang et al. (2005)
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SCC mec typing by multiplex PCR
Chromosomal DNA was extracted as described previously (Enright et al., 2000). Nine 
pairs of primers, designed by Zhang et al., (2005), were used in 25 pL PCRs intended 
to characterize the SCCmec type of MRSA isolates (Table 4.1). Reactions contained 
0.5 pL of chromosomal DNA (approximately 0.5 pg), 0.032 to 0.104 pL of each 
primer (see Table 4.1), 1 U of Taq DNA polymerase (Bioline Ltd, London, UK), 5 pL 
of 10x buffer (Bioline Ltd), and 0.2 mM deoxynucleoside triphosphates (Bioline Ltd). 
The PCR was performed in a PTC-200 DNA engine (MJ Research, Waltham, USA) 
with an initial denaturation step at 94°C for 5 min followed by 10 cycles of 94°C for 
45 s, 65°C for 45 s, and 72°C for 90 s and a further 25 cycles of 94°C for 45 s, 55°C 
for 45 s, and 72°C for 90 s, ending with a final extension step at 72°C for 10 min 
before a hold at 4°C. All PCR assay runs incorporated a reagent control (template 
DNA replaced with molecular grade water). PCR amplicons were analyzed using UV 
transillumination after electrophoresis on a 2% agarose gel containing 0.5 pg mL'1 
ethidium bromide. 1 kb Plus DNA ladder™ (Invitrogen, Carlsbad, USA) was run 
alongside the samples as a molecular weight marker.
Questionnaire and data analysis
Each participant completed a standardized questionnaire. Students’ age, gender, 
exposure to healthcare personnel and medical history over the preceding 6 months, 
including previous hospitalization and medication history were collated. Data were 
analyzed with SPSS release 12.0.2 (SPSS Inc, Chicago, USA) and correlated with S. 
aureus and CoNS carriage data. Comparison of categorical variables was done by the 
Pearson chi-square test or Fisher’s exact test, as appropriate. Minitab release 14 
software (Minitab Inc., Pennsylvania, USA) was used to test for significant difference 
between the susceptibility of S. aureus and CoNS using Student’s t-test, carried out at 
the 95% confidence interval. If the assumptions required to perform this test were 
violated, the Mann-Whitney test was performed at 95% confidence intervals.
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Results
93 students were recruited for this study, of which 53 (57%) were male and 40 (43%) 
were female. Participant age ranged from 18-24 years, with a mean age 19.03 years 
(males, 19.13 years; females, 18.90 years). Of the 93 students 89 (95.7%) were found 
to be colonized with staphylococci. CoNS were the most readily recovered organisms, 
being isolated from 81 students (87.1%), whilst S. aureus was isolated from 30 
students (32.3%). 26 S. aureus isolates (86.67%) were recovered from the anterior 
nares, whilst the majority of CoNS, 78 (96.3%), were isolated from the axilla.
Antimicrobial resistances were significantly more prevalent in CoNS than S. aureus 
(P <0.01; Table 4.2). 77 CoNS (95.1%) showed resistance to at least one 
antimicrobial whilst 6 S. aureus (20.0%) showed the same number of resistance traits. 
CoNS were also more likely to show multi-drug resistance (Fig. 4.4.1). Strikingly, 77 
(95.06%) of the CoNS isolated showed triclosan MICs >0.25 mg L'1, causing 82.80% 
of participants to be identified as carrying staphylococci with reduced susceptibility to 
triclosan. There was no significant difference in the triclosan susceptibility of 
methicillin-resistant or susceptible CoNS (P = 0.687). Reduced susceptibility to 
triclosan was not found amongst S. aureus isolates, including one MRSA isolate. No 
resistance to the cationic biocides CHX or CPC was found amongst the isolates. 
Penicillin resistance was most prevalent, followed by methicillin and then 
ciprofloxacin resistance (Table 4.2).
p-lactamase production was detected in all isolates that showed penicillin resistance, 
implying that this was the mechanism of resistance. The mecA gene was detected in 
all staphylococci with MICs of oxacillin >1 mg L'1, confirming that methicillin 
resistance was associated with this element.
Correlation of participants’ questionnaire answers with the microbiological data 
revealed that there was no significant difference between the frequency of S. aureus 
or CoNS carriage in males and females (P -  0.570 and 0.413, respectively). There
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was also no significant difference in resistance to penicillin or methicillin between 
genders (.P > 0.05). Neither S. aureus or CoNS carriage were significantly different
Fig. 4.1 Frequency distribution of number of resistance traits per staphylococcal isolate. The
median number of resistance traits per isolate was zero for S. aureus (■) and two for CoNS ( ).
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Table 4.2. Antimicrobial susceptibility of staphylococci isolated from 93 undergraduate students.
Antimicrobial3 Organism
MIC (mg L '1) Resistance
Range Median Frequency % isolates % students
Triclosan S. aureus 0.03-0.13 0.03 0 0 0
CoNS 0.13-8.0 4.00 77.00 95.06 82.80
CHX S. aureus 1.0-2.0 1.00 0 0 0
CoNS 0.5-2.0 1.50 0 0 0
CPC S. aureus 1.0-2.0 1.00 0 0 0
CoNS 0.5-2.0 2.00 0 0 0
Penicillin S. aureus 0.02-48 0.02 6.00 20 6.45
CoNS 0.13-64 8.00 52.00 64.20 55.91
Oxacillin S. aureus 0.13-64 0.38 1.00 3.33 1.08
CoNS 0.13-32 0.13 22.00 27.16 23.66
Vancomycin S. aureus 1.0-1.5 1.00 0 0 0
CoNS 1.0-1.5 1.00 0 0 0
Mupirocin S. aureus 0.19-0.75 0.25 0 0 0
CoNS 0.06-1024 0.19 7.00 8.64 7.53
Chloramphenicol S. aureus 4.0-8.0 5.00 0 0 0
CoNS 4.0-8.0 6.00 0 0 0
Tetracycline S. aureus 0.19-0.5 0.38 0 0 0
CoNS 0.13-4.0 0.25 2.00 2.47 2.15
Erythromycin S. aureus 0.38-256 0.50 1.00 3.33 1.08
CoNS 0.06-2.0 0.12 2.00 2.47 2.15
Gentamicin S. aureus 0.13-0.5 0.19 0 0 0
CoNS 0.064-16 0.25 3.00 3.70 3.23
Linezolid S. aureus 0.19-0.5 0.50 0 0 0
CoNS 0.25-1.0 0.50 0 0 0
Teicoplanin S. aureus 0.19-0.75 0.44 0 0 0
CoNS 0.19-0.75 0.38 0 0 0
Ciprofloxacin S. aureus 0.19-32 0.19 1.00 3.33 1.08
CoNS 0.13-48 0.25 4.00 4.94 4.30
P-lactamaseb S. aureus - - 3.00 10 3.23
CoNS - - 55.00 67.90 59.14
mecAc S. aureus - - 1.00 3.33 1.08
CoNS - - 22.00 27.16 23.66
mupAd S. aureus - - 0 0 0
CoNS - - 5.00 6.17 5.38
a CHX, Chlorhexidine gluconate; CPC, cetylpyridinium chloride; 
b (3-lactamase production was assessed by nitrocefin stick.
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c The presence of mecA was used to confirm the genetic determinant for methicillin resistance 
d Presence of mupA was used to confirm the genetic determinant for mupirocin resistance and indicated 
high-level resistance.
between participants who had visited a hospital in the last 30 days (P -  0.612 and 
0.430, respectively), been hospitalized for >2 days (P = 0.694 and 0.343) or lived with 
a member of the healthcare profession (P = 0.513 and 0.308). Similarly, carriage of 
CoNS resistant to methicillin or penicillin could not be correlated with prior 
hospitalization (P = 0.967 and 0.8, respectively) or recent use of antibiotics (P = 0.619 
and 0.409).
Whilst 22 methicillin-resistant CoNS were isolated (27.16%) only a single MRSA 
strain was detected. This MRSA isolate was recovered from an 18 year old female 
student who had no history of hospitalization within the last 6 months, had not used 
any prescribed antimicrobial products and did not live with any healthcare 
professionals. However, during a follow-up session it was revealed that the girl’s 
mother was currently undergoing treatment for an MRSA infection acquired whilst 
attending a South Wales hospital. Subsequently, a swab specimen was recovered from 
the mother, which yielded coagulase-positive cocci with resistance to penicillin, 
methicillin, erythromycin and ciprofloxacin, the same resistance profile to the strain 
isolated from her daughter. Multiplex PCR confirmed both isolates as S. aureus and 
as mecA positive. SCC mec typing using a second multiplex PCR revealed both 
MRSA isolates to harbour a type III SCC mec element.
Discussion
Whilst variations in sampling techniques make comparison between studies difficult, 
staphylococcal carriage amongst this student population was similar to that of 
previous community studies (Abudu et a l, 2001; Sa-Leao et al, 2001; Maudsley et 
al, 2004). Our results clearly show that commensal CoNS are often multiply-resistant 
and generally carry more resistance traits than S. aureus. Consequently, CoNS 
infections, which are largely from a patients own microflora (Tan et al, 2006), may 
provide a greater challenge during antimicrobial treatment.
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We were interested to find that CoNS appear to show reduced susceptibility to 
triclosan, when compared with S. aureus. One previous report that found similar 
results also found that methicillin-resistant CoNS were more likely to show reduced 
susceptibility to triclosan (Schmid & Kaplan, 2004). In contrast we found no 
significant difference in triclosan MIC between methicillin-resistant and methicillin- 
susceptible CoNS (P = 0.687). This could be a consequence of variations between the 
strain collections and testing methods. Alternatively, our results may indicate that 
there is little relationship between methicillin resistance and triclosan susceptibility, 
as has been reported previously in S. aureus (Bamber & Neal, 1999; Suller & Russell, 
2000; Russell, 2004). If there is indeed a relationship between these two resistances 
we are unaware of any biochemical of physical reason as to why they may be related 
and propose that is possibly a reflection of the augmented ability of multiply-resistant 
isolates to acquire and maintain resistance traits.
The median MIC of triclosan in CoNS (4 mg L'1) is similar to the MIC of S. aureus 
fab l mutants, which show reduced susceptibility to triclosan (1-4 mg L 1; Fan et al., 
2002; Seaman et a l , 2007b). Triclosan inhibits Fabl (enoyl-acyl carrier protein 
reductase) via the formation of a stable triclosan-NAD+-FabI complex (Fan et al.,
2002). Hence, the reduced susceptibility in CoNS may be due to sequential and 
structural differences between CoNS and S. aureus Fabl and these differences affect 
the formation of the triclosan-NAD+-FabI complex, reducing the inhibitory effect of 
triclosan on the protein. However, triclosan is known to act through several 
mechanisms (Seaman et a l , 2007b), so future work should be directed towards 
characterizing the mechanism of action of triclosan in CoNS.
It is notable that CoNS were predominantly isolated from the axilla, whilst S. aureus 
were more commonly recovered from nasal swabs. The reduced susceptibility seen in 
CoNS may reflect the presence of antimicrobial compounds in underarm preparations 
such as deodorants, whilst the exposure of the nares to antimicrobials is limited. It 
should also be remarked that the clinical significance of the MICs for triclosan seen in 
the CoNS of this study is ambiguous; they are still far below the in-use concentrations 
of triclosan (0.1 to 2%) and in addition, specific ratios of surfactants, wetting agents, 
detergents and chelating agents are included in commercial preparations of triclosan, 
which affect the overall antimicrobial activity of the formulation.
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Our study highlights the genetic resource for antimicrobial resistance that CoNS 
maintain. Furthermore, S. aureus and CoNS are closely related, and as such share 
similar genetic systems, they also often colonize the same locale. As a consequence of 
this, we theorize that CoNS may represent a potential reservoir of resistance that S. 
aureus could exploit. In particular they may be a source for the development of S. 
aureus isolates with reduced susceptibility to triclosan. However, recent work failed 
to detect any transfer of triclosan resistance amongst S. aureus isolates or from S. 
epidermidis (Seaman PF, Day MJ & Ochs D, 2007, unpublished work). Hence it 
remains to be shown what role CoNS may play in the evolution of triclosan resistance 
in the more pathogenic S. aureus.
Our study did not identify any risk factors for staphylococcal carriage. However, we 
report a suspected example of familial transfer of MRSA. Both mother and daughter 
specimens recovered MRSA with identical resistances profiles and both were found to 
be SCCmec type III (Class A mec complex and type 2 ccr complex). These data lead 
us to conclude that both isolates are the same strain. Hence it appears that the 
daughter had acquired it from her mother, following the mother developing the initial 
infection whilst hospitalized. Indeed, it has been demonstrated previously that family 
members can serve as reservoirs of MRSA and that familial transfer of MRSA can 
prolong the eradication (Huijsdens et al., 2006). This may amplify the problems 
already associated with containing the spread of MRSA and provides an example of 
how previously nosocomial strains can become community-based.
In conclusion we have identified that CoNS show reduced susceptibility to triclosan 
than S. aureus and that familial transfer of MRSA strains is an ongoing phenomenon 
that has the potential to severely impact upon public health. Although the 
susceptibilities of CoNS are below the in-use concentrations of triclosan, these 
organisms should be closely monitored for susceptibility, particularly in light of their 
emerging clinical significance.
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Chapter 5
Gene transfer of biocide resistance in staphylococci
Submitted for publication in the Journal of Antimicrobial Chemotherapy
Synopsis
Objectives: To identify the potential for gene transfer of triclosan resistance by 
conjugation, transduction and transformation in S. aureus and related species.
Methods: A collection of low-GC, Gram-positive organisms were investigated for 
ability to transfer plasmid- and chromosome-encoded antimicrobial resistance during 
bi- and tri-parental filter matings, transduction with bacteriophages 80a and K and 
transformation experiments. These were supported by analysis of the fabl gene and 
surrounding region from 10 staphylococcal genomes for %GC; GC frame plot; Karlin 
Signature Difference as indicators of horizontal acquisition.
Results'. Plasmid-encoded resistances including mupirocin, quaternary ammonium 
compound and chloramphenicol resistance could be transferred by conjugation and 
could also be mobilized by transduction. However, no transfer of triclosan resistance 
could be detected and no association between mupirocin and triclosan resistance was 
found. Triclosan was also found to significantly effect the gene transfer of 
antimicrobial resistance (P = >0.05), with concentrations between 1 and 10 mg/L 
generally reducing transfer, whilst lower concentrations had less effect. No indication 
that fabl had been horizontally acquired in the staphylococcal genomes was found. 
Conclusions: Whilst some antimicrobial resistances are readily transferable amongst 
staphylococci and other genera our data question the significance of this phenomenon 
in the dissemination of low-level triclosan resistance. Furthermore, triclosan does not 
appear to promote the transfer of other resistances and triclosan resistance does not 
readily form associations with mupirocin resistance.
Introduction
Bacteria can develop resistance to antimicrobial compounds either by spontaneous 
mutation of their genome or by acquisition of exogenous genetic material. Whilst 
mutations are generally associated with development of resistance to a single, or very 
closely related antimicrobials, acquisition of new genes by horizontal gene transfer 
(HGT) often confers resistance to multiple, frequently unrelated, antimicrobials. 
Hence HGT can facilitate the rapid evolution of a micro-organism, indeed it has been 
proposed that it is HGT that drives bacterial speciation; basal mutation events such as 
point mutations rarely confer a phenotype enabling a bacterium to colonize new
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environments, however HGT can more often provide the genetic information for this 
goal. Take for example the divergence of Escherichia coli and Salmonella enterica; 
all those phenotypic characteristics that distinguish these two species originate from 
horizontally transferred genes.1 Comparative analysis of staphylococcal genomes has 
revealed that genomic islands in nonsyntenic regions are the principal source of 
diversity in pathogenicity and resistance,2 and that the distribution of mobile cassettes 
carrying virulence and drug-resistance determinants may explain the phenotypic 
differences, and variation in clinical importance, between an epidemic methicillin- 
resistant Staphylococcus aureus (MRSA) clone and a community-acquired 
methicillin-susceptible S. aureus (MSSA) clone.3 The transfer of genes between 
staphylococci and low-GC-content Gram-positive bacteria appears to have moulded 
their virulence and ability to resist antimicrobial chemotherapy.
HGT of antibiotic resistance has been a hot topic for study, especially since 
Staphylococcus aureus showed itself to be so adept at acquiring antibiotic resistance 
by this mechanism.4 Many mobile genetic elements (MGE; plasmids, genomic 
islands, transposons, insertion sequences (IS) and phage-associated elements) can 
harbour antibiotic resistance genes. Examples include staphylococcal cassette 
chromosome mec (SCCmec), the key genetic component of methicillin resistance,5 
multiresistance plasmid pSK41 which, along with other resistances, confers resistance 
to aminoglycosides6 and ileS2-carrying plasmids which play a significant role in the
7 0dissemination of high-level mupirocin resistance among pandemic MRSA lineages. "
Bacterial genomes are highly plastic, being able to donate and receive DNA 
(generally MGE) to and from each other. MGE can move between cells by several 
routes; conjugation, transduction, phage-mediated conjugation or transformation. 
Bacterial conjugation is a highly specific process whereby DNA (plasmid, or less 
familiarly transposon) is transferred from donor to recipient by a specialized multi­
protein complex present on the cell surface, named the conjugation apparatus. A key 
prerequisite for conjugative transfer is an intimate association between the cell 
surfaces of the donor and recipient cells. In Gram-negative bacteria, this physical 
contact is established by the sex pili. For the majority of Gram-positive bacteria the 
means to achieve this intimate cell-cell contact have not yet been fully identified, but a 
strong level of homology has been found with type IV secretion systems.10 Some
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plasmids carry all the genes necessary for self-transmission and are known as 
conjugative plasmids. Others lack these genes but are able to be mobilized by 
conjugative plasmids resident in the same organism.11,12 Interestingly, S. aureus 
strains have been shown to secrete a peptide, staph-cAM373, that stimulates in vitro 
conjugative transfer of plasmids from Enterococcus faecalisP  Conjugal plasmids are 
able to mediate transfer over a wide range of pH values and temperatures.14
Bacteriophages (phages) are widely distributed in staphylococcal populations and 
many integrated phage have been identified in sequenced staphylococcal genomes, 
with at least one prophage in every genome, except that of S. epidermidis ATCC 
12228.2 It appears probable that transduction is the mechanism by which the mecA 
determinant has spread amongst staphylococci; mecA has never been found on mobile 
DNA but has spread among several S. aureus lineages and among different coagulase- 
negative species.15 Gene transfer by transduction can be either generalized or 
specialized, the former entails a mis-incorporation of host DNA (chromosomal or 
plasmid) into the phage head which is then released during cell lysis and infects 
another cell, injecting the DNA from the previous host. The genetic material to be 
transferred by specialized transduction arises from an illegitimate recombinational 
event occurring during excision of a prophage from the host genome, leading to the 
packaging of a phage ‘genome’ lacking some phage functions but gaining some host 
traits. The fate of the transferred DNA is independent of the process of transduction 
and depends on the recipient cell’s mechanisms of recombination and DNA 
stabilisation.16 The requirement for the death of the donor cell, the need to protect the 
recipient from destruction by normal phage particles in addition to the artificial 
conditions needed for the transduction process in vitro has raised doubts as to whether 
transduction could be a significant process in nature.17 However, transduction in situ
1 8 Ofthas been described ' and the potential for transduction to greatly affect evolution of 
bacteria is apparent.16 Furthermore, induction of staphylococcal prophage, triggered 
by P-lactam antibiotics, can induce the horizontal transfer of virulence factors.21
The ability to take up free DNA is relatively rare in species of Gram-positive bacteria.
However S. aureus, under specific conditions, is able to take up ‘naked’ DNA from
• 22the environment. The natural competence system of S. aureus is induced only in 
very early exponential growth.23 Either chromosomal or plasmid DNA can be
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transformed into S. aureus, although competence requires high calcium concentrations 
(0.1 M). Indeed, the requirement for a non-physiological calcium concentration and a 
short period of competence (when nucleases are absent) are likely to reduce the 
likelihood of staphylococcal transformation in situ.24
Mupirocin (Bactroban; pseudomonic acid) and triclosan (Irgasan DP300; 2,4,4'- 
trichloro-2'-hydroxydiphenyl ether) are important antimicrobials for the control of 
MRSA.25'37 However, in 1991 transferable low-level resistance to triclosan (MIC = 2- 
4 mg/L) was linked to mupirocin resistance in isolates of S. aureus isolated after 
exposure to both of these compounds.38 No further evidence has been offered in 
support of this phenomenon and several investigations have failed to identify any link 
between reduced susceptibility to triclosan and mupirocin resistance.39"42 Herein we 
discuss the gene transfer of reduced triclosan susceptibility in S. aureus and 
coagulase-negative staphylococci (CoNS), investigate possible associations with other 
resistances and the effect of triclosan on the transfer of resistance genes.
Materials and Methods
Unless otherwise stated, all concentrations are % weight/volume. All experiments 
were performed in triplicate (n=3) and unless otherwise stated results are presented as 
mean ± standard error of the mean (s.e.).
Bacterial strains and growth conditions. Table 5.1 describes the bacterial strains, 
plasmids and bacteriophages used within this investigation. Prior to experimentation 
strains were confirmed as S. aureus or coagulase-negative staphylococci (CoNS) by 
streaking on Vogel-Johnson agar (VJA; Oxoid), latex-agglutination test for extra­
cellular coagulase (Staphylase test; Oxoid) and multiplex PCR, as described 
previously43,44 Staphylococcal strains were stored in 50% glycerol at -80°C and, 
when required, maintained on either nutrient agar (NA; Oxoid), Iso-Sensitest agar 
(ISA; Oxoid) or Mueller Hinton agar (MHA; Oxoid). Over-night cultures were 
prepared by inoculation of 10 mL nutrient broth (NB; Oxoid) or Iso-Sensitest broth 
(ISB; Oxoid) with colonies from a streak plate and incubation in an orbital shaker at 
37°C for 15 h. E.faecalis and Streptococcus pneumoniae strains were stored similarly
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Table 5.1. Bacterial strains, plasmids and bacteriophage used in the study of transfer of antimicrobial resistance amongst staphylococci.
Name Description8 Resistance phenotypeb,c Phage susceptibility Reference/Sourced
S. aureus NCTC6571 Oxford strain, isolated in 1940. Widely used control strain - O 80a NCTC
S. aureus 6571 R if Rifampicin resistant mutant o f NCTC6571 Rif O80a This study
S. aureus RN450 Plasmid-ffee recipient strain cured o f 011 , 012  & 013 Nov, R if O80a, OK 78
S. aureus NCIM B9518 Triclosan susceptible industrial strain - O80a, <DK 41,79
S. aureus 9518T1 Reduced triclosan susceptibility mutant o f NCIMB9518 Trie (1) O80a, OK 41,79
S. aureus 9518T2 Reduced triclosan susceptibility mutant o f NCIMB9518 Trie (2) O80a, OK 41,79
S. aureus 9518T3 Reduced triclosan susceptibility mutant o f NCIMB9518 Trie (2) O80a, OK 41,79
S. aureus 9518T3Mup 9518T3 with /7eS2-carrying plasmid from S. aureus Eagles MupH, Trie (2) O80a, OK This study
S. aureus 9518T3pG01 9518T3 with pGOl plasmid from S. aureus 661 Gen, Kan, Neo, Tob, Tmp, QAC, Trie (2) O80a, OK This study
S. aureus 9518T3pIP501 9518T3 with pIP501 plasmid from S. pneumoniae T4N 514 Chi, MLS, Trie (2) O80a, OK This study
S. aureus 9518T4 Reduced triclosan susceptibility mutant o f NCIMB9518 T ric ( l) O80a, OK 41
S. aureus 9518Rif Rifampicin resistant mutant o f NCIMB9518 R if O80a, OK 41
S. aureus 24500 Clinical MRSA isolate Pen, Oxa, Cip, Amp, Cec, Cro O80a, OK 41
S. aureus 24500T1 Reduced triclosan susceptibility mutant o f 24500 Pen, Oxa, Cip, Amp, Cec, Cro, Trie (1.5) O80a 41
S. aureus 24532 Clinical MRSA isolate Pen, Oxa, Ery, Tec, Cip, Amp, Cec, Cro O80a 41
S. aureus 247378 Clinical MRSA isolate with high-level mupirocin resistance Pen, Oxa, MupH, Ery, Cip, Amp, Cec, Cro O80a, OK 41
S. aureus Eagles Carries plasmid-bome, high-level mupirocin resistance Pen, MupH, Ery, Tec, Amp, Cec O80a, OK 9
S. aureus EaglesT4 Reduced triclosan susceptibility mutant o f S. aureus Eagles Pen, MupH, Ery, Tec, Amp, Cec, Trie (1.5) O80a, OK This study
S. aureus EaglesT4Mup‘ S. aureus EaglesT4 cured o f z7eS2-carrying plasmid Pen, Ery, Tec, Amp, Cec, Trie (1.5) O80a, OK This study
S. aureus 661 Donor strain carrying pGOl (pWBG613) Gen, Kan, Neo, Tob, Tmp, QAC, Etbr OK 80
S. aureus W BG541 Plasmid-ffee recipient Rif, Fus O80a, OK 81
S. epidermidis 12228 Non-biofilm forming, non-infection associated strain Oxa, Tet OK 82
Table 5.1 cont. Bacterial strains, plasmids and bacteriophage used in the study of transfer of antimicrobial resistance amongst staphylococci.
Name Description* Resistance phenotype6 ' Phage susceptibility Reference/Sourced
S. epidermidis LTN Clinical isolate from UHW, Cardiff, Wales Pen, Oxa, Cip, Amp, M upH, Fus, Trie (4) d>K This study
S. pneumoniae T4N514 Apathogenic donor strain carrying pIP501 Chi and MLS EG
E. faecalis JH2-2 Recipient strain Rif, Fus 83
pGOl pWBG613, 52 kb plasmid (nhr) Gen, Kan, Neo, Tob, Tmp, QAC 10,80
pIP501 30.2 kb plasmid originally identified in S. agalo Chi and MLS 10,84
Bacteriophage 80a Mosaic genome related to 4>1 land known to me - 46,85
Bacteriophage K Polyvalent Myoviridae with a 127 kb genome (bhr) - 86
a UHW, University Hospital of Wales; nhr, narrow host range; bhr, broad host range; SaPll, staphylococcal pathogenicity island 1.
b Amp, ampicillin; Cec, ceflacor; Chi, chloramphenicol; Cip, ciprofloxacin; Cro, ceftriaxone; Ery, erythromycin; Fus, fusidic acid; Gen, gentamicin; Kan, 
kanamycin; MLS, macrolide, lincosamide, streptogramin B antibiotics; MupH, high-level mupirocin; Neo, neomycin; Nov, novobiocin; Oxa, oxacillin; Pen, 
penicillin; QAC, quaternary ammonium compounds; Rif, rifampicin; Tec, teicoplanin; Tet, tetracycline; Tmp, trimethoprim; Tob, tobramycin; Trie, triclosan.
0 MIC of triclosan (mg/L) is given in brackets if resistance is indicated.
d NCTC, The National Collection of Type Cultures; EG, Dr Elisabeth Grohmann, University of Technology, Berlin, Germany.
but brain heart infusion agar (BHIA; Oxoid) and brain heart infusion broth (BHIB; 
Oxoid) were used as growth media. Due to the requirement for calcium during 
transduction and transformation experiments all media contained 400 mg/L CaCb.
Biocide and antibiotic susceptibility. MICs for three biocides, triclosan (gift from 
Ciba Speciality Chemicals, Germany), chlorhexidine gluconate (CHX; ICN 
Biomedicals Inc.) and cetylpyridinium chloride (CPC; ICN Biomedicals Inc.), were 
calculated according to the guidelines of the British Society for Antimicrobial 
Chemotherapy (BSAC).45 Etest® strips (Bio-stat Ltd) were utilized to attain the MIC 
for antibiotics, as per the manufacturer’s directions.
Curing o f mupirocin resistance. High-level mupirocin resistance was cured by 
incubation in antibiotic free-media at 43 °C for 24 h. Curing of the //eS'i-carrying 
plasmid was confirmed by assessing the reduction in mupirocin MIC and by loss of 
the mupirocin resistance gene as assessed by multiplex PCR.43,44
Isolation o f resistant mutants. Mutants of S. aureus resistant to rifampicin, for use as 
recipients in gene transfer experiments, were isolated as described previously. Low- 
level reduced triclosan susceptibility mutants, used as donors, were also isolated as 
described previously.41
Conjugation. Mating experiments were performed by a method adapted from Thomas 
et al.. (1999)9. Briefly, donor and recipient cells were grown overnight at 37 °C in 10 
ml of the appropriate broth. 1 ml of the donor cell culture and 3 ml of the recipient 
cell culture were mixed and the mixture filtered through a 0*2 pm cellulose nitrate 
membrane filter (Millipore) held in a sampling manifold (Millipore). Using sterile 
forceps the membranes were placed with the bacterial cells facing upwards onto a NA 
plate and incubated overnight at 37 °C (ISA agar was used for transfers involving 
coagulase-negative staphylococci or BHIA for those with E. faecalis or S. 
pneumoniae). Following incubation, the membranes were removed and vortex mixed 
in 1 ml NB (or appropriate media). These suspended mating mixtures were serially 
diluted with phosphate buffered saline (PBS; Oxoid) and spread onto plates 
containing appropriate selective antimicrobials to select for growth of either recipient
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or transconjugant cells. Antimicrobials were used at the following concentrations: 
chloramphenicol, 10 mg/L; CPC, 10 mg/L; erythromycin, 100 mg/L; gentamicin, 10 
mg/L; mupirocin, 100 mg/L; rifampicin, 50 mg/L; triclosan, 1 mg/L. The lithium salt 
of mupirocin was a gift from GlaxoSmithKline (Harlow, UK) whilst, unless 
previously stated otherwise, all other antimicrobials were purchased from Sigma. 
Separate donor and recipient cultures were run alongside as controls. Colonies were 
counted after incubation for 48 h at 37°C and the transfer frequencies calculated as the 
number of transconjugants per recipient cell. Each cross was repeated three times and 
the results represent mean values. When required, the direction of transfer was 
determined by replica plating and utilizing secondary markers not used for selection 
in the original cross. Additionally, when examining transfer of high-level mupirocin 
resistance (HL-mupR) suspected transconjugants were confirmed as carrying the ileS2 
(mupirocin resistant) gene by multiplex PCR.43,44 This PCR was also employed to 
confirm the species identification of a selection of transconjugants from each 
experiment. Tri-parental matings were performed similarly, except 1 mL of each 
donor and 3 mL of recipient was used.
Transduction. The ability of staphylococcal transducing phages 80a and K to transfer 
resistance traits by transduction was investigated by a method adapted from Jiang & 
Paul, (1998)18 and Novick (1991)46. Briefly, transducing particles were produced by 
infecting a donor strain with <X>80a by the overlay method.47 If either donor or 
recipient were unsusceptible to O80a, phage K was used. Phages were purified from 
the plates after overnight incubation by flooding overlay plates, showing near 
confluent lysis, with 10 mL of warm 0.5 M Tris-HCl and incubating at room 
temperature for 20-30 min. The liquid was recovered, filtered (0.2 pm Minisart 
syringe units; Sartorius) and a second round of high-titre phage lysate was produced 
with the same donor strain to ensure that the transducing particles contained only 
donor strain DNA. Lysates were stored at 4°C until required. Phage lysates were 
digested with 50 U of DNase I per mL before use in transduction assays to remove 
any free DNA that would be available for transformation.
0.5 mL of phage lysate was mixed with an equal volume of mid-log phase recipient 
culture H O 10 cells) at multiplicities of infection (MOI) ranging from 0.01 to 1.
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Control experiments contained the recipient cell culture but 0.5 mL of quarter-strength 
Ringers solution (Oxoid) replaced the lysate. Following incubation at 30°C for 30 min 
to allow for adsorption, unadsorbed phages were removed by three rounds of 
centrifugation and washes with broth. The final washed cell pellet was resuspended in 
1 mL of broth. The cells were allowed to recover for 10 to 20 min before they were 
plated onto selective plates containing appropriate antimicrobials at concentrations 
described above. The recipient-free transducing phage lysate was also plated onto 
selective plates as a control. After 48 h incubation at 37°C, transductants were 
counted. The recipient titre at the start of each transducing period was determined
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using the drop plate method allowing transfer frequency to be calculated as 
transductants per recipient. This was performed in triplicate for each lysate/recipient 
combination and the results presented as mean ± s.e.
Transformation, Cell lysates were prepared from overnight cultures of donor bacteria 
washed 3 times by centrifugation at 13,000 rpm for 5 min to remove any extracellular 
nuclease. Following a final centrifugation the pellet was resuspended in 0.5 mL sterile 
saline citrate/detergent solution (0.15 M NaCl, 0.015 M Sodium citrate and 0.05% 
Sodium dodecyl sulphate) and incubated for 1 hour at 60°C with agitation every 15 
min. Recipient cells were prepared by 3 washes in broth to remove extracellular 
nucleases, followed by resuspension in broth to ~1010 cells/mL. 100 pL of the 
resulting cell suspension was added to an equal volume of cell lysate and mixed 
thoroughly. This mixture was subsequently transferred to a sterile 47 mm 
nitrocellulose filter membrane (Millipore; pore size 0.2 pm) placed on the surface of a 
NA plate. Transformation membranes were incubated for 3, 6, 12 or 24 hours at 37°C. 
Lysate-free controls were prepared in parallel, containing 100 pL of recipient and 100 
pL of sterile Ringer’s solution. Following incubation membranes were removed with 
sterile forceps and vortex mixed in 1 mL NB (or appropriate media) for 1 minute to 
re-suspend the filter bound bacteria. Serial dilutions of the resuspended cells were 
plated on to the appropriate selective agar and, following incubation at 37°C for 24-48 
h the transformation frequency was calculated as transformants per recipient. This 
was performed in triplicate and the results presented as mean ± s.e.
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Effect o f triclosan on gene transfer. The effect of sub-inhibitory triclosan on gene 
transfer was investigated for all three mechanisms of transfer. Conjugation 
experiments were performed exactly as described above except 0.01, 0.1, 1 or 10 
mg/L triclosan was included in the agar upon which the filter and bacteria were 
incubated. Triclosan-free experiments were run alongside as controls. The effects of 
triclosan on transduction were examined by three approaches: pre-exposure of the 
transducing particles; pre-exposure of the recipient; presence of triclosan in the 
infection mixture. 1 mL of transducing lysate was mixed with triclosan to give final 
concentrations of 0.01, 0.1, 1 or 10 mg/L. The triclosan was then neutralized with 4 
mL of neutralizing solution and the remainder of the transduction process continued 
as described above. This method was repeated but using 1 mL of bacterial culture, 
creating recipients pre-exposed to triclosan. To assess the effects of triclosan exposure 
in the infection mixture the mixed recipient and lysate cultures were adjusted to 0.01,
0.1, 1 or 10 mg/L triclosan, incubated as described above, followed by the addition of 
4 mL of neutralizing solution. Each sample was then taken to completion with the 
standard protocol detailed above. The transformation protocol described above was 
adapted to assess the effect of triclosan by supplementing the growth media used 
during the incubation of bacterial cells and free DNA with 0.01, 0.1, 1 or 10 mg/L 
triclosan. Triclosan-free controls were run alongside all transfer experiments.
Efficacy and toxicity o f triclosan neutralizing solution. The neutralizer used here 
was based on the British Standard EN 1499.49 The solution was made fresh in distilled 
water and contained 30 g/L Tween 80 (Sigma), 3 g/L lecithin (Sigma), 1 g/L L- 
histidine (Sigma) and 5 g/L sodium thiosulphate (Fisher). The efficacy and toxicity of 
the neutralizer to bacteria were confirmed as satisfactory as described previously.41 
This method was adapted to examine the suitability of the solution to neutralize 
triclosan in phage lysates by replacing the bacterial culture with a high titre lysate of 
O80a or phage K. There was no significant difference (P = 0.798) between the viable 
phage count of lysates exposed to triclosan and the neutralizer and where water was 
substituted for triclosan, confirming the ability of the neutralizer to quench the 
virucidal activity of triclosan at 100 mg/L. When examining the possible toxicity of 
the neutralizer, there was no significant difference (P = >0.05) between the viable 
phage counts of lysates exposed to sterile water and those exposed to the neutralizer
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for 15 min, confirming that the neutralizer was non-toxic to the phages under 
investigation.
Bioinformatic analyses. The evolutionary histories of staphylococcal fabl genes and 
surrounding sequences were investigated for potential horizontal acquisition with two 
bioinformatic programmes: Artemis50 and alienhunter51. Sequence files of 
prokaryotic genomes were retrieved from Entrez Genome. Artemis was used to view 
genome sequences and to display parameters used for inferring horizontal acquisition: 
%GC; GC frame plot; Karlin Signature Difference and data output from alien hunter. 
Two databases containing predictions of the likelihood that a gene has been 
horizontally acquired were also used: The Horizontal Gene Transfer Database (HGT- 
DB)53 and Horizontal Gene Transfer Predictions in Archaea and Bacterial Genomes 
by IBM's Bioinformatics & Pattern Discovery Group.54 These databases were 
searched to identify if they predicted fab l or any gene within 20 kb either side offabl 
to be horizontally acquired. Artemis and the sequence resources of Entrez Genome 
were also used to identify any putative MGE (prophage, transposons, IS and remnants 
thereof) located within this ~41 kb region.
Statistical analyses. All experiments were performed in triplicate (n=3) and unless 
otherwise stated results are presented as mean ± standard error of the mean (s.e.; 
calculated by dividing the standard deviation of the mean by the square root of n). 
Significant effect was investigated by t test or one-way ANOVA, carried out at 95% 
confidence interval. This was performed using Minitab® release 14 software (Minitab 
Inc.). If the assumptions required to perform these tests were violated, the Mann- 
Whitney or Kruskal-Wallis tests were performed at 95% confidence intervals.
Results
Bioinformatic analysis o f fabl gene. Bioinformatic analysis of the gene which, when 
mutated can confer reduced susceptibility to triclosan, revealed it to be highly 
conserved amongst S. aureus strains and no obvious signs of horizontal acquisition. 
Querying the HGT-DB and Horizontal Gene Transfer Predictions in Archaea and 
Bacterial Genomes databases did not indicate that any of the staphylococcal genomes 
stored in these databases contained fab l sequences that may have been horizontally
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acquired. Moreover, neither database was able to identify any notable regions within 
20 kb (up and down stream) as being horizontally acquired. This was supported by 
our own analyses; we detected no major variation in %GC, GC frame plot or Karlin 
Signature Difference amongst the same ~41 kb locus in all staphylococcal genomes 
available currently, including CoNS (data not shown). Similarly, no major area of 
horizontally acquired DNA was identified when viewing the data from alien hunter 
analyses. Additionally, no putative MGE where identified within the proximity of 
fabl. To corroborate this approach these analyses were also performed on a known 
horizontally acquired gene, mecA, the genetic determinant for methicillin resistance. 
The sequence environment of mecA was found to be quite different to the of fa b f  the 
HGT-DB identified 5 genes within 20 genes of mecA in MRSA strains Mu50 and 
N315, whilst the same region of the community-associated MRSA, MW2, contained
7. As expected, further analysis identifies a high density of resistance genes and a 
large number of MGE associated sequences, including 5 transposases, 3 recombinases 
(including the cassette chromosome recombinases A and B) and plasmid-associated 
genes.
Gene transfer o f triclosan resistance. Although bi-parental filter matings of plasmid- 
bearing S. aureus and S. pneumoniae with various recipients resulted in transfer of 
antimicrobial resistance traits, no transfer of reduced triclosan susceptibility was 
detected (Table 5.2). Mupirocin resistance was transferred from S. aureus Eagles and 
clinical mupirocin resistant strain S. aureus 247378 at low frequencies (10’8 to 10‘10), 
whilst pGOl from S. aureus 661 transferred at higher frequencies (10'6 to 10'9). 
EaglesT4, a mutant of S. aureus Eagles showing reduced susceptibility to triclosan, 
was still able to transfer MupR at similar frequencies to it’s parent (data not shown) 
however, no transfer of mupirocin and triclosan resistance in combination was 
detected. Similarly, transconjugants of S. aureus 9518T3, now carrying MupR, were 
able to transfer Mupirocin resistance, but not in association with triclosan resistance. 
This was repeated with 9518T3 transconjugants carrying pGOl or pEP501, again these 
were able to transfer the plasmid-associated resistance (GenR and ChlR, respectively; 
Table 5.2) but transfer in combination with reduced susceptibility to triclosan was 
below the level of detection. No transfer of reduced-triclosan susceptibility was 
detected from mutated strains with a range of genetic backgrounds; MRSA, MupR- 
SA and an industrial strain (NCIMB9518; Table 5.1).
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Table 5.2. Conjugative transfer of antimicrobial resistance during bi-parental matings. Transfer frequencies are presented as transconjugants per recipient.
Donor
Trait(s)
transferred8
Recipient
S. aureus 9518Rif S. aureus 9518T3 S. aureus RN450 S. aureus 6571Rif S. aureus WBG541 E. faecalis JH2-2
S. aureus Eagles Mupr 1.92x10‘9 4.29 xlO'9 5.14xl0*8 9.94x1 O*10 2.86xl0*8 <6.04x10*"
S. aureus 9518T3 Tricr <2.31x10*" - <8.33x10*" <9.18x10*" <2.71x10" <4.70x10*"
S. aureus EaglesT4 Mupr 7.23xlO*10 - 2.35 xlO*8 7.88xlO*10 4.41 xlO*9 <3.81x10*"
S. aureus EaglesT4 Mupr & Tricr <9.07xl0*u - <1.87xlO*10 <5.48x10*" <3.25x10*" <2.12x10*"
S. aureus 9518T3Mup Mupr 6.74xl0*9 - 1.33xlO*8 2.93xlO*10 5.47xl0*9 <7.43x10*"
S. aureus 9518T3Mup Mupr & Tricr <1.77xl0*u - <2.31x10*" <8.45x10*" <7.91x10*" <2.24x10*"
S. aureus 24500T1 Tricr <1.64x10*" - <1.64x10*" <1.64x10*" <1.64x10" <8.61x10*"
S. aureus 247378 Mupr 4.03 xlO*9 1.37xl0*8 7.41 xlO*8 5.48 xlO*9 8.47 xlO*8 <4.27x10*"
S. aureus 661 Genr 8.98xl0*7 5.58xl0*8 2.12xl0*7 5.22 xlO"9 2.31 xlO*6 <5.35x10*"
S. aureus 9518T3pGO 1 Genr 6.07 xlO*9 - 1.17xl0*8 5.84xlO*10 9.36xl0*9 <8.71x10*"
S. aureus 9518T3pG01 Genr& Tricr <6.35x10*" - <4.29x10*" <3.12x10*" <6.33x10" <4.24x10*"
S. pneumoniae T4N514 Chlr 8.53 xlO*8 6.86x10*9 7.39xl0*9 2.02xl0*10 9.67xl0*7 3.11 xlO*6
S. aureus 9518T3pIP501 Chlr 3.47xl0*9 - 6.68xl0*9 7.89xlO*10 4.58xl0*8 <5.41x10*"
S. aureus 9518T3plP501 Chlr & Tricr <5.50x10’" - <1.09xl0*12 <6.24x10*" <8.94x10*" <7.84x10*"
S. epidermidis LTN
a * m _ _r
Tricr
rri • f • i
<3.06x10*" - <5.66x10*" <1.87x10*" <7.11x10*" <4.49x10*"
8 Mupr, mupirocin resistance; Tricr, triclosan resistance.
Strains of S. epidermidis are less susceptible to triclosan than their coagulase-positive 
relatives.55 S. epidermidis has also been described as a source of a mupirocin 
resistance plasmid in an MRSA strain.56 As a consequence of this we theorized that S. 
epidermidis may represent a potential reservoir of resistance that S. aureus, being 
closely related, found often in the same locale, could exploit. Hence, we investigated 
S. epidermidis LTN as a potential triclosan resistance donor. However, no transfer of 
triclosan resistance from S. epidermidis was detected (level of detection was 
<1.87x 1 O'11 to <7.11x 1 O'11 transconjugants per recipient).
It is known that some plasmids have the ability to mobilize other, non-self- 
transmissible, plasmids and MGE.10 Consequently, we used tri-parental matings to 
examine this phenomenon in our strain collection. These matings involved mixing a 
primary donor, carrying a conjugative plasmid, with a secondary donor, carrying 
another resistance trait and a recipient strain. We were specifically looking for the 
ability of three conjugative plasmids, Eagles’ mupirocin resistance plasmid, pGOl 
and pIP501, to mobilize the genetic determinant for reduced triclosan susceptibility 
from a selection of secondary donors. However, none of these plasmids were able to 
transfer triclosan resistance from the secondary donor into either S. aureus 9518Rif or 
WBG542 (data not shown). Remarkably, when we used strains of S. aureus that 
carried mupirocin resistance in addition to triclosan resistance as secondary donors the 
frequency of mupirocin resistance transfer was significantly increased (P -  <0.05), 
but the frequency of triclosan resistance transfer remained below our levels of 
detection (level of detection, <4.17x10'n to <6.25X1 O'11; Table 5.3). Neither triclosan 
or mupirocin resistance could be transferred into E. faecalis JH2-2 at frequencies 
above the level detection (level of detection, <2.04xl0'n to <5.70x10'n).
Interestingly, we found that the MIC for triclosan in S. aureus EaglesT4 before and 
after curing of the ileS2-carrying plasmid was 0.03 mg/L. Similarly, when 9518T3 
received and expressed plasmid-bome mupirocin resistance, from either S. aureus 
Eagles or clinical isolate 247378, it’s triclosan MIC (2 mg/L) was unaffected. Indeed, 
the triclosan susceptibility of all S. aureus 9518T3 transconjugants was unchanged 
from the parent and subsequent curing did not alter this (data not shown). So we 
found no evidence for plasmid carriage or strain background affecting the MIC to 
triclosan.
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Table 5.3. The ability of plasmids pGOl and pIP501 to mobilize resistance to triclosan in association with mupirocin resistance during tri-parental matings.
Transfer frequencies are transconjugants per recipient. For each mating, selective media were used to calculate the transfer of mupirocin resistance (Mupr) on its own 
and mupirocin resistance in combination with reduced susceptibility to triclosan (Mupr, Tricr).
Donor 2
Donor 1
Trait(s)
transferred
S. aureus EaglesT4 
Mupr Mupr, Tricr
S. aureus 9518T3Mup 
Mupr Mupr, Tricr
S. aureus 
Mupr
EaglesT4 
Mupr, Tricr
S. aureus 9518T3Mup 
Mupr Mupr, Tricr
S. aureus 661 Genr 2.83 xlO'8 <6.25x10'" 8.66x1 O'8 <4.17x10'" <5.70x10'" <5.70x10'" <2.64x10'" <2.64x10'"
S. pneumoniae T4N514 Chlr 5.06x1 O'9 <4.32x10'" 7.37xlO'10 <5.21x10'" <2.04x10'" <2.04x10'" <4.25x10'" <4.25x10'"
S. aureus WBG542 S. aureus WBG542 E. faecalis JH2-2 E. faecalis JH2-2
Recipient
To investigate the potential for reduced susceptibility to triclosan to be disseminated 
by transduction, we created lysates of bacteriophages 80a and K propagated on a 
selection of resistance bearing staphylococci. Whilst examining transduction we 
found a MOI of 0.1 to be optimum for gene transfer (data not shown). Consequently, 
all results presented herein were obtained using this ratio of phages to bacteria. S. 
aureus strains NCIMB9518, RN450, NCTC6571 and WBG541 were able to receive 
and express resistance traits transferred by transduction (Table 5.4). Mupirocin 
resistance was transferred to S. aureus recipients at frequencies of between 3.02x1 O'9 
and 1.34x1 O'10 transductants per recipient, whilst transfer of rifampicin resistance was 
transferred at higher frequencies (9.35x1 O'8 to 6.79x10'9 transductants per recipient). 
Gentamicin resistance was transferred at similar frequencies to mupirocin resistance, 
whilst no transfer of triclosan resistance was detected. As above, we investigated the 
potential of S. epidermidis LTN to donate triclosan resistance. However, no CoNS to
S. aureus transfer of triclosan resistance was detected and neither was it able to 
transfer this resistance to S. epidermidis 12228.
Due to the rarity of the event, transformation is difficult to study in species of Gram- 
positive bacteria and particularly S. aureus, which produces large amounts of 
extracellular DNase. These enzymes digest any free DNA which would otherwise be 
available for transformation. The process is further complicated by the window of 
competency being fairly short and reliance upon high calcium concentrations. In an 
effort to reduce digestion of the free DNA all recipients were washed extensively to 
remove as much extracellular staphylococcal DNase as possible. However, we were 
unable to identify any frequency of transformation above our level of detection 
(between 3.76x1 O'10 and 5.02x10 11 transformants per recipient).
Effects o f triclosan on gene transfer. Several studies had shown that the presence of 
antibiotics or biocides can affect the frequency of gene transfer events.14,21,57'61 
Consequently, we aimed to model the effects of triclosan upon gene transfer of 
antimicrobial resistance traits amongst staphylococci and some other low-GC, Gram- 
positive bacteria.
Triclosan had noticeable effects on gene transfer of antimicrobial resistance by 
conjugation; concentration of triclosan had a significant effect upon conjugal transfer
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Table 5.4. The transfer of antimicrobial resistance traits by transduction. Both chromosomally encoded (rifampicin resistance; Rif) and plasmid encoded (mupirocin 
resistance and gentamicin resistance; Mupr and Genr, respectively) resistance traits were transferred between S. aureus by transduction. However, no transduction of triclosan 
resistance was detected. Transduction frequency was optimal when using an MOI of 0.1. Bacteriophage 80a was used for all transductions, unless either donor or recipient 
was unsusceptible to this phage and bacteriophage K was used instead. Transfer frequencies are shown as transductants per recipient.
Donor Trait(s) transferred
Recipient
S. aureus 9518 S. aureus RN450 S. aureus 6571 S. aureus WBG541 S. epidermidis 12228
S. aureus Eagles Mupr 9.86xl010 1.47 xlO'9 1.34x10"'° 3.02x10'9 <1.78x10"'°
S. aureus 9518Rif Rif 1.93 xlO'8 9.35 xlO'8 6.79x1 O'9 8.59xl0'8 <9.68x10"
S. aureus 9518T1 Tricr <5.02x10'" <1.32x10'" <9.02x10'" <8.43x10'" <8.67x10'"
S. aureus 9518T3 Tricr <7.08x10'" <7.49x10'" <5.40x10'" <5.46x10'" <4.12x10'"
S. aureus 9518T4 Tricr <8.11 xlO'11 <1.24x10-'° <8.89x10'" <3.93x10'" <1.55x10"'°
S. aureus EaglesT4 Mupr & Tricr <3.77x10'" <8.21x10'" <5.25x10'" <8.91x10'" <3.61x10'"
S. aureus 9518T3Mup Mupr & Tricr <9.08x10'" <5.32x10'" <2.50x10'" <9.11x10'" <7.35x10'"
S. aureus 24500T1 Tricr <7.67x10'" <6.96x10'" <9.65x10'" <6.20x10'" <1.50x10'"
S. aureus 661 Genr 6.44xl0'9 1.07x1 O'9 2.13x10''° 6.74xl0'9 <7.96x10'"
S. aureus 9518T3pGO 1 Genr& Tricr <3.92x10'" <8.56x10" <6.09x10'" <7.52x10'" <9.24x10'"
S. epidermidis LTN Tricr <7.94x10'" <4.21x10'" <2.00x10'" <8.96x10'" <2.82x10'"
of mupirocin resistance (P = 0.001; Figure 5.1a). The presence of 0.1 mg/L triclosan 
increased significantly the frequency of mupirocin transfer (P = 0.09), but this 
increase did not hold true for 1 mg/L, and when exposed to 10 mg/L of triclosan 
conjugation was decreased significantly (P -  <0.001). However, no transfer of 
reduced triclosan susceptibility was detected during exposure to any level of triclosan 
(Figure 5.1b). Triclosan significantly affected the conjugal transfer of other plasmids 
and their associated resistances (P -  0.034; Figure 5.1c). No significant difference in 
the transfer of pGOl or pIP501 was observed with 0 to 0.1 mg/L triclosan (P = 
<0.05), but 10 mg/L significantly reduced the frequency of transfer of these MGE (P 
= 0.008).
We were keen to investigate the effects of triclosan upon the interspecies transfer of 
resistance determinants by conjugation and found that triclosan also significantly 
affected the transfer of pIP501 from S. pneumoniae T4N514 to S. aureus WBG542 (P 
= 0.391; Figure 5.Id). Interestingly, 0.1 mg/L triclosan appeared to slightly, but 
significantly, increase the transfer of pGOl from S. aureus 661 to S. epidermidis 
12228 {P -  0.041). However, the presence of triclosan failed to induce neither the 
transfer of pGOl to E. faecalis JH2-2 nor the transfer of triclosan resistance from S. 
epidermidis LTN to S. aureus WBG542. The presence of DMSO, the solvent in our 
triclosan solutions, had no significant effect upon conjugation when compared with 
water (P = <0.05).
Whilst the pre-exposure of the phages to triclosan did not induce the transduction of 
triclosan resistance to detectable levels, it was shown to affect transduction 
frequencies of other resistance traits (Figure 5.2a). Transduction of rifampicin 
resistance and pGOl-encoded QAC and Gentamicin resistance were significantly 
reduced by pre-exposure of the transducing phages to 1 or 10 mg/L triclosan (P = 
>0.05). We were unable to test the effects of exposing recipient cells to 1.0 and 10 
mg/L triclosan since this was lethal to the recipient. However, pre-exposure of the 
recipient to 0-0.1 mg/L triclosan had no significant effect upon transduction frequency 
(P -  <0.05). Interestingly, the presence of triclosan in the transducing mixture had the 
most potent effect upon transduction. Whilst 0 and 0.01 mg/L triclosan did not 
significantly effect transduction (P = <0.05), 0.1,1 and 10 mg/L triclosan did
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Figure 5.1. Effect of triclosan on gene transfer of antimicrobial resistance by conjugation, (a) 
Conjugal transfer of mupirocin resistance w as significan tly  affected  by  10 m g/L triclosan (black bar, 
Eagles x 9518R if; g rey  bar, E ag lesT 4  * 9518R if; w hite bar, 247378 x 9518Rif). (b) Transfer of 
triclosan resistance w as no t induced  by  the add ition  o f  triclosan during conjugation, either singularly  
o r in com bination  w ith  m up irocin  resistance  (b lack  bar, 9518T3 x 9518Rif; grey bar, E aglesT 4 x 
9518R if; w hite bar, 9518T 3m up x 9 5 1 8Rif). (c) The conjugative transfer of other resistances w as 
also significan tly  affected  by  10 m g/L  tric lo san  (P  =  0 .008). S. aureus  661 was used as the donor for 
gentam icin  resistance and S. p n eu m o n ia e  T 4N 541 the dono r o f  chloram phenicol resistance (black bar, 
661 x W B G 542; grey bar, 661 x 9518R if; w hite  bar, T 4N 514  x JH 2-2). (d) Interspecies transfer of 
resistance w as affected  by  the p resence o f  tric losan , h ow ever no  transfer o f  triclosan resistance from  S. 
epiderm idis  LTN  w as induced. A gain  S. aureus  661 and  S. p n eu m o n ia e  T4N 541 w ere used  as donors, 
additionally  L TN  w as em ployed as a po ten tia l d o n o r o f  tric losan  resistance (black bar, T4H 514 x 
W B G 542; grey bar, 661 x JH 2-2; w hite bar, 661 x 12228; chequered  bar, L TN  x W B G 542). T he 
dashed line represents the lim it o f  detection.
(a)
1x10^ 
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1X10'11
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H20  DM SO  0 .0 1  0 .1  1 1
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Figure 5.2. Effect of triclosan on transduction. Triclosan was shown to affect transduction during (a) 
pre-exposure of the transducing particles (b) Pre-exposure of the recipient had the least effect upon 
transduction, (c) whilst the presence of triclosan during infection significantly reduced the frequency 
of transduction (P = >0.05). Black line, rifampicin resistance; grey line, CPC resistance; dashed line, 
triclosan resistance.
(b)
(c)
H20  D M SO  0 .0 1  0 .1  1 10
Triclosan concentration (mg/L)
—i
H20  D M SO  0 .0 1  0 .1  1 10
Triclosan concentration (mg/L)
S  1x10'
HzO  D M SO  0 .0 1  0 .1 1 10
Triclosan concentration (mg/L)
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significantly reduce the frequency of transduction of both rifampicin resistance and 
pGOl-associated resistances (P = 0.808 and 0.415, respectively). The presence of 
DMSO had no significant effect upon transduction when compared against water (P = 
<0.05).
Although we had been unable to detect the gene transfer of antimicrobial resistance 
genes by transformation, as described above, we hypothesized that the presence of 
triclosan may induce the transformation of reduced susceptibility to this antimicrobial 
by providing a strong selective pressure for its transfer. However, no transformation 
of S. aureus was detected; triclosan did not induce the transformation of the 
determinants for reduced susceptibility to triclosan amongst S. aureus.
Discussion
If horizontal transfer of triclosan resistance has occurred, it may reasonably be 
hypothesized that a gene associated with this resistance would show signs of 
horizontal acquisition. However, our analyses of eight S. aureus and four CoNS 
genomes revealed no such indication. We conclude that the chromosomal location, 
high-level of conservation and essentiality for survival, in combination with this 
bioinformatic analysis, signify that the likelihood of horizontal transfer of triclosan 
resistance, as mediated by fabl, is very low. This is also important in light of the 
knowledge that bacterial fatty acid biosynthesis is becoming a popular target for 
experimental chemotherapeutics.62'68 However, the high-level of conservation of the 
genes that encode the fatty acid biosynthetic pathway does provide the homology 
required for effective recA-mediated recombination, if transfer was to occur.
Previous transfer of triclosan resistance was associated with a mupirocin resistance 
plasmid and presumably the mode of transfer was conjugation. Therefore, we aimed 
to study the conjugative transfer of triclosan resistance, both singularly and in 
combination with mupirocin resistance. Whilst transfer of mupirocin and other 
antimicrobial resistances was mediated by conjugation, no transfer of triclosan 
resistance was detected. Indeed, when S. aureus strain Eagles, carrying plasmid-bome 
mupirocin resistance, was mutated to triclosan resistance, only mupirocin resistance 
was transferable. Similarly, whilst a triclosan resistant mutant, which had received the
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mupirocin resistant plasmid by conjugation, was able to disseminate the plasmid, we 
did not detect any transfer of triclosan resistance. This indicates that within these 
strains no ‘transfer relationship’ was developed between the mupirocin and triclosan 
resistances and thus co-transfer is unlikely. This occurred in a variety of S. aureus 
strains, indicating that transfer was not reliant upon the evolutionary history of the 
host. This was also seen with resistance plasmids pGOl and pIP501.
We hypothesized that the movement of plasmids through a secondary donor may 
provide the apparatus necessary for transfer and facilitate the dissemination of 
triclosan resistance. We found that mupirocin resistance transfer was increased; the 
presence of the more promiscuous plasmids, pGOl and pIP501, augmented the 
conjugation of z7e<S2-carrying plasmids. Yet, tri-parental matings failed to yield any 
detectable transfer of triclosan resistance. This also held true for inter-species transfer, 
which may play a significant role in the evolution of S. aureus and its clinical impact. 
For example, Enterococcus faecium has been identified as a source of high-level 
vancomycin resistance in MRSA, following conjugative transfer of an 100 kb plasmid 
in a poly-microbial biofilm.69 So other species appear to be a source of resistance 
genes for S. aureus and since S. epidermidis is less susceptible to triclosan than S. 
aureus we investigated whether this organism could be a donor for triclosan 
resistance. A lack of detectable transfer does not support this theory, by conjugative 
transfer at least. However, our in vitro model does not accurately replicate the 
complex interactions of a natural biofilm, which may affect this process.
Evidence that removing or introducing an z/e-S^-carrying plasmid from or into a 
triclosan resistant strain had no effect upon triclosan susceptibility reiterates the lack 
of association between these two resistances. Indeed, it appears that several other 
groups have failed to find an association between these resistances in S. aureus.39'42
A MOI of 0.1 was optimum for transfer of rifampicin and mupirocin resistance by 
transduction. However, no intra- or inter-species transduction of triclosan resistance 
was detected at any MOI (0.01 to 1). We thus conclude that whilst transduction may 
be an important factor in the dissemination of other resistance phenotypes, it is 
unlikely to be involved in the transfer of triclosan resistance amongst staphylococci.
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Furthermore, an alternative mode of transfer, transformation, also failed to facilitate 
triclosan resistance transfer.
As discussed above, we did not detect any transfer of triclosan resistance by 
conjugation, transduction or transformation. These transfer experiments were 
performed in the absence of triclosan, so we wanted to investigate the effects of 
triclosan on these interactions. We aimed to identify whether the presence of triclosan 
can induce the transfer of its resistance, in addition to elucidating the effects of 
triclosan upon gene transfer of other resistances, including resistances to other 
biocides. Triclosan did affect resistance transfer; a low concentration of triclosan (0.1 
mg/L) appeared to stimulate the transfer of mupirocin resistance, whilst higher 
concentrations reduced the efficiency of transfer. This also occurred, with lower 
significance, during the transfer of pGOl from S. aureus 661 to S. epidermidis 12228. 
We are unable to explain why low levels of triclosan had this promotional effect on 
conjugation. We could hypothesise it influences the surface properties and hence 
promotes the interaction between the mating cells. Such an interaction would reflect 
the complex nature of the conjugation process. More expectedly, the conjugative 
transfer of pGOl and pIP501 amongst most strains was diminished during exposure to 
triclosan, a phenomenon which may be a result of the cell wall effects of triclosan; 
previous hypotheses have speculated that cell wall targeting antimicrobials reduce 
conjugation efficiency by disrupting the cell wall-associated conjugation 
apparatus.57,60
Transduction frequencies were most notably affected by introducing triclosan in to the 
infection mixture. Pre-exposure of the transducing particles did also have a significant 
effect, although this was probably due to triclosan-induced inactivation of phages. The 
potent nature of triclosan exposure during infection was possibly a combination of the 
biocidal effects upon the virus, the host and again there is the possibility that, again, 
cell wall-associated aspects of the process were disrupted by the activity of triclosan 
on the cell wall.
Neither transduction nor transformation facilitated the transfer of triclosan resistance, 
and transfer was not induced by the presence of triclosan. The lack of transfer in the
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face of such strong selective pressure leads to the conclusion that the transfer of 
triclosan resistance is rare.
Several authors have also questioned the significance of low-level triclosan resistance 
in S. aureus, where MICs of 1-4 mg/L are magnitudes lower than the in-use 
concentrations of this antimicrobial.41,43,70 It should also be considered that, whilst 
most in vitro studies have used pure triclosan preparations, clinical and domestic 
formulations contain complex ratios of surfactants, detergents, chelating agents and 
wetting agents, which have their own antimicrobial effects and will affect the 
efficacy of the formulation. Although, low-level antimicrobial resistance in S. aureus 
may be associated with greater clinical risks than we might expect, such as increased 
mutation to higher resistance, augmented virulence, enhanced in vivo fitness and 
resistance to unrelated compounds.71
We have shown that, whilst mupirocin, QAC, chloramphenicol and rifampicin 
resistance could be transferred by conjugation and transduction, transfer of triclosan 
resistance was not detected. Additionally, the lack of historical transfer of the 
triclosan resistance-associated gene, fabl, draws us to question the significance of just 
one previous description of transferable triclosan resistance, which has attracted 
many citations and thus may have lead to it having become an accepted phenomenon. 
This is supported by a lack of significant triclosan resistance amongst clinical, 
domestic and industrial staphylococci exposed to triclosan,72'76 which would not be 
unexpected if resistance was readily disseminated.
Although triclosan has been shown to inhibit Fabl, it is not the sole target, 
consequently, other modes of resistance may exist41,43,70,77 Therefore it should be 
considered that the transferable resistance described by Cookson et a/.38 may have 
been conferred by one of these alternative, possibly more easily mobilized, 
mechanisms. Indeed, this previous report reminds us of the need to use a selection of 
antimicrobial ‘tools’ in our approaches to control the spread of infection.
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Synopsis
Objectives: A little understood mode of antimicrobial resistance in Staphylococcus 
aureus is the evolution of a sub-population of small-colony variants (SC Vs). SC Vs 
are a cause of persistent and recurring infections refractory to antimicrobial 
chemotherapy. Following the inadvertent isolation of suspected SCVs growing in the 
presence of triclosan we set out to evaluate the formation of these colonial mutants 
and assess their antimicrobial susceptibility.
Methods: SCVs were isolated on Mueller-Hinton agar supplemented with 1 mg/L 
triclosan. SCV formation frequency was calculated using a selection of both clinical 
meticillin resistant S. aureus (MRSA) isolates and meticillin-susceptible S. aureus 
(MSSA) strains. Antimicrobial susceptibility was assessed and the fabl gene of SCVs 
was sequenced to ensure resistance was not mediated by mutation of this gene. 
Results: We have found in vitro that triclosan can select for S. aureus colonies 
showing the characteristic SCV phenotype with low-level triclosan resistance and 
which coincidently have reduced susceptibility to penicillin and gentamicin. 
Additionally, triclosan isolated SCVs were shown to have an increased tolerance to 
the lethal effects of triclosan.
Conclusions: We propose the formation of SCVs by S. aureus is a novel mechanism 
of resistance to low concentrations of triclosan, which for twenty five years has been 
used widely in the domestic setting in various consumer healthcare products. More 
recently it has been recommended for the control of MRSA. Consequently, our results 
identify the potential for treatment failure in infections already notoriously difficult to 
eradicate. It remains unclear to what extent isolates with decreased susceptibility to 
triclosan would develop and have the fitness to survive under real world conditions.
Introduction
SCVs of S. aureus arise as a drug resistant sub-population during exposure to 
antimicrobial chemotherapeutics.1 Two types of SCV are regularly isolated; those 
with an interrupted electron transport chain (ETC) and those showing thymidine 
auxotrophy. ETC deficient SCVs can be further divided into those with mutations 
affecting menaquinone (vitamin K), haemin, thiamine or heme A biosynthesis. ETC 
SCVs are associated with persistent and relapsing osteomyelitis, sinusitis, muscle
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abscesses and device related infections2,3 whilst thymidine SCVs are seen in cystic 
fibrosis patients.4 Although data concerning the virulence of SCVs is ambiguous, 
infections have proven fatal.5'7 Mutations knocking out menaquinone, haemin or 
heme A biosynthesis block the S. aureus ETC. The subsequent energy deficiency 
bestows a characteristic pleiotropic phenotype including slow growth (hence small 
colonies), lack of pigmentation, non-production of virulence factors and reduced
o
spectrum of carbohydrate utilisation. The basis for thymidine-auxotrophic SCVs is 
not currently understood.1
The ability to form a variant subpopulation affords S. aureus a number of survival 
advantages. SCV persistence intracellularly within nonprofessional phagocytes shields 
them from host defences and decreases exposure to antimicrobial agents and SCVs 
show reduced antimicrobial susceptibility. It is well documented that S. aureus has 
been adept at developing resistance to antimicrobials.9 Exposure of S. aureus to 
antimicrobials through prophylaxis and treatment has contributed to the isolation of 
multi-drug resistant staphylococci. These resistances have generally been mediated by 
spontaneous chromosomal mutations and acquisition of genes encoded on plasmids or 
other mobile genetic elements that modify drugs, induce their efflux, or alter the target 
molecule.9,10 However, resistance in SCVs does not follow one of these ‘classic’ 
mechanisms, but is instead a direct consequence of the SCV phenotype.
Reduced antimicrobial susceptibility in SCVs is conferred through three known 
processes. Firstly, reduced growth rate has been shown to reduce the susceptibility to
o
cell wall targeting antimicrobials by up to 4-fold. Secondly, the break down in
bacterial ETC reduces the transmembrane potential (AT) resulting in reduced uptake
of cationic compounds.11 Lastly, subsistence within host cells confers resistance to
those chemotherapeutics unable to pass into host cells. Interestingly it has been shown
that the appearance of SCVs following exposure to gentamicin results from a rapid
switch, and those bacteria exposed to cycles of gentamicin followed by antibiotic-free
medium repeatedly switched between a resistant SCV and a susceptible parental
phenotype (revertants). The fitness of revertants relative to S. aureus with stable
gentamicin resistance was greater in drug-free media, which suggests that the SCV
phenotype has evolved as an inducible and reversible resistance mechanism that
1 0evades a permanent fitness cost.
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Triclosan (2,4,4,-trichloro-2'-hydroxydiphenyl ether) is a synthetic bisphenol 
antimicrobial agent, which shows activity against a wide range of Gram-positive and 
Gram-negative bacteria. For over twenty five years it has been included efficaciously 
in many hygiene and consumer health products, such as soaps, skin cleansers and 
mouthwashes, and is increasingly incorporated into a range of domestic plastics 
including toys, tea towels and chopping boards.13 In 1998, it was recommended for the 
control of MRSA14 after being successfully used to control outbreaks in a neonatal 
nursery,15 cardiothoracic surgical unit16 and to provide an alternative to expensive 
vancomycin administration.17 Subsequently, 2% triclosan baths are now a 
recommended rationale for skin decolonisation of MRSA carriers in the United 
Kingdom.18
Since the introduction of triclosan into clinical practice, strains of S. aureus exhibiting 
low-level resistance to triclosan have been isolated. MRSA strains with minimum 
inhibitory concentrations (MICs) of 2-4 mg/L have been isolated from patients treated 
with daily triclosan baths; this compares with MICs of 0.01-0.1 mg/L for susceptible 
strains.19 Traditionally triclosan has been regarded as a biocide rather than an 
antibiotic and, as such, has been thought to have numerous intracellular and 
cytoplasmic target sites.20 23 However, this view has been challenged by evidence that 
triclosan may act on a specific target, FabI, an enoyl reductase enzyme involved in 
bacterial fatty acid biosynthesis.24'26 Notably, fabl mediated resistance to triclosan in
S. aureus remains low-level and of ambiguous clinical significance. In addition 
studies have failed to demonstrate any explicit link between triclosan exposure and 
resistance in ex-situ isolates, microcosms or the domiciliary environment.27'30
Thus, although the development of S. aureus SCVs upon exposure to antibiotics, and 
in particular aminoglycosides, is well documented, this is not the case with biocides. 
So the small, non-pigmented colonies which arose on Mueller Hinton (MH) agar, 
containing 1 mg/L triclosan, inoculated with S. aureus were initially suspected to be 
contaminants. However, these atypical colonies proved to be S. aureus SCVs. Here, 
we aimed to study these organisms to see if they represent a novel resistance 
mechanism to this antimicrobial and to further examine their biology.
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Materials and Methods
Experimental conditions. Unless otherwise stated, all experiments were performed in 
triplicate (n-3) and results are presented as mean ± standard deviation (s.d.). 
Staphylococcus aureus strains NCTC6571,31 NCIMB9518, F89 (high-level mupirocin 
resistant) and clinical MRSA isolates 24500 and 27343 were maintained on nutrient 
agar (Oxoid Ltd, UK) from which cultures in nutrient broth (Oxoid Ltd, UK) were 
prepared when required. SCVs were isolated by the growth of S. aureus strains to 
mid-log phase in 10 mL Mueller-Hinton (MH) broth (Oxoid Ltd, UK) at 37°C. At this 
point pre-warmed triclosan solution (100 mg/L) was added to achieve a final 
concentration of 0.01 mg/L, further incubation was performed for 6 h at 37°C. Cells 
were harvest by centrifugation (5000 rev/min for 15 min), washed and resuspended in 
10 mL quarter-strength Ringer’s solution. 100 pL volumes of 109 cells/mL were 
spread on to the surface of MH agar (Oxoid Ltd, UK) plates containing 0-10 mg/L 
triclosan. Plates were incubated for 48 h at 37°C. Suspected reduced triclosan 
susceptibility SCVs were observed as tiny, non-pigmented colonies on plates 
containing triclosan. Such colonies were maintained on MH agar supplemented with 1 
mg/L triclosan, from which over-night cultures prepared in MH broth with 1 mg/L 
triclosan were made when required. Triclosan powder (Irgasan DP300) was a gift 
from Ciba Specialty Chemicals (Grenzach-Wyhlen, Germany) and was dissolved in 
sterile dimethylsulphoxide (DMSO). DMSO concentrations were maintained below 
1% in growth media and DMSO controls were run alongside experiments where 
required.
Electron microscopy. Cells in logarithmic growth phase were prepared for SEM by 
fixing in 2% glutaraldehyde in 0.1% sodium phosphate buffer, pH 7.4, for 2 h and 
subsequently treated with 1% osmium tetroxide for 2 h at 4°C. Cells were dehydrated 
with graded concentrations of ethanol and sputter coated with gold. Samples were 
analysed with a Philips XL-20 high vacuum scanning electron microscope (Phillips, 
Netherlands). Samples for TEM were prepared as for SEM, but following ethanol 
dehydration were embedded in SPI-Chem™ Araldite® CY212. Ultra-thin sections 
were stained with uranyl acetate and lead citrate, and examined with transmission 
electron microscope JEM-1210 (JEOL, Japan).
Species confirmation. All suspected SCVs were confirmed as S. aureus by multiplex- 
PCR as previously reported.32
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SCV characterisation. SCVs were analysed for haemolysis by streaking on MH agar 
supplemented with 5% defibrinated sheep blood (Oxoid Ltd, UK) and incubation at 
37°C for 48 h. The presence of coagulase production was investigated by Staphylase 
test kit (Oxoid Ltd, UK) according to the manufacturers directions. 4-5 colonies were 
transferred to a microscope slide followed by the addition of hydrogen peroxide, the 
presence of bubbling was taken as an indication of catalase production. Auxotrophy 
for haemin, menaquinone and thiamine was examined as described previously. 
Growth curves were attained by spectrophotometric analysis (580 nm) of MH broth 
cultures using a DYNEX Technologies MRX® Microplate Absorbance Reader with 
Revelation™ application programme. In each well of a sterile 96-well microtitre plate 
(Fisher Scientific, UK) 100 pL of MH broth, containing 2x final concentration of
o
triclosan was inoculated with 100 pL of MH broth culture, diluted with broth to 10 
cells/mL. Plates were sealed with adhesive plate seals (ABgene, UK) and incubation 
was performed at 37°C with agitation for 48 h. Significant effect of triclosan on 
bacterial growth was tested with analysis of variance (ANOVA). All data are 
presented as the mean ± s.d.
SCV formation and reversion rates. The rate of mutation towards the SCV phenotype 
was assessed by growth of S. aureus strains to mid-log phase in 9 mL MH broth at 
37°C. At this point either MH broth or pre-warmed triclosan solution was added to 
give final concentrations of 0, 0.01, 0.1 and 1 mg/L, and further incubation was 
performed for 6 h at 37°C. Cells were harvested by centrifugation (5000 rev/min for 
15 min), washed, resuspended in quarter-strength Ringer’s solution and adjusted to 
1010 cells/mL. 100 pi volumes of 1010 cells/mL were spread on to the surface of MH 
agar plates containing 1 mg/L triclosan. Additionally, dilutions of the cultures were 
plated onto MH agar in order to calculate the number of wild type cfu. Plates were 
incubated for 48 h at 37°C. Non-pigmented colonies that grew to less than 1 tenth of 
the size of wild type colonies were recorded as SCVs. The frequencies were expressed 
as numbers of SCVs per cfu. Reversion rates were calculated by inoculating a MH 
agar plate with cells from ten SCV colonies suspended in 3 mL of 0.9% NaCl. After 
48 h growth at 37°C SCVs and wild-type colonies were counted and the frequency of 
reversion was determined as number of wild-type cfu per SCV.
Antimicrobial susceptibility. MICs for the three biocides, triclosan, chlorhexidine 
gluconate (CHX; ICN Biomedicals Inc., USA) and cetylpyridinium chloride (CPC; 
ICN Biomedicals Inc., USA), were calculated according to the guidelines of the
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British Society for Antimicrobial Chemotherapy (BSAC).34 Due to the slow growth of 
the SCVs MIC plates were incubated for 48 h. Etest® strips (Bio-stat Ltd, UK) were 
utilized to attain the MIC for antibiotics, as per the manufacturer’s directions. The 
bactericidal effects of triclosan on wild-type S. aureus and their SCVs were compared
i f  7
as previously reported except the inoculum was adjusted to 10 cfu/mL, 2% 
Azolectin and 5% Tween 80 in molecular grade de-ionized water was used as the 
neutralizing solution and sampling was continued up to 2 h. Logio reduction was then 
calculated from logioNc- logioNt where Nc and Nt represent the numbers of cfu/mL in 
the control and triclosan solutions, respectively. Significant effect of triclosan on the 
reduction in cell density was tested with ANOVA. All data are presented as the mean 
± s.d.
Validation of triclosan neutralize!*. 2% Azolectin and 5% Tween 80 in molecular 
grade de-ionized water was used as the triclosan neutralizer. Its ability to neutralize
36 37triclosan without toxicity to bacterial cells was examined as described previously. ’ 
Briefly, 8 mL of neutralizer, 100 pL of triclosan (10 mg/mL) and 900 pL sterile de­
ionized water was inoculated with 1 mL of an overnight culture of S. aureus 
NGEMB9518 grown at 37°C. The viable cell count was enumerated after 5 min 
contact time at ambient temperature. As controls, sterile de-ionized water was added 
to the incubation mixture instead of the triclosan solution or the neutralizer. When the 
cells were exposed to triclosan without the neutralizer no viable cells were detected in 
the sample after the 5 min incubation period. There was no significant difference (P = 
0.879) between the viable cell count of cultures exposed to triclosan and the 
neutralizer and where water was added instead of triclosan. This confirmed the ability 
of the neutralizer to quench bactericidal activity of triclosan at 100 mg/L. When 
examining the possible toxicity of the neutralizer, there was no significant difference 
(P = >0.05) between the viable cell counts of cultures exposed to sterile water and 
those exposed to the neutralizer for 15 min, confirming that the neutralizer was non­
toxic.
FabI gene sequencing. Chromosomal DNA was extracted as described previously.38 
Primers adapted from those designed for the amplification of the staphylococcal fabl 
gene and putative fabl promoter region39 were used in 50 pL PCRs, (FabIF, 
tgttccgcatggagatacac and FablR, taaggactaattctgtggatgt). Reactions contained 0.5 pL 
of chromosomal DNA (approximately 0.5 pg), 0.5 pg of each primer, 1 U of Taq 
DNA polymerase (Bioline Ltd, UK), 5 pL of 10x buffer (Bioline Ltd, UK), and
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0.2 mM deoxynucleoside triphosphates (Bioline Ltd, UK). The PCR was performed in 
a PTC-200 DNA engine (MJ Research, USA) with an initial 5-min denaturation at 
94°C, followed by 40 cycles of denaturation at 95°C for 30 s, annealing at 50°C for 30 
s and extension at 72°C for 45 s, followed by a final extension step at 72°C for 5 min. 
The amplified products were purified by QIAquick PCR purification kit (Qiagen Ltd, 
UK) and the sequences of both strands determined with an ABI Prism 377 DNA 
sequencer, BigDye fluorescent terminators and primers used in the initial PCR 
amplification. To ensure complete sequence coverage a further set of primers, again 
adapted from Slater-Radosti et al. (2001) were also used (Fab2F, 
atgttaaatcttgaaaacaaaac and Fab2R, ttatttaattgcgtggaatccgc).
Results
Suspected SCVs were isolated from MH agar plates containing 1 mg/L triclosan and 
spread with a heavy inoculum of S. aureus strains NCTC6571 (Oxford strain), 
NCIMB9518, F89 (high-level mupirocin resistant) and clinical MRSA isolates 24500 
and 27343. Non-pigmented colonies were approximately one tenth the size of wild 
type S. aureus colonies and non-haemolytic on sheep blood agar. Most appeared 
coagulase negative during examination by latex agglutination test, although SCVs of 
F89 and 24500 showed very weak positive reactions. Upon addition of hydrogen 
peroxide the colonies were shown to be weakly catalase positive. The cells generally 
appeared as Gram-positive cocci, although some cultures of suspected SCVs appeared 
to show a heterogeneous cellular morphology; apparently normal S. aureus mixed 
with larger cell morphotypes. Subsequent scanning electron microscopy (SEM) of 
SCV samples revealed bacterial cells of different sizes, in distinction to homogeneous 
cocci of the isogenic wild type S. aureus (data not shown). Kahl et al. (2003)40 
suggests the larger cells are due to impaired cell separation. Transmission electron 
microscopy (TEM) disclosed this to a greater extent, by revealing SCV cultures to 
contain 48.7% large cells with incomplete cross walls and 2.3% ‘empty’ cells (Figure 
6.1), significantly more than were found in wild type cultures (P -  <0.05, for both 
phenomena).
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Figure 6.1. Heterogeneous SCV cultures containing a mixture of large and small cell 
morphologies. A nalysis o f  a tric losan  induced  SC V  cultu re  revealed  a large num ber o f  unusually  large 
cells (2 .13:1), attributed  to  in terrup ted  cell d iv ision , (a) T E M  analysis o f  a triclosan induced a SCV 
show ing a heterogeneous cu ltu re  o f  cells, som e (48 .7% ) contained incom plete cell w alls, (b), in 
com parison, w ild  type cu ltu res con ta in ed  on ly  hom ogeneous cocci w ith  clear single cell w alls, (c), 
A lso observed in cultures o f  SC V s w ere  a  sm aller num ber (2 .3% ) o f  ‘em p ty ’ cells, w hich w ere unseen 
in w ild-type cultures.
(a) (b) (c)
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Species confirmation of S. aureus SCVs is notoriously challenging and can often lead 
to misidentification as coagulase negative staphylococci (CoNS).6 Consequently, the 
suspected colonies were ultimately identified as S. aureus by genomic analysis. 
Suspected SCVs were interrogated for the presence of four genes (Staphylococcal 16s 
rRNA, nuc, mecA and mupA) by multiplex PCR.32 The presence of a Staphylococcal 
16s rRNA gene and S. aureus specific nuc gene was recorded for all suspected SCVs 
analysed, (Figure 6.2). This procedure also indicated that the SCVs maintained the 
mecA and mupA resistance determinants associated with their parents.
None of the SCVs were identified as haemin, menaquinone or thymidine auxotrophs 
and neither did any show a combination of menaquinone, haemin or thymidine 
auxotrophy. Thus the reason for their expression of the SCV phenotype remains 
uncharacterised.
When grown in unmodified MH broth, SCV growth was significantly different to 
wild type (P -  <0.05). SCVs exhibited extended lag periods (3 h compared to 1 h), 
greatly reduced maximal growth rates (0.23 compared to 1.65 generations/h) and 
achieved maximal cell densities approximately one half of their parent strain (Figure 
6.3). However, when grown in MH broth adjusted to 1 mg/L triclosan, SCV growth 
remained unaffected, whilst wild-type S. aureus growth was greatly restricted, 
indicating the advantage of SCV growth under conditions of antimicrobial stress. The 
SCVs showed similar antimicrobial susceptibilities, all of which differed from their 
wild type parent (Table 6.1). Susceptibility to triclosan was decreased by between 24- 
and 60-fold and to gentamicin by between 2.5- and 10-fold. The MIC of penicillin 
was raised by up to 4-fold in all SCVs for which the progenitor were penicillin 
susceptible (MSSA). The penicillin MIC for the two MRSA strains that had existing 
penicillin resistance was either unaffected (24500) or lowered (27343).
Additionally, SCV susceptibility to two other biocides was investigated. 
Chlorhexidine (CHX) a bis-biguanide biocide used widely in mouthwashes, 
toothpastes and clinical hand washes and cetylpyridinium chloride (CPC), a 
quaternary ammonium compound (QAC). Both are cationic, and as such the uptake of 
these compounds may be affected by a reduction in A1?, reducing their antimicrobial 
effect11. However, none of the SCV strains showed any reduction in susceptibility to
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Figure 6.2. SCVs were confirmed as S. aureus by amplification of the staphylococcal 16s rRNA 
(756 bp) and nuc (279 bp) genes. A dditionally  m ecA  (310 bp) and m upA  (457 bp) w ere also targeted 
to identify m eticillin  and h igh-level m up irocin  resistance  respectively . 1, no tem plate control; 2, E. coll, 
3; S. epiderm idis 1228; 4 &  5, 27343 and  27343S C V ; 6 &  7, 24500 and 24500SC V ; 8 & 9, F89 and 
F89SCV ; 10 & 11, N C IM B 9518 an d  9518SC V ; 12 &  13 ,N C T C 6571 and6571S C V .
M 1 2 3 4 5 6 7 8 9 10 11 12 13 M
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Figure 6.3. Typical SCV and wild-type growth dynamics. SCV (grey lines) and their wild type S. 
aureus parent (black lines) were grown in broth with (dashed lines) and without (solid lines) 1 mg/L 
triclosan. Typical SCV growth was significantly retarded in comparison to typical wild-type S. aureus 
(P = <0.05). SCVs characteristically exhibited extended lag phases and reduced maximal growth rate 
and cell density. Data are the mean of three measurements ± s.d.
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Table 6.1. MICs for S. aureus SCVs and their corresponding wild type parent.
Minimum Inhibitory Concentration (mg/L)
Strain p e n t OXAt VAN' MUPt CHLt TET e r y t g e n t LZDt TEC' CIPT Trie1 CHX1 CPC*
6571 0.023 0.13 1.5 0.19 4 0.064 0.19 0.19 0.25 0.19 0.25 0.063 1 1
6571 SCV 1.0 0.25 2 0.19 4 0.75 0.38 2 1 0.5 1 4 1 1
9518 <0.016 0.13 1 0.19 8 0.19 0.38 0.19 0.5 0.38 0.19 0.063 1 1
9518SCV 0.5 0.05 0.75 0.19 4 0.19 0.13 1 1 1 0.25 3 1 1
F89 1 0.75 1.5 >1024 4 0.5 >256 0.19 0.5 0.75 0.38 0.063 1 1
F89SCV 1.5 0.38 1.5 512 4 0.5 >256 1 0.5 2 1 2 1 1
24500 48 64 1.5 0.25 4 0.5 0.38 0.19 0.5 0.25 >32 0.063 3 3
24500SCV 48 64 1.5 0.25 2 0.5 0.38 0.5 1 1 >32 1.5 3 3
27343 32 >256 1 0.38 8 0.5 0.38 0.19 0.38 0.5 >32 0.063 2 2
27343SCV 16 >256 1 0.38 4 0.5 0.19 1 0.50 1 >32 3 2 2
^Calculated by Etest (AB Biodisk, Sweden). Calculated in accordance with BSAC guidelines. PEN, Penicillin; OXA, Oxacillin; VAN, Vancomycin; MUP, 
Mupirocin; CHL, Chloramphenicol; TET, Tetracycline; ERY, Erythromycin; GEN, Gentamicin; LZD, Linezolid; TEC, Teicoplanin; CIP, Ciprofloxacin; Trie, 
triclosan; CHX, chlorhexidine gluconate; CPC, cetylpyridinium chloride.
either of these compounds in comparison to their isogenic wild type, perhaps 
indication that a reduction in A'F is not associated with these SCVs, or that the 
permeability of these biocides remains unaffected.
Commonly, antibiotics possess single target sites, and consequently increased MICs 
and reduced bactericidal effectiveness are linked. In contrast, this correlation is not so 
for biocides; biocides have multiple targets and increased MICs often do not correlate 
with decreased bactericidal activities of that compound.23 It has been shown 
previously that increases in triclosan MIC in S. aureus have resulted in little to no 
increase in bactericidal effectiveness of the compound.21 Contrary to these data, our 
SCVs showed significantly increased resistance to the lethal effects of 7.5 mg/L 
triclosan (P -  <0.05). Five logio reductions in cell density by 7.5 mg/L triclosan were 
achieved in times ranging from 15 to 20 min for wild type S. aureus, this compares to 
times of over 2 h for SCV strains (Figure 6.4a). However, the bactericidal efficacy of 
triclosan at 20 and 40 mg/L was comparable between wild type and SCV strains 
(Figure 6.4 b, c).
DNA sequences for the fab l gene and preceding promoter region were ascertained for 
all SCVs and compared to those of their wild type parent. Sequence comparison failed 
to identify any mutations within the gene, showing that the reduced susceptibility 
within the SCVs was not mediated by mutation of fabl. This implies that fabl is not 
the sole target for triclosan.
SCV formation occurs at rates as high as 1 in 1000 when selected by gentamicin.12,39
1 9The rate of reversion can also be very high, although some SCVs can show stability 
under non-selective conditions. Triclosan was shown to select for SCVs at rates 
between 1.86x10‘n and 9.46><1 O'10 SCV/cfu. Interestingly, these frequencies were 
increased by up to four orders of magnitude when strains were subject to a pre­
exposure to triclosan (Figure 6.5). Subsequent reversion occurred at variable 
frequencies, with some SCVs of strains 9518, F89 and 24500 exhibiting a stable 
phenotype (e.g. less than 10~10). Revertants exhibited antimicrobial susceptibilities 
comparable to their wild type parent i.e. upon reversion all strains lost any SCV- 
associated reduction in antimicrobial susceptibility.
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Figure 6.4. Typical death curves for wild type and SCV S. aureus exposed to triclosan. Reduction 
in viable cell count following exposure to various concentrations of triclosan was measured for a wild 
type S. aureus (solid line) and its isogenic SCV (dashed line) (a) The lethal effects of 7.5 mg/L 
triclosan where shown to be greatly reduced against SCVs. The lethal effect of triclosan is significantly 
different between typical wild type and typical SCV (P= <0.05). The times for a five log10 reduction in 
cell density were increased from 15-20 min for wild type S. aureus to >2 h for SCVs strains. However, 
at higher concentrations of triclosan, (b) 20 and (c) 40 mg/L, no significant difference was observed 
between the lethal effect upon wild type and SCV (P = >0.05). Data are the mean of three 
measurements ± s.d.
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Figure 6.5. (a) Frequency of mutation to the SCV phenotype fo llow ing  exposure to zero (open bar), 
sub-M IC (0.01 m g/L; ligh t g rey  ba r) and  h ig h er than  M IC  (0.1 m g/L ; dark  grey bar) concentrations o f  
triclosan and (b) the rate of reversion to wild-type of SCVs selected  on various concentrations o f  
triclosan. D ata are the m ean  o f  th ree  m easu rem en ts ±  s.d.
9518 F89 24500 27343
Strain
F89
Strain
24500 27343
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Discussion
We have shown that in vitro exposure to triclosan can trigger the emergence of 
reduced drug-susceptible SCVs, and this was augmented by a pre-exposure to sub- 
MIC triclosan. These SCVs showed the characteristic SCV phenotype, as a 
consequence of this the organisms were difficult to culture and identify by classical 
methods. These findings raise potential issues in healthcare; although clinical 
evidence for failure of triclosan has not yet been shown, the findings create the 
possible scenario that selection of SCVs during skin decolonization with triclosan 
may cause patients to be misidentified as MRSA free. These missed SCVs may then 
be transmitted between patients and/or revert to the wild type state and initiate more 
familiar MRSA infections. Additionally, we have shown that MRSA SCVs retain the 
genetic determinants for meticillin resistance; hence these may provide a longstanding 
reservoir of resistance genes to be shared amongst the microbial community, although 
it remains to be shown that these variants are able to partake in horizontal gene 
transfer.
Fitness of the SCVs was severely impaired with regards growth rate, however this 
was negated by their refraction to antimicrobial therapy. In vivo this phenotype may 
also confer ability for intracellular maintenance. If able to persist intracellularly, 
further reductions in antimicrobial susceptibility may be expected,42 and the potential 
for more deep seated infections is increased. Susceptibility to three widely used 
antimicrobials (penicillin, gentamicin and triclosan) was shown to reduce notably and 
the lethal effects of triclosan at 7.5 mg/L likewise. However, the lethality of triclosan 
at 20 and 40 mg/L and no cross-resistance to CHX and CPC show that these 
staphylococcal variants can be controlled by pertinent use of antimicrobial 
chemotherapeutics. Reductions in triclosan susceptibility were comparable to those 
achieved through alteration of the fabl gene product, and as such are hypothetically of 
equal clinical significance. It is important to understand that in laboratory studies 
susceptibility is not comparable to that in situ. During clinical or domestic use, 
triclosan is delivered often as part of a complex formulation. These formulations 
contain various combinations of surfactants, detergents, chelating agents and wetting 
agents, all of which will affect their action, and ultimately the susceptibility of 
microorganisms exposed to them. Moreover, typical in-use concentrations of triclosan
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in hand wash, bath formulations and surface disinfectants are 0.3% to 1%, for hospital
1 Rwash applications for MRSA eradication even 2% triclosan is recommended. These 
in-use concentrations are magnitudes higher than the concentrations of triclosan 
needed to inhibit SCV isolates of MRSA reported herein.
We were unable to identify any auxotrophy towards haemin, menaquinone or 
thymidine; hence the reason for the expression of the SCV phenotype remains 
uncharacterised.
This investigation highlights a microbial phenomena (SCV formation) affecting 
antimicrobial chemotherapy. Despite this, it is important to appreciate the differences 
between in vitro susceptibility to triclosan in pure culture conditions and those in situ 
where mixed microbial populations are exposed to complex formulations. Further 
investigations should be targeted to elucidate the existence of this phenomenon under 
conditions better reflecting the environments in which triclosan is used.
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On March 2?* 2007 the Journal o f Antimicrobial Chemotherapy published an 
article by Roger Bayston et aL entitled ‘Triclosan resistance in methicillin-resistant 
Staphylococcus aureus expressed as small colony variants: a novel mode of evasion 
of susceptibility to antiseptics’ (doi:10.1093/jac/dkm03). We believe that this article 
has several shortcomings in the methods used to collect the data and during their 
subsequent interpretation. Consequently, we have submitted a letter to the Journal 
of Antimicrobial Chemotherapy to raise these issues and add to the discussion on 
triclosan-induced SCVs. The full text o f this letter is included in appendix 9.2.
186
Chapter 7
Horizontal gene transfer in triclosan-resistant small colony variants
of Staphylococcus aureus
187
Synopsis
Objectives: Following the isolation of triclosan-resistant small colony variants (SCVs) 
of Staphylococcus aureus we aimed to elucidate their potential involvement in the 
evolution of S. aureus by horizontal gene transfer.
Methods: SCVs were isolated on Mueller-Hinton agar supplemented with 1 mg/L 
triclosan. Phage-mediated transfer (transduction) of antibiotic resistance genes was 
assessed with bacteriophages 80a and K. Transformation experiments were 
performed, investigating the transfer of resistance genes between wild-type and SCV 
forms of S. aureus and filter matings were employed to assess gene transfer by 
conjugation.
Results: Triclosan SCVs showed the same phage susceptibility as their parent strains 
but no gene transfer by transduction was detected. Multiplex PCR confirmed the 
presence of antibiotic resistance plasmids in SCVs, however no conjugal transfer was 
detected. Transformation of antibiotic resistance markers was detected, indicating a 
higher level of competency in S. aureus SCVs compared to wild-type.
Conclusions: Whilst many studies have investigated the direct impact of S. aureus 
SCVs upon patient morbidity the data presented here demonstrate their potential as a 
critical source of resistance genes. We propose that SCVs can act as a genetic 
‘middleman’, capable of surviving antibiotic treatments and host defences whilst 
receiving and donating mobile DNA.
Introduction
We previously isolated small colony variants (SCVs) of Staphylococcus aureus 
during exposure to triclosan (Seaman et al., 2007a). Triclosan-induced SCVs showed 
the characteristic SCV phenotype with low-level triclosan resistance and coincidently 
had reduced susceptibility to penicillin and gentamicin. In addition to raised MICs, 
triclosan isolated SCVs were also shown to have an increased tolerance to the 
bactericidal effects of triclosan. SCVs are an intriguing form of S. aureus; the 
phenotype enables them to persist intracellularly within several human cell types 
including keratinocytes, non-professional phagocytes and cultured endothelial cells 
(Balwit et al., 1994; von Eiff et a l, 1997; von Eiff et a l, 2001; Bayles & Bohach, 
2002) and also confers a level of resistance to various antimicrobials, especially
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aminoglycosides (Proctor et al., 1995; Proctor, 1998; Proctor et al., 2006; Seaman ef 
a l , 2007a). They are also able to switch rapidly between SCV and wild-type and so 
each form will amplify when conditions suit them, e.g. when antibiotic treatment has 
ceased SCVs can switch to wild-type growth (Massey et al. 2001). These qualities 
enable SCVs to persist and cause recurring infections that can return several weeks or 
even years later (McNamara & Proctor, 2000).
The biochemical differences that lead to the distinction of SCVs from wild-type S. 
aureus and the role that SCVs play in human infection have attracted most attention. 
Consequently, there is a paucity of data regarding the role of SCVs in the 
dissemination of resistance and virulence genes by horizontal gene transfer.
Horizontal gene transfer in staphylococci is discussed in depth in chapter 5. However, 
we do not yet know the extent to which SCVs can partake in gene transfer, and 
consequently what their involvement in the evolution of S. aureus is. SCVs are 
physiologically very different to wild-type S. aureus, hence their ability to partake in 
conjugation, transduction and transformation may also be impacted. For example 
transduction relies upon the ability of phages to attach to and infect host cells, 
however the phenotypic alterations encountered in SCVs may also include 
modification of phage receptors conferring resistance to phage infection. 
Transformation and conjugation might be effected similarly if the uptake sites and 
related factors are impacted. Herein we describe for the first time the potential for 
SCVs to mediate gene transfer of antibiotic resistance and discuss their role within 
staphylococcal evolution.
Materials and Methods
Experimental conditions. Unless otherwise stated, all experiments were performed in 
triplicate {n-3) and results are presented as mean ± standard error (SE). 
Staphylococcus aureus strains NCTC 6571 (Heatley, 1944), NCIMB 9518, RN450 
(Novick, 1967), Eagles (high-level mupirocin resistant) and F89 (high-level 
mupirocin resistant) were maintained on nutrient agar (NA; Oxoid Ltd, UK) from 
which cultures in nutrient broth (NB; Oxoid) were prepared when required. Triclosan-
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induced SCVs were isolated as described previously (Seaman et al., 2007a). 
Following isolation SCVs were maintained on Mueller-Hinton agar (MHA; Oxoid) 
supplemented with 1 mg/L triclosan, from which over-night cultures prepared in 
Mueller-Hinton broth (MHB; Oxoid) with 1 mg/L triclosan were made when required. 
Triclosan powder (Irgasan DP300) was a gift from Ciba Specialty Chemicals 
(Grenzach-Wyhlen, Germany) and was dissolved in sterile dimethylsulphoxide 
(DMSO). To circumvent DMSO related effects solvent concentrations were 
maintained below 1% in growth media and DMSO controls were run alongside 
experiments where required.
Species confirmation. All suspected SCVs were confirmed as S. aureus by multiplex- 
PCR as reported previously (Seaman et al., 2007a). This multiplex PCR was also used 
to confirm the presence of plasmid-encoded mupirocin resistance.
SCV characterization. The haemolytic ability of SCVs was evaluated by streaking on 
MH agar supplemented with 5% defibrinated sheep blood (Oxoid) and incubation at 
37°C for 48 h. The presence of coagulase production was investigated by Staphylase 
test kit (Oxoid) according to the manufacturer’s directions. 4-5 colonies were 
transferred to a microscope slide followed by the addition of hydrogen peroxide, the 
presence of bubbling was taken as an indication of catalase production. The 
manufacturer’s directions were adapted to use DNase agar (Oxoid) to estimate the 
secretion of extracellular nucleases from SCV and wild type S. aureus. Briefly, 
Deoxyribonuclease (DNase) enzymes were detected by spotting of over night cultures 
on to DNase agar, which contains 2% DNA, supplemented with 1 mg/L triclosan. 10 
pi spots were applied in triplicate and allowed to dry before incubation at 37°C for 24- 
48 hours. Once a thick plaque of growth was achieved for each spot the plates were 
flooded with 1 M hydrochloric acid (HC1). Following incubation at room temperature 
for ~3 minutes the spots were examined for surrounding areas of clear agar; HC1 
hydrolysis of DNA results in the agar turning opaque, the presence of DNase digests 
the DNA and as a consequence none is available to be hydrolyzed. Hence, well 
defined clear zones indicated a presence of DNase enzymes whilst no clear zone 
indicated a lack of DNase. Width of clear zones was measured from the edge of 
bacterial growth to the boundary between clear and opaque agar. Triplicate spots were 
compared to ensure reliability and any ambiguous isolates were repeated. Significant 
difference between the width of clear zones was tested with Student’s t-test using 
Minitab® release 14 software (Minitab Inc.).
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Conjugation. Bi-parental matings were performed as described previously (Seaman et 
al., 2007b) except, due to the low cell density of SCV cultures, when SCVs were used 
as donor or recipient cells their volume filtered on to the filter was doubled. 
Additionally, incubation times were increased to 72 h to enable the slower growing 
SCVs to be visualized effectively.
Transduction. Prior to performing transduction experiments strains were examined 
for their susceptibility to phage infection. This was performed as described previously 
(Seaman & Day, 2007) using bacteriophages 80a, K and NCTC 9319 and MHA as the 
growth medium. Transduction experiments were performed using bacteriophages 80a 
and K as described previously (Seaman et al., 2007b), except incubation times were 
increased to allow for the slow growth of SCVs.
Transformation. Transformation experiments were performed as described 
previously (Seaman et al., 2007b).
Results
SCVs with reduced triclosan susceptibility were observed as tiny, non-pigmented 
colonies on plates containing triclosan (Figure 7.1). All SCVs were non-haemolytic 
on sheep blood agar (Figure 7.2) and were not found to produce extracellular 
coagulase (Figure 7.3). As with previous triclosan-induced SCVs colonies were found 
to be weakly catalase positive (Seaman et al., 2007a). The level of extracellular 
DNase secretion had not previously been tested in SCVs. The use of DNase agar 
revealed SCVs to produce significantly less extracellular DNase than wild-type 
colonies (P = <0.001; Table 7.1). DNase diffusion around SCVs was seen on average 
only 11.5% of the distance achieved by wild-type cells. Since diffusion through agar 
is logarithmic, we can estimate that the actual amount of DNase secreted by SCVs is 
-1/100 of that produced by wild-type cells.
Prior to conjugation experiments being performed SCVs were checked for the 
presence of plasmid-encoded mupirocin resistance. This was confirmed in SCVs of 
both strains known to carry this plasmid, S. aureus Eagles and S. aureus F89. To test 
the ability of SCVs to act as recipients during conjugal transfer of antibiotic resistance
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Figure 7.1. SCVs with reduced triclosan susceptibility were observed as tiny, non-pigmented 
colonies on plates containing triclosan. A s illu stra ted  w ith  N C IM B  9518, SCV  colonies w ere 
approxim ately  one tenth  the  size o f  w ild -type  colon ies. S. aureus  cells tha t had  m utated  to low -level 
triclosan resistance b y  m eans o th e r than  th rough  SC V  form ation  rem ained  as characteristic large, 
gold/yellow  colonies.
5 mm Wild type
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Figure 7.2. All SCVs were non-haemolytic on sheep blood agar. T he p ic tu re  show s 9518SC V  and 
N C IM B  9518 streaked on  a  b lo o d  ag ar p la te . T he  c lear zone around  the w ild-type cells indicates 
haem olysis, w hilst no haem olysis w as show n  b y  the  SCV.
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F ig u re  7.3. la te x -a g g lu tin a tio n  te s t  d id  n o t  d e te c t th e  p ro d u c tio n  o f  e x tra c e llu la r  coagu lase  in
SC V s. Clumping indicates a positive reaction, as seen with the three wild type cultures.
S. aureus strain 
Eagles RN450 F89
Wild type
SCV
IVTiKTJS
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Table 7.1. SCVs secreted significantly less DNase than wild-type S. aureus (P  = 0.001).
S. a u reu s  s tra in M e a n  w id th  o f  D N A -fre e  zone  ±  SE  (n  = 3, m m )
N C T C  6571 10.7 ± 0 .0 4
6571 SC V 1.1 ± 0 .0 9
N C IM B  9518 9 .7  ± 0 .0 3
9 518S C V 1.2 ± 0 .1 0
R N 450 9.1 ± 0 .0 4
R N 450S C V 1.0 ±  0 .18
E ag les 5 .7  ± 0 .1 5
E ag lesS C V 0 .9  ±  0 .09
F 89 12.1 ± 0 .0 7
F 89S C V 1.2 ±  0 .12
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genes bi-parental matings we performed using either wild-type S. aureus Eagles and 
S. aureus F89 as donors and RN450SCV as recipient the recipient. Conversely, to 
examine whether S. aureus SCVs can disseminate genes by conjugation, EaglesSCV 
and F89SCV were used as donors and wild-type S. aureus RN450 was used as the 
recipient. The experiment was also repeated using SCV isolates as both donor and 
recipient. However, no conjugative transfer either out of or into SCVs was detected 
(levels of detection were between <1.21 x10'9 and <3.25x1 O’11 transconjugants per 
recipient).
SCVs were found to have the same phage susceptibility pattern as their parent strain 
(Figure 7.4 and Table 7.2). Subsequently, the appropriate bacteriophage was used in 
attempts to transfer rifampicin resistance from S. aureus RN450 to 9518SCV, from 
RN450SCV to S. aureus NCIMB 9518 and from RN450SCV to 9518SCV. However, 
once again no transfer was detected (levels of detection were between <3.68xl0‘9 and 
<4.74x 10'11 transductants per recipient).
The last method of gene transfer we investigated was the uptake of free DNA or 
transformation. Free DNA was provided by lysing cells with antibiotic resistance 
genes (mupirocin and rifampicin) and mixing this with recipient (SCV) cells on a 
filter paper support. Whilst transformation was not detected in wild-type NCIMB 
9518 it was successfully detected in the SCV of this strain (Figure 7.5). Both 
mupirocin resistance and rifampicin resistance could be transferred by transformation 
in to the SCV form at frequencies of between 1.48xl0"6 transformants per recipient 
and 2.35X1 O'5 transformants per recipient. Control plates indicated that spontaneous 
mutation of SCVs to rifampicin or mupirocin resistance was below the level of 
detection (6.48X1 O'8 to 3.75x10"9 transformants per recipient).
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Figure 7.4. Triclosan-induced SCVs shared the same phage susceptibility profile as their 
progenitor. Suscep tib ility  to  bac te riophages 8 0 a , K  and  N C T C  9319  w as tested, (a) B o th  F89 and (b) 
F89SC V  w ere  suscep tib le  to  all th ree  phages, (c) N C IM B  9518 and  (d) 9518SC V  w ere susceptible to 
8 0 a  and  K , bu t n o t N C T C  9319 . In teresting ly , w ith  c loser inspection  one cou ld  see the  law ns o f  (e) 
F89SC V  and  (f) 9518S C V  also  con ta ined  revertants. T he revertan ts d id  n o t occur in  the presence o f  the 
phages, ind icating  th e ir suscep tib ility .
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Table 7.2. Phage susceptibility o f S. aureus strains and their SCV progeny.
S> a u t eus strain
B ac te rio p h ag e
8 0 a K N C T C  9319
N C T C  6571 + - -
65 71 SCV + - -
N C IM B  9518 + + -
9518SC V + + -
R N 450 + + +
R N 450S C V + + +
Eagles + + +
E aglesSC V + + +
F89 + + +
F89SC V + + +
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Figure 7.5. Horizontal gene transfer of antibiotic resistance by transformation in S. aureus SCVs.
(a) T ransform ation  o f  m up iroc in  resistance  in S. aureus  N C IM B  9518 ( ) and its SCV (□) (b) and 
transform ation o f  rifam p ic in  res is tance  in the sam e strains. D ashed horizontal line represents highest 
level o f  detection. E ach  tran sfo rm atio n  experim en t w as repeated  three tim es. V alues are m ean ±SE.
(a)
1x10'
1x10"
1x10'
1 x 1 0 '
1x10'
1x10,-10
1x10,-11
_____T
— f —
I 1
Experiment 1 Experiment 2 Experiment 3
(b)
1x10'
1x10"
1 x10 '
Experiment 1 Experiment 2 Experiment 3
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Discussion
S. aureus SCVs have been recognised for several decades (Proctor et al., 2006), 
however recently increasing attention is being paid to this intriguing phenotype. 
Recent reports have discussed the clinical impact of SCVs (Moisan et al., 2006; Sifri 
et al., 2006; Besier et al., 2007) and intriguingly their selection by the presence of 
Pseudomonas aeruginosa during infection of the lungs of cystic fibrosis patients 
(Hoffman et al., 2006). However, this small study concentrated on identifying the 
potential for horizontal gene transfer in S. aureus SCVs.
All SCVs described herein grew with the characteristic pin-point SCV colony 
morphology and possessed the typical SCV phenotype. Consequently, we propose 
that these results are not exclusive to triclosan-induced SCVs, but the phenomena that 
we describe here may also occur in other classes of SCV. Further work would be 
needed to confirm this, but we believe it is pertinent to consider this whilst discussing 
these results.
We report for the first time that extracellular DNase production is attenuated in SCVs. 
This result correlates well with our prior knowledge of extracellular and accessory 
protein production in SCVs; coagulase, catalase, pigmentation proteins are among 
proteins known to be absent/present at low levels in SCVs (Proctor et al., 2006). This 
attenuation could be a direct result of the energy deficit experienced by SCVs, since 
they need to focus their energy resources towards those processes essential for 
survival. Alternatively it is possible that the characteristics of SCVs are as a result of 
alterations to a global regulator. A global regulator, such as those seen in quorum 
sensing systems (Swift et al., 1996; Williamson et al., 2006), may be altered such 
that it no longer directs the expression of those genes associated with the SCV 
phenotype, consequently the alteration of a single target can lead to a pleiotropic 
effect.
In the absence of selection for specific functions such as antibiotic resistance, 
plasmids can confer a fitness cost upon their host (Dykhuizen & Hard, 1983; Lee & 
Edlin, 1985; Cooper et al., 1987; Lenski & Bouma, 1987; Lenski, 1988; Lenski, 
1997); energy is required to sustain the extra-chromosomal DNA. Plasmids generally
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encoded accessory functions that are not essential for survival. Consequently, we 
hypothesized that when S. aureus mutate to the SCV form they would lose their 
plasmids in an effort to conserve energy. Furthermore, we know that cell division of 
SCVs is severely impaired (Kahl et al., 2003; Seaman et al., 2007a). Hence, upon cell 
separation the inheritance of plasmids by daughter cells may be affected. However, 
we found that SCVs were able to maintain plasmids, namely the //e<S2-carrying 
plasmid that confers high-level mupirocin resistance in S. aureus Eagles and F89. So 
S. aureus SCVs maintain the potential to disseminate important resistance and 
virulence traits by conjugation.
When we investigated conjugation in SCVs, using them as both donors and recipients, 
we were unable to detect any transfer. This was surprising, since we had shown they 
were able to sustain plasmids, but our results may be a consequence of experimental 
problems. Due to the nature of SCV cultures it was difficult to attain the desired cell 
densities during filter matings. Hence, the ratio of donor to recipient cells may not 
have been at the optimum, a variable known to impact upon conjugation frequencies 
(al-Masaudi et al., 1991). Likewise, the growth phase of cells strongly influences the 
frequency of plasmid transfer (al-Masaudi et al., 1991). Again, the abnormal growth 
dynamics of SCVs in culture, which show extended lag phases, short log phase 
growth and retarded maximum growth rates (Seaman et a l , 2007a) may have been 
detrimental to conjugation. Alternatively, the physiological state of SCVs may have 
precluded conjugation. Although plasmid transfer in Gram-positive organisms doesn’t 
require the synthesis of complex conjugation apparatus (sex pili) seen in Gram- 
negative bacteria, they still need to achieve intimate cell-cell contact. The processes 
for this have not been fully identified, but a strong level of homology has been found 
with type IV secretion systems (Grohmann et al., 2003). The synthesis of these 
elements requires energy, which SCVs have in very short supply. Consequently, 
SCVs may have been unable to synthesize the proteins necessary for the conjugation 
apparatus, impacting severely upon their ability to act as either donors or recipients.
It is possible that the plasmids were transferred, but were not expressed in the 
recipient cells. However, this appears unlikely; SCVs of plasmid-bearing S. aureus 
are able to express plasmid genes (EaglesSCV and F89SCV are high-level mupirocin 
resistant). Furthermore, whilst a plasmid may impose a fitness cost upon its host, this
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is negated when a strong selective pressure for their maintenance is applied, such as 
antibiotic treatment. This could be checked by avoiding the selection of 
transconjugants on selective agar, but using genetic analysis, PCR or pulsed field gel 
electrophoresis (PFGE), to scrutinize recipient cells for the presence of plasmids. 
Indeed, further work is required to better identify whether SCVs can undergo 
conjugation. A wider selection of plasmids, donors and recipients should be used in 
conjunction with a broader set of experimental methods, adapting the method to one 
that better suits SCVs.
The fact that the SCVs were susceptible to phage infection tells us that they are able 
to express the cell surface features used by these phages as attachment sites. 
Furthermore, the formation of visible plaques implies that phage replication occurred; 
if phage replication did not occur the infection would not pass further than the initial 
cell infected and the number of cells lysed would not be enough to form visible 
plaques. Consequently, we know that genes introduced in to SCV cells by phage 
particles were expressed and so we can identify SCVs as potential donors and 
recipients for gene exchange by transduction.
We were unable to detect the transfer of resistance traits by transduction with SCVs. 
This is little harder to explain than why conjugation may have failed. Transduction is 
a more passive process for the cells, during the early stages at least. It doesn’t require 
synthesis of specialized proteins and we know that those genes pass into cells by 
phages are expressed. Again the attenuated growth of SCVs may have caused 
practical problems. Whilst it was possible to adjust the multiplicity of infection by 
controlling the number of phages added to the transduction mixture it was difficult to 
achieve the high cell densities required for satisfactory levels of detection. Further 
work should be targeted at analyzing transduction in SCVs. This should encompass a 
broader selection of selective markers and will require further optimization for use 
with SCVs.
Interestingly, transformation was detected in SCVs whilst wild-type strains were 
unable to take up and express free DNA at frequencies above our level of detection. In 
fact the transformation frequencies seen with SCVs was high (2.38><10'5 to 1.48x1 O'6 
transformants per recipient) in comparison to other gene transfer events in S. aureus
2 0 2
(Seaman et al. 2007b). Although transformation does occur in S. aureus it is a 
generally rare event; transformation requires, high calcium concentrations (0.1 M) and 
the natural competence system of S. aureus is induced only in very early exponential 
growth (Novick, 1989). Either chromosomal or plasmid DNA can be transformed into 
S. aureus, however the production of nucleases by S. aureus further complicates the 
situation since these digest DNA that would otherwise be available for transformation 
(Lacey, 1984). Hence it is pertinent that, as discussed above, SCVs produce 
significantly less DNase (over 100-fold) than wild type S. aureus. Although the 
method employed herein involved several wash steps designed to minimize the effects 
of DNA digestion by nucleases, wild-type cells would have continued to produce 
these enzymes, degrading the free DNA. As a consequence more intact DNA would 
have been available to SCVs than wild-type. This may help explain why SCVs are 
capable of higher rates of transfer by transformation than wild-type S. aureus.
These transformation results indicate that recA was present in SCV cells. Thus the 
failure of conjugation and transduction to yield recombinants was not due to the 
absence or shortage of this enzyme.
The role of SCVs in gene transfer is yet to be fully gauged, however it appears they 
are able to partake in transformation and the potential for conjugation and 
transduction exists. The role of SCVs as mediators of gene transfer is of importance 
due to their unique lifestyle; their persistence during infections, even during 
antimicrobial chemotherapy means that they are in turn a persistent genetic resource 
and are available to accept and donate DNA under strong selective pressure. Hence, 
SCVs could act as a ‘DNA dealers’, trading DNA with other microorganisms that 
they encounter during the course of long-term infection. For this reason more 
experimentation should be performed to understand their role in the evolution of S. 
aureus with an ultimate aim to model this in vivo.
203
References
al-Masaudi SB, Russell AD & Day MJ (1991) Factors affecting conjugative transfer 
of plasmid pWG613, determining gentamicin resistance, in Staphylococcus 
aureus. J  Med Microbiol 34: 103-107.
Balwit JM, van Langevelde P, Vann JM & Proctor RA (1994) Gentamicin-resistant 
menadione and hemin auxotrophic Staphylococcus aureus persist within cultured 
endothelial cells. J  Infect Dis 170: 1033-1037.
Bayles K & Bohach G (2002) Internalization of Staphylococcus aureus by 
nonprofessional phagocytes. Infectious Agents and Pathogenesis: Staphylococcus 
aureus Infection and Disease. (Honeyman AL, Friedman H & Bendinelli M, eds). 
pp. 247-270. Springer US, New York.
Besier S, Smaczny C, von Mallinckrodt C, Krahl A, Ackermann H, Brade V & 
Wichelhaus TA (2007) Prevalence and clinical significance of Staphylococcus 
aureus small-colony variants in Cystic Fibrosis lung disease. J  Clin Microbiol 45: 
168-172.
Cooper N, Brown M & Caulcott C (1987) A mathematical method for analysing 
plasmid stability in micro-organisms. J  Gen Microbiol 133: 1871-1880.
Dykhuizen DE & Hartl DL (1983) Selection in chemostats. Microb Rev 47: 150-168.
Grohmann E, Muth G & Espinosa M (2003) Conjugative plasmid transfer in Gram- 
positive bacteria. Microbiol Mol Biol Rev 67: 277-301.
Heatley NG (1944) A method for the assay of penicillin. Biochem J  38: 61-65.
Hoffman LR, Deziel E, D'Argenio DA, Lepine F, Emerson J, McNamara S, Gibson 
RL, Ramsey BW & Miller SI (2006) Selection for Staphylococcus aureus small- 
colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc 
Nat Acad Sci USA: 0606756104.
Kahl BC, Belling G, Reichelt R, Herrmann M, Proctor RA & Peters G (2003) 
Thymidine-dependent small-colony variants of Staphylococcus aureus exhibit 
gross morphological and ultrastructural changes consistent with impaired cell 
separation. J  Clin Microbiol 41: 410-413.
Lacey RW (1984) Evolution of microorganisms and antibiotic resistance. Lancet 324: 
1022-1025.
Lee SW & Edlin G (1985) Expression of tetracycline resistance in pBR322 
derivatives reduces the reproductive fitness of plasmid-containing Escherichia 
coli. Gene 39: 173-180.
204
Lenski R & Bouma J (1987) Effects of segregation and selection on instability of 
plasmid pACYC184 in Escherichia coli B. JBacteriol 169: 5314-5316.
Lenski RE (1988) Experimental studies of pleiotropy and epistasis in Escherichia 
coli. 1. Variation in competitive fitness among mutants resistant to virus-T4. 
Evolution 42: 425-432.
Lenski RE (1997) The cost of antibiotic resistance—from the perspective of a 
bacterium. Ciba Foundation Symposium 207: 131-140.
Massey RC, Buckling A & Peacock SJ (2001) Phenotypic switching of antibiotic 
resistance circumvents permanent costs in Staphylococcus aureus. Curr Biol 11: 
1810-1814.
McNamara PJ & Proctor RA (2000) Staphylococcus aureus small colony variants, 
electron transport and persistent infections. Int J  Antimicrob Agents 14: 117-122.
Moisan H, Brouillette E, Jacob CL, Langlois-Begin P, Michaud S & Malouin F 
(2006) Transcription of virulence factors in Staphylococcus aureus small-colony 
variants isolated from cystic fibrosis patients is influenced by SigB. J  Bact 188: 
64-76.
Novick R (1967) Properties of a cryptic high-frequency transducing phage in 
Staphylococcus aureus. Virol 33: 155-166.
Novick RP (1989) Staphylococcal plasmids and their replication. Ann Rev Microbiol 
43: 537-565.
Proctor RA (1998) Bacterial energetics and antimicrobial resistance. Drug Resist 
Updates 1: 227-235.
Proctor RA, van Langevelde P, Kristjansson M, Maslow JN & Arbeit RD (1995) 
Persistent and relapsing infections associated with small-colony variants of 
Staphylococcus aureus. Clin Infect Dis 20: 95-102.
Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M & Peters G 
(2006) Small colony variants: a pathogenic form of bacteria that facilitates 
persistent and recurrent infections. Nat Rev Microbiol 4: 295-305.
Seaman PF & Day MJ (2007) Isolation and characterization of a bacteriophage with 
an unusually large genome from the Great Salt Plains National Wildlife Refuge, 
Oklahoma, USA. FEMS Microbiol Ecol doi: 10.1111/j.l574-6941.2006.00277.x.
Seaman PF, Ochs D & Day MJ (2007a) Small-colony variants: a novel mechanism for 
triclosan resistance in methicillin-resistant Staphylococcus aureus. J  Antimicrob 
Chemother 59: 43-50.
205
Seaman PF, Ochs D & Day MJ (2007b) Gene transfer of biocide resistance in 
staphylococci. J  Antimicrob Chemother Submitted.
Siffi CD, Baresch-Bemal A, Calderwood SB & von Eiff C (2006) Virulence of 
Staphylococcus aureus small colony variants in the Caenorhabditis elegans 
infection model. Infect Immun 74: 1091-1096.
Swift S, Throup JP, Williams P, Salmond GPC & Stewart GSAB (1996) Quorum 
sensing: a population-density component in the determination of bacterial 
phenotype. Trends Biochem Sci 21: 214-219. 
von Eiff C, Becker K, Metze D, Lubritz G, Hockmann J, Schwarz T & Peters G 
(2001) Intracellular persistence of Staphylococcus aureus small-colony variants 
within keratinocytes: a cause for antibiotic treatment failure in a patient with 
darier's disease. Clin Infect Dis 32: 1643-1647. 
von Eiff C, Heilmann C, Proctor RA, Woltz C, Peters G & Gotz F (1997) A site- 
directed Staphylococcus aureus hemB mutant is a small-colony variant which 
persists intracellularly. JBact 179: 4706-4712.
Williamson NR, Fineran PC, Leeper FJ & Salmond GPC (2006) The biosynthesis and 
regulation of bacterial prodiginines. Nat Rev Microbiol 4: 887-899.
206
Chapter 8 
General Discussion and Perspectives
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8.0 General discussion and perspectives
Since each practical-based chapter (2-7) contains a discussion pertinent to the findings 
of that investigation this chapter will mainly relate information across the thesis in a 
more general manner and will discuss future perspectives and further research.
S. aureus has a long history of causing disease and advances in medicine have created 
further opportunities for infections. Surgery and the wide spread use of intravenous 
cannulae and catheters facilitate entry in to the body of potential hosts. A huge 
increase in the use of in-dwelling devices, such as prosthetic joints and heart valves, 
has also provided new niches for S. aureus to exploit (Dickinson & Bisno, 1989). 
Additionally, patients are living longer and surviving trauma or diseases that would 
previously have been fatal. This is resulting in an increased population of 
immunocompromised individuals, often with the other risk factors for infection 
mentioned above. So whilst these advances caused an increase in the number of hosts 
for S. aureus infections modem medicine also promised the answer: antibiotics.
However, evolution has facilitated the development of antibiotic resistance. 
Consequently, we are now faced with the enormous problem of multiply-resistant 
bacteria, the most significant of which is MRSA. Our hospitals, and to some extent 
homes, represent an environment populated by a high density of suitable hosts with a 
strong selective pressure for the growth of antimicrobial resistant organisms. 
Consequently, large numbers of patients are contracting MRSA, which is causing 
substantial morbidity and mortality. Moreover, MRSA infections have been estimated 
to be costing the UK National Health Service (NHS) £1 billion per year (Bourn et al., 
2004). Indeed MRSA is endemic in many UK hospitals (Coia et al., 2006). There has 
also been a substantial increase in the incidence of community-associated infections 
(Ribeiro et al., 2005; Huang et al., 2006; Johnson et al., 2006).
Consequently, an extensive list of procedures to reduce the incidence of MRSA 
infections has been introduced (Coia et al., 2006; Pratt et al., 2007). These include 
systematic surveillance of MRSA, avoiding the inappropriate or unnecessary use of 
antibiotics, which should also reduce the likelihood of the emergence and spread of 
strains with reduced susceptibility to glycopeptides. Patients and clinical areas are
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screened for MRSA carriage, patient isolation is often employed and strict 
handwashing regimes have been put in place. Nasal and skin decolonization are also 
an important part of infection control procedures. Consequently, triclosan, as one of 
the antimicrobials used during skin decolonization, has a major in reducing the 
transmission and initiation of MRSA infections.
Hence, when Cookson et al., (1991) described the appearance of triclosan resistance 
in S. aureus the potential for decolonization failure and increased infection rates 
became apparent. This was made worse by the report also stating that triclosan 
resistance was transferable - increasing the likelihood and speed of dissemination. 
Moreover, triclosan is used widely in other applications, particularly in consumer 
healthcare products and domestic goods. Therefore, there several authors have 
expressed concern that exposure of S. aureus to triclosan in domestic and industrial 
settings may provide additional selective pressure for resistance (Fraise, 2002; 
Beumer et al., 2003; Cole et al., 2003; Aiello et a l , 2005; Weber & Rutala, 2006). 
Indeed, triclosan has been at the centre of controversy for some time. Of particular 
interest has been the potential for triclosan to select for resistance to other 
antimicrobials (Russell, 1999; Russell et a l , 1999; Russell, 2000; Levy, 2001; 
Russell, 2002; Aiello & Larson, 2003; Aiello et a l , 2005).
Whilst one mechanism of ‘resistance’ to triclosan in S. aureus has been elucidated and 
studies have investigated the effect of triclosan exposure upon antimicrobial 
resistance, there is a paucity of data regarding the evolutionary effects and 
consequences of reduced susceptibility to triclosan. There have also been few data on 
the gene transfer of reduced triclosan susceptibility. Consequently, we have 
investigated several factors surrounding the development and gene transfer of reduced 
susceptibility to triclosan in S. aureus.
8.1 Mechanisms of triclosan resistance in S. aureus
8.1.1 A role for capsule polysaccharide in antimicrobial resistance?
There are 11 known serotypes of S. aureus capsular polysaccharides. Serotypes CP5 
and CP8  are by far the most common amongst isolates recovered from humans
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(O'Riordan & Lee, 2004). These serotypes are considered as microcapsules because 
they are much thinner than the mucoid serotypes 1 and 2. Capsule polysaccharides, 
and particularly CP5 and CP8 , are involved in impeding phagocytosis (O'Riordan & 
Lee, 2004). Moreover, they may also present a permeability barrier to antimicrobial 
agents, reducing the susceptibility of certain strains (Kolawole, 1984). However, we 
found that strains that expressed either CP5 or CP8  were equally as susceptible to a 
range of antimicrobials as an isogenic strain that was engineered to be deficient in 
capsule formation. This indicates that whereas S. aureus capsule polysaccharides are 
implicated in virulence, they are not involved in conferring reduced antibiotic or 
biocide susceptibility.
Subsequent work has found that the vancomycin-intermediate MRSA strain Mu50 
was as susceptible to triclosan, CHX and CPC as vancomycin susceptible MRSA 
strains. This is interesting, since the reduced susceptibility to vancomycin in Mu50 
and other clinical VISA and heteroVISA strains has been attributed to thickened cell 
walls (which can reduce permeability) and reduced cross linking of glycan chains 
(Hiramatsu et al., 1999; Cui et al., 2000; Cui et al., 2006). Hence, there appears to be 
no co-resistance between triclosan and vancomycin, and thickening of S. aureus cell 
walls does not confer reduced susceptibility to common biocides; triclosan and CHX 
should remain efficacious against these infections.
After elucidating the role of the major capsule serotypes upon triclosan susceptibility 
we aimed expound other methods of reduced susceptibility to triclosan in S. aureus. 
These centred around chromosomal mutations affecting fatty acid biosynthesis.
8.1.2 FabI and triclosan susceptibility
We found that we could isolate S. aureus mutants with reduced susceptibility to 
triclosan at rates of between 3.5><1 O'9 and ~1.0x10"n per CFU (Chapter 4, Figure 4.1). 
These mutants had triclosan MICs that were generally 100-200 times higher than their 
parent. Following previous reports that mutations affecting the fabl gene may lead to 
reduced triclosan susceptibility (Heath & Rock, 2000; Fan et al., 2002), we sequenced 
the entire fab l  gene and preceding promoter region. Comparison of parent and mutant 
sequences revealed a novel mutation, C284T. This mutation confers an alanine to
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valine substitution at the 95th residue of the Fabl protein. Due to the position of this 
substitution, we hypothesize that the location of the A95V affects the formation of the 
inhibitory triclosan-NAD+-FabI complex. Binding and inhibition studies would be 
needed to test this hypothesis; analyzing the ability of wild-type and mutant Fabl to 
form the complex with triclosan and NAD+ and calculating the inhibitory effects of 
this upon the enzyme (such as I50; concentration of triclosan than produces 50% 
inhibition). Similar studies have been performed previously with other fabl mutants 
and protein targets (Stewart et al., 1999; Thomas et al., 1999; Heath & Rock, 2000; 
Fan et al., 2002). This could be aided by X-ray crystallographic analysis of the 
complex, which would provide data on the structure of the protein, its binding sites 
and structural interactions within triclosan and NAD+ (Qiu et al., 1999).
Possession of C284T conferred an increase in triclosan MIC to ~1 mg/L, however we 
found that when this occurred in combination with a further mutation, T-108G, within 
the putative fabl promoter region, the MIC was further increased (~2 mg/L). 
Following from prior evidence that increased expression of fab l can reduce triclosan 
susceptibility (Fan et al., 2002) we hypothesize that this mutation is affecting the 
expression of fab l and increasing the bioavailability of enoyl-ACP reductase. 
Confirmation of increased Fabl levels in T-108G cells would be needed to support 
this hypothesis. This could be performed by examination of Fabl abundance in T- 
108G and wild-type S. aureus strains by Western immunoblotting as described by Fan 
et al., (2002). Alternatively, reverse transcription, real-time PCR could be used to 
calculate the abundance of fab l  mRNA, and subsequently the level of expression of 
fabl.
Further work should also be aimed at confirming the role of the identified mutation(s) 
in triclosan resistance by transfer to a triclosan-sensitive host via transduction, cloning 
or allelic replacement. This would identify whether these known fabl mutations are 
the sole explanation for the reduced susceptibility of mutants, or whether other, yet 
unidentified, alterations are also involved. One possible method for the construction 
of isogenic strains to evaluate effects of Fabl over expression and C284T on triclosan 
susceptibility would involve the cloning of the wild-type fabl gene from S. aureus 
into an E. coli-S. aureus shuttle vector, that allows expression of S. aureus genes in E. 
coli (such as pYH4; Huang et al., 2004). Site-directed mutagenesis could then be used
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to change the fab l contained within this plasmid to contain the mutations described by 
us in chapter 4. Following the introduction of this mutani-fabl bearing plasmid into a 
triclosan susceptible S. aureus the effects of C284T and T-108G could be elucidated.
Indeed, we also isolated a reduced susceptibility strain with an unaltered fabl gene, 
indicating that there are mutations other than within fab l that can confer reduced 
triclosan susceptibility. So it remains a possibility that the reduced-susceptibility 
strains identified as C284T and T-108G mutants may also carry other mutations. 
However, it could be argued that since the identified and unidentified mutations 
appear to involve separate mechanisms their effects would be cumulative -  it could be 
expected that whereas possession of C284T and T-108G or unidentified mutations 
confer triclosan MICs of ~2 mg/L, possession of both would result in yet higher 
MICs.
Furthermore, the frequency of mutation to triclosan resistance was close to that 
expected from spontaneous mutation (~1.0X10‘8; see section 1.2.3). If multiple sites 
were subjected to spontaneous mutation, then the evolution of mutants resistant to 
triclosan would be expected to occur at much lower rates (Battista & Earl, 2004). This 
was not found, providing further support for the hypothesis that it was solely the 
C284T and T-108G mutations conferring resistance. However, it is possible that if a 
small increase in resistance occurs in one bacterium it will have an increased growth 
rate/survival rate and thus be a larger proportion of the population. Thus further 
mutations occurring in this ever increasing population will occur. Ultimately, the 
‘hitchhiking’ of one mutation on another could cause multiple mutations to appear at 
an increased rate; the chance of a double mutation is not simply the sum of the the 
probabilities.
8.1.3 Alternative mechanisms o f resistance
We isolated reduced susceptibility mutants with no obvious Fabl alteration, hence an 
alternative method of resistance must have evolved. Similar phenomena have been 
reported previously, but have failed to offer an explanation for the reduced 
susceptibility (Brenwald & Fraise, 2003). So what are the possible candidates? Firstly, 
we must look at the known sites that triclosan targets in S. aureus; Fabl and the
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cytoplasmic membrane. Although no mutation was found within fabl, the abundance 
of Fabl protein could have been altered by gene duplication or changes to a global 
expression control system. An increase in fab l copy-number could bring about an 
increased abundance of Fabl, reducing the susceptibility of the strain. This would not 
have been detected by the sequence analysis, but could be identified by quantitative 
PCR and enumeration of Fabl.
S. aureus cells utilise a global regulatory network, constituents of which include the 
loci agr, sar, sigB, rot, arlR/S, svrA, and saeRJS (Arvidson & Tegmark, 2001; 
Beenken et al., 2004; Benton et al., 2004; Cheung et al., 2004; Goerke et al., 2005). 
Consequently, an up-regulation of the expression of fabl could have mediated by a 
global regulator, circumventing the involvement of fabl or its promoter. This would 
possibly have led to other physiological changes, but these would have gone 
undetected; we were only looking for a narrow range of phenotypic changes. If 
exposure to triclosan does affect the global control systems, then this could have 
many interesting effects. Virulence and/or resistance could be up- or down-regulated 
and many other metabolic processes could be affected, such as induction of stress 
response.
An interesting experiment would be to compare the expression of S. aureus genes 
with and without triclosan exposure. This could be facilitated by using a S. aureus 
microarray, such as the one described previously by Witney et al., (2005). This 
microarray contains 3,623 PCR products representing every predicted open reading 
frame in seven genome sequencing projects. The microarray can be used to scrutinise 
gene expression and hence those genes affected by triclosan exposure and could be 
identified. Subsequent bioinformatic analysis would give clues as to what processes 
and functions are affected by triclosan, perhaps providing evidence of previously 
unknown resistance mechanisms and associated effects. However, microarrays are 
limited in providing quantitative data; they can discriminate between on and off, but 
resolution between up-regulated and down-regulated is poor. Hence, to quantify the 
expression of genes of interest quantitative PCR could be performed on individual 
genes (which are compared to controls with constant expression rates). This will 
provide a greater level of discrimination, identifying discrete changes in gene 
expression, such as the possible up-regulation of fabl.
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A review by Russell suggested that the bacterial cytoplasmic membrane was the major 
target for triclosan action (Russell, 2003b). Indeed, we have shown that triclosan- 
induced potassium ion leakage, indicative of membrane damage, occurs at bactericidal 
levels. Additionally, membrane-destabilizing effects have been demonstrated by 
Guillen et al., (2004) and Villalain et al., (2001). Triclosan has also been reported to 
demonstrate a Z-pattem type of adsorption, which is suggested to be due to the 
breakdown of the membrane (Denyer & Maillard, 2002). Recent studies have 
demonstrated that triclosan arrests the growth of the parasites Trypanosoma brucei, 
Plasmodium falciparum and Toxoplasma gondii by inhibition of their enoyl-acyl 
carrier protein reductase (Paul et al., 2004; Muench et al., 2007). However triclosan 
has also been found that to act on these organisms by a non-specific perturbation of 
the membrane structure, which leads to disruption of sensitive membrane-resident 
biochemical pathways (Paul et al., 2004). In Gram-negative bacteria these effects can 
be reduced by the reduced permeability of their cell wall and removal of the 
antimicrobial by efflux.
Gram-negative bacteria have demonstrated an ability to decrease their susceptibility to 
antimicrobials by enhancing the impermeability barrier function of their outer 
membrane. Lipopolysaccharides (LPS) of Gram-negative bacteria are responsible for 
part, if not most, of the cell impermeability characteristics. Hence, any changes in the 
expression or structure of LPS are likely to have an effect on permeability (Russell & 
Furr, 1986). Altered LPS composition in Proteus spp., P. aeruginosa and 
Burkholderia cepacia, has been linked to resistance to cationic biocides (Tattawasart 
et al., 1999; Denyer & Maillard, 2002; Maillard, 2002). Additionally, loss of porin 
proteins can be important in the permeability of the outer membrane of Gram- 
negative bacteria, particularly to hydrophilic molecules. Alteration of porin size or 
loss of porin proteins implicated in the uptake of antimicrobial agents has been shown 
to result in an increase in bacterial resistance (Achouak et al., 2001). Furthermore, 
Gram-negative bacteria have developed other mechanisms to reduce the intra-cellular 
concentration of antimicrobials, such as xenobiotic degradation processes, particularly 
in the periplasm (Beveridge, 1995; Heinzel, 1998).
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The intrinsic resistance of P. aeruginosa to triclosan has been shown to be a 
combination of outer membrane permeability and an active efflux system (Levy, 
2002; Poole, 2002; Chuanchuen et al., 2003; Champlin et al., 2005). Efflux removes 
intracellular triclosan, lowering its concentration and causing the organism to become 
less susceptible. Efflux pumps may be specific for one substrate or may transport a 
range of structurally disparate compounds. Pumps that are associated with multiple 
drug resistance are termed MDR efflux pumps. Whilst these have been most 
extensively studied in Gram-negative bacteria, efflux pumps have been described in S. 
aureus (Huang et al., 2004; Kaatz et al., 2005; McAleese et al., 2005; Piddock, 2006). 
No efflux system for the removal of triclosan has been described in S. aureus. 
However, some authors have speculated that triclosan could select for the up- 
regulation or mutation of S. aureus MDR efflux pumps, resulting in augmented 
resistance to a variety of antimicrobials (Levy, 2001; Fraise, 2002; McBain et al., 
2002). There is currently no evidence to support these perspectives, but it remains that 
this is a potential mechanism for triclosan resistance in S. aureus. As research into 
staphylococcal efflux systems progresses we may learn the full implications of this 
phenomenon, this would certainly be of interest due to the potential for co-resistance.
Triclosan was found to directly inhibit glycolysis in Streptococcus mutans by 
irreversibly inhibiting the glycolytic enzymes pyruvate kinase, lactic dehydrogenase, 
aldolase and the phosphoenolpyruvate: sugar phosphotransferase system (Phan & 
Marquis, 2006). The authors concluded that triclosan is a multi-target inhibitor for 
mutans streptococci, which lack a triclosan-sensitive Fabl enoyl-ACP reductase. This 
raises the possibility that glycolysis is also s target in S. aureus, providing further 
mutated loci that may arise when grown under selective pressure for resistance to 
triclosan.
8.1.4 Triclosan resistant SCVs
A major finding during the course of this research was the identification that triclosan 
can select for small colony variants (SCVs) of S. aureus. We have found that triclosan 
can select for S. aureus SCVs with low-level triclosan resistance and which 
coincidently had reduced susceptibility to penicillin and gentamicin. Additionally, 
triclosan isolated SCVs were shown to have an increased tolerance to the lethal effects
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of triclosan. SCV status has previously been associated with a reduction in bacterial 
energy generation and/or transport, accounting for the down-regulation of such 
functions as synthesis of cell walls and pigments and toxin production (Proctor, 1998; 
McNamara & Proctor, 2000; Proctor et al., 2006). A number of loci have been 
identified as causing SCV growth, namely those involved in electron transport 
(menaquinone, haemin and haem A), thymidine biosynthesis and processes of the 
Krebs cycle (TCA cycle). Whereas the source of resistance to aminoglycosides and 
cationic compounds in SCVs has been elucidated, the mechanism of resistance to 
triclosan is unknown.
Our current knowledge of SCVs provides several candidates for how explaining how 
triclosan selects for SCVs and how their reduced triclosan susceptibility is facilitated. 
Firstly, we will consider the ATP producing process of electron transport. As briefly 
discussed above several constituents of the staphylococcal ETC can mutate, blocking 
ATP production by this process (a more comprehensive analysis is provided in section 
1.6). These electron carriers are not known targets for triclosan, however biosynthesis 
of S. aureus cytochromes requires isoprenoid -  a lipid based organic molecule 
(Collins, 1981; Collins & Jones, 1981; Bentley & Meganathan, 1982; Lange et al., 
2000; Voynova et al., 2004). Since isoprenoid contains lipid it is reliant upon bacterial 
fatty acid synthesis, a target for triclosan. It is possible that the presence of triclosan 
perturbs the synthesis of isoprenoid and prevents the production of functional 
cytochromes, resulting in the isolation of SCVs, Figure 8.1.
As discussed above glycolysis may also be a target for triclosan. This provides 
another putative mechanism for the selection of SCV growth by triclosan. Glycolysis 
is a key ATP and NADH producing process in S. aureus and is also involved in the 
provision of substrate (pyruvate) for ATP production by the Krebs cycle. Hence, 
perturbation of glycolysis could also have severe ATP limiting effects upon the cell, 
resulting in SCVs, Figure 8.1.
It is intriguing that all the antimicrobial compounds described as selecting for SCVs 
are bacteriostatic (vancomycin, cycloserine, bacitracin, methicillin, gentamicin, 
kanamycin, chloramphenicol, sulfamethoxazole-trimethoprim) and it is only at 
bacteriostatic concentrations that triclosan selected for SCVs. We hypothesise that the
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Figure 8.1. Potential mechanisms for selection of S C V  growth by triclosan. T riclosan  is know n to 
target fa tty  ac id  b io sy n th esis , a  p ro ce ss  th a t is k ey  to  several constituen ts o f  ce llu lar A TP production . 
Isop reno id  b io sy n th es is  w ill b e  p ertu rbed , as w ill syn thesis o f  A cy l-C oA  and  the conversion  o f  
m enadione. C on seq u en tly , the  ce ll w ill b e  u n ab le  to p roduce  functional cytochrom es, e lec tron  carriers 
tha t are  k ey  to  th e  stap h y lo co cca l E T C . S evera l o th e r enzym es invo lved  in  conversion o f  pyruvate  and 
fatty  ac ids to  p ro v id e  A ce ty l-C o A  to  th e  K rebs cycle  m ay  also  be  affected  b y  F ab l inh ib ition  by  
tric losan  ( ed text). T he  co m b in a tio n  o f  th ese  e ffec ts w ou ld  cause an  A T P deficiency  and b ring  about 
the characteristic  SC V  p h en o ty p e . A d d itio n a lly , g lyco lysis  is a po ten tia l ta rget fo r tric losan  tha t w ould 
have a c lea r A T P  and  N A D H  lim itin g  ou tcom e.
Glucose
Glycolysis X  4  Triclosan
Pyruvate Fatty add biosynthesis \ j |
pdh corr: I X  Triclosan
”  FadE FadFG T
Acetyt-CoA 4  — Acyl-CoA
FadB FadA
Citrate
Krebs
CycleMqo2 NADH and FADH2
5dh complex
T riclosan
NADH and FADH2
Metabolic sensors 
and regulators
Fatty acid biosynthesisIsoprenoid lipidQox or SnoD
Shikimate
Thiamine
diphosphate Menadione
biosynthesis Haemin biosynthesisMenaquinone
Cytochromes + HaeminMenadione
|  Fatty add biosynthesis^ Isoprenoid lipid tRNAIII; 
other signals
Mixed function oxidasetATPElectrochemical gradient (AV)
Cell wall biosynthesis; amino- 
acid transport and protein 
synthesis
Aminoglycoside and 
cationic antimicrobial 
transport
Carotenoid
biosynthesis
Antibiotic Rapid growth. Pigmented Toxin
susceptibility large colonies colonies production
217
difference in action between bacteriostatic and bactericidal compounds allows for the 
selection of SCVs. This should be investigated further by directly comparing the 
propensity for SCV formation when exposing S. aureus so a selection of bacteriostatic 
and bactericidal compounds.
Finally, we hypothesize that those parts of ATP production that are membrane- 
associated may be affected by triclosan. Triclosan is known to intercalate into the cell 
wall causing it to become destabilised and compromising its functional integrity 
(Villalain et al., 2001; Guillen et al., 2004). Hence there is potential for triclosan to 
interrupt membrane-associated ATP production. Indeed the majority of proteins and 
other elements that constitute the staphylococcal ETC are membrane-associated, 
including ATPase itself (Gross & Coles, 1968; Kubak & Yotis, 1981). So both the 
traditional (membrane targeting) and recent (Fabl targeting) mechanisms of action 
could bring about the evolution of SCVs, but how are they able to grow in the 
presence of triclosan?
We have shown that SCV fa b l  genes were unaltered from their parent, so this was not 
the mechanism of resistance. Triclosan is not cationic, therefore transport across the 
cell membrane is not thought to be affected by reductions in AT and we have shown 
that the effects of triclosan are not affected by growth state, so slow growth is unlikely 
to confer resistance. Hence, one or more alternative mechanisms must be in place. 
These could include undetected alterations to fatty acid biosynthesis, alterations in the 
genes of the glycolytic pathway, changes to cell permeability or other triclosan target. 
Further work is needed to elucidate this resistance mechanism. Identifying the 
mechanism of resistance would expand our knowledge of resistance systems in 
bacteria and would also facilitate research in to methods to prevent or circumvent 
SCV-associated problems. An important part of this work would involve elucidating 
the expression profile of triclosan-induced SCVs and comparing it to their parent. 
Further work could also be performed on S. aureus under anaerobic conditions, since 
this is known to induce SCV growth (McNamara & Proctor, 2000).
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8.2 Triclosan resistance in the environment
There have been a number of conflicting reports on the incidence of reduced triclosan 
susceptibility outside of the laboratory. Cookson et al. described the isolation of 
triclosan resistant staphylococci in 1991 and Bamber & Neal, (1999) reported that 
7.5% of S. aureus clinical isolates they investigated had triclosan MICs of at least 1 
mg/L. Fan et al. (2002) identified fab l mutations in clinical isolates with reduced 
susceptibility to triclosan and (Brenwald & Fraise, (2003) reported that 2% of clinical 
S. aureus show reduced susceptibility to triclosan. Conversely, Al-Doori et al., (2003) 
maintain that there has not been a significant increase in reduced triclosan 
susceptibility amongst nosocomial MRSA in Scotland. A study by (Ledder et al.,
2006) failed to indicate any explicit link between triclosan exposure and resistance in 
ex-situ bacterial isolates. Triclosan resistance was not found in sink drain microcosms 
or domiciliary environments repeatedly exposed to triclosan (Cole et al., 2003; 
McBain et al., 2003a; McBain et al., 2003b; Aiello et al., 2004; McBain et al., 2004). 
Lear et al., (2002) found that residual biocide concentrations in a triclosan 
manufacturing site did not promote the emergence of bacterial tolerance for them. 
Suller & Russell, (2000) found a low incidence of triclosan resistance amongst 
antibiotic resistant S. aureus isolates. Finally, the results presented in chapter 3 
indicate that the frequency of resistance to triclosan is very low amongst MRSA and 
MSSA isolates from South Wales hospitals.
The disparity between these findings may reflect differences in sampling and testing 
techniques. Various methods were used to assess triclosan susceptibility and a 
selection of sampling methods were employed, some possibly more effective than 
others. Alternatively, the results may be accurate, but reflect the differences between 
the individual test locations; some hospitals may rely more heavily upon CHX or 
other antimicrobials as part of their infection control policy, rather than triclosan. 
Most of the investigations included a large selection of S. aureus isolates, so bias 
towards clones with reduced susceptibility to triclosan appears unlikely -  although 
this would be an interesting route of investigation.
In an attempt to investigate the carriage of triclosan resistant staphylococci in a 
specific community setting we analyzed samples recovered from 93 undergraduate
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students attending a practical teaching class at Cardiff University. We found no 
evidence of reduced susceptibility to triclosan amongst the recovered S. aureus 
isolates, indicating that prevalence of triclosan resistance is low in this population. 
This and previous reports of low prevalence of triclosan resistance in the community 
are encouraging. They fail to support the hypothesis that triclosan exposure in the 
home can lead to the development of antimicrobial resistance as mooted by several 
authors (Russell, 1999; Russell, 2000; Levy, 2001; McBain & Gilbert, 2001; White & 
McDermott, 2001; McBain et al., 2002; Poole, 2002; Tan et al., 2002; Russell, 2003a; 
White et al., 2005; Sattar, 2006). Carriage of S. aureus was found to be inline with 
previous studies (Abudu et al., 2001; Sa-Leao et al., 2001; Maudsley et al., 2004). 
CoNS carriage was more prevalent than S. aureus and these organisms were also 
significantly less susceptible to triclosan, showing a median triclosan MIC of 4 mg/L 
(133-fold higher than the median MIC for S. aureus). However, CoNS MICs were 
still far below the typical in-use concentrations of triclosan (0.1 to 2%).
8.3 Significance of low-level triclosan resistance
Analysis of staphylococcal triclosan susceptibility by MIC has identified that some 
strains of S. aureus and most CoNS can demonstrate low-level resistance to this 
antimicrobial. There has been some speculation on the clinical significance of this 
resistance, but the data available currently appear ambiguous (Cookson et al., 1991; 
Suller & Russell, 2000; Brenwald & Fraise, 2003; Russell, 2004; Seaman et al.,
2007).
There are several factors that lead to this ambiguity: MIC may not be appropriate for 
assessment of triclosan susceptibility; triclosan formulations differ; there are 
differences between triclosan uses; physiological state of the bacteria may vary; there 
is a paucity of data on the clinical efficacy of triclosan against low-level resistant 
organisms.
8.3.1 Biocide MIC: an indication of efficacy?
Assessing an antibiotic’s MIC for a particular organism is a useful method for 
examining susceptibility. It is used widely by clinical microbiologists to aid their
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formulation of treatment plans for patients and to monitor resistance levels within the 
environment. It is also used widely in the laboratory to assess susceptibility for 
research purposes. Whereas MIC is appropriate for the assessment of susceptibility to 
antibiotics, this may not be the case for biocides, where MIC is does not always 
correlate with bacterial killing (Russell, 2004). A lack of correlation between MICs 
and lethal effects has been demonstrated previously (Cookson et al., 1991; Suller & 
Russell, 2000; Russell, 2004; Gomez Escalada et al., 2005) and by the data presented 
in chapter 3. This has been hypothesised to be a consequence of the mechanisms of 
action of triclosan (Suller & Russell, 2000); generally, antibiotics have single target 
sites and consequently increased MICs and reduced bactericidal effectiveness are 
linked. In contrast, biocides have multiple targets and increased MICs often do not 
correlate with decreased bactericidal activities (McDonnell & Pretzer, 1998). It has 
been proposed that additional triclosan-induced cellular changes are required to 
produce a bactericidal effect whether the strain is resistant or sensitive to triclosan, as 
judged purely by the MICs (Russell et al., 1999). Consequently, whilst clinical strains 
may be identified as triclosan-resistant by laboratory MIC, they may be killed in-situ 
just as effectively as triclosan-susceptible strains. More research is required to 
develop better methods for assessing bacterial susceptibility to biocides.
8.3.2 Formulation effects of triclosan products
In many instances triclosan is incorporated into products that have other ingredients 
that are bactericidal or bring about cellular changes. Such ingredients include 
detergents, surfactants, chelators or alcohols, the inclusion of which depends on the 
product application. For example, the commercial triclosan preparation, Irgacide 
LP10, as used in this study, contains sodium lauryl sulphate, a surfactant with not 
inconsiderable antimicrobial activity (Jenkins et al., 1991; Babich & Babich, 1997). It 
is reasonable to assume that these ingredients will increase the antimicrobial activity 
of the product. They may also affect the development of resistance by placing 
additional stress on the bacteria and providing yet further targets for activity.
Additionally, these ingredients may affect the efficacy of the product by more indirect 
methods. For example surfactants aid the physical removal of dirt from soiled surfaces 
and the inclusion of moisturisers increase the frequency of use of handwash products.
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As mentioned above, the inclusion of additional ingredients in a triclosan product 
depends on the intended function. Triclosan has a broad spectrum of applications, 
from bar soap to toothpastes and from preoperative washes to chopping boards, 
therefore each formulation must be adapted to its particular function. This may cause 
the efficacy to vary significantly (Russell & McDonnell, 2000; Suller & Russell, 
2000). The nature of the application will also have an effect, for example bathing of 
hospital patients in 2% triclosan provides a highly controlled exposure to a high 
concentration of triclosan in combination with other ingredients, whereas inclusion of 
triclosan in polymers, such as chopping boards, will confer chronic, low-level 
exposure to triclosan. Clearly these will provide different opportunities for the 
development of resistance. So studies into the efficacy of triclosan should also 
consider both the direct and indirect effects of additives included in triclosan 
preparations and also the intended use of the formulation.
8.3.3 Slime problems: the effects of biofilm upon susceptibility
The vast majority of investigations that have linked triclosan exposure to resistance 
development have been conducted in planktonic pure culture (McBain et a l , 2003a), 
however natural communities of bacteria are often polymicrobial and biofilm-based. 
Biofilms can confer antimicrobial resistance, mainly by physically blocking the 
compound from coming into contact with cells; antimicrobial diffusion through 
biofilms can be limited so that only those cells close to the surface are exposed to 
lethal concentrations of antimicrobial (Stewart & Costerton, 2001; McBain et al., 
2003a). Other hypotheses for the mechanism of resistance in biofilms include the 
theory that some of the community differentiate into a protected phenotypic state and 
that in zones of nutrient depletion or waste accumulation antimicrobial action may be 
antagonised (Stewart & Costerton, 2001).
So the mechanisms of resistance in natural biofilms are different to those studied in 
the majority of laboratory experiments. However, some studies have looked at the 
effects of triclosan upon biofilms. Interestingly, these have failed to show the 
development of resistance in biofilms such as those found in the domestic drain and in 
dental plaque communities. Indeed, a study by Jones et a l, (2006) found that loading
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the retention balloons of urinary catheters with a triclosan solution (10 g/L) provided 
sufficient antibacterial activity to prevent catheter encrustation by Proteus mirabilis 
and biofilm formation by several other common pathogens of the catheterized urinary 
tract.
8.3.4 Small... but insignificant? Triclosan resistant SCVs in healthcare.
Another form that S. aureus cells may take is that of SCVs. We have shown that 
triclosan can induce the growth of SCVs with reduced susceptibility to triclosan, 
gentamicin and penicillin. They also displayed attenuated production of the 
extracellular proteins coagulase and DNase. SCV growth was significantly slower 
than wild-type. SCV Growth rate was significantly reduced and cultures demonstrated 
extended lag periods. This caused sizeable practical problems, especially when 
attempting experiments that required high cell densities or when assessing 
antimicrobial susceptibility. Practical problems were compounded by poor genetic 
stability of SCVs. Hence it was necessary to consistently apply a selective pressure 
for the maintenance of the SCV phenotype. These problems are associated with 
growth in vitro, however the full impact of SCVs can only be realised in vivo.
Several features of SCVs are pertinent only during infection of a host. These include 
intracellular survival and the impact of attenuated virulence factor production. We 
were able to demonstrate that SCVs had a reduced susceptibility to several 
antimicrobials. Subsequently, we are able to hypothesise that this could cause 
treatment problems if these colonial mutants initiated/arose during an infection. 
However, we do not know whether these SCVs can support intracellular growth and, 
if it is possible, what the impact of this would be upon antimicrobial susceptibility and 
virulence. Therefore further work, either performed in animal models or cell culture 
(principally macrophages) should be performed, such as that carried out on other 
SCVs by Bates et a l, (2003), Jonsson et a l, (2003) and Barcia-Macay et a l, (2006). 
Alternatively, advances made by Sifri et a l, (2006), who were able to assess the 
virulence of SCVs in a Caenorhabditis elegans model, could be used. These would 
help .to better understand the interaction between triclosan-induced SCVs and host 
cells -  a key feature of infections. It appears that there are several 
genetically/biochemically different SCV types, so it is reasonable to hypothesise that
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these may have different capacities to survive in cells. Hence, these models could also 
be used to distinguish between the SCV types and identify the potential clinical 
significance of each type.
A significant difference between triclosan and other antimicrobials known to select 
for SCVs is that it is only used topically. It is thought that it is not the SCV form that 
initiates an infection, rather, once a wild-type infection has been established 
antibiotic treatment selects for mutation to SCV form (section 1.6, Figure 1.11 ). The 
significance of this is that selection for SCVs by systemic antibiotics occurs once the 
bacterium has broached the skin and is at the site of infection, whereas triclosan- 
induced SCVs will presumably be on the skin surface. It is not known whether these 
would then be capable of initiating an infection. Data on the virulence of SCVs are 
unclear; characteristics of SCV phenotypes, such as attenuation of virulence factors, 
can seemingly reduce and increase the chance of pathogenesis. Vimlence factors aid 
the infection process but also increase the host’s immune response (Pelletier et al., 
1979; Jonsson et al., 2003; Moisan et al., 2006; Siffi et al., 2006).
It is an obvious step to assess the prevalence of SCVs in the environment, most likely 
starting with hospitals. This would provide evidence for or against the existence of 
triclosan-induced SCVs in real-life situations. However, such a study is not as 
straightforward as it may seem. Firstly, SCVs are difficult to isolate, identify and 
work with, so specialised techniques would need to be developed (especially to avoid 
confusion with CoNS). Secondly, it is desirable to distinguish triclosan-induced SCVs 
from others. How may this be achieved? Even SCVs isolated during the same 
experiment can often vary in their phenotypic (and presumably genotypic) 
characteristics and at present we known too little about the mechanisms behind SCVs 
needed to distinguish between types. This could be surmounted partially by using a 
randomized controlled trial in which the recovery of SCVs was compared between 
individuals who had undergone triclosan therapy and those who had not (an 
appropriate control should be used).
Since, as discussed above, triclosan-induced SCVs are assumed to be at the skin 
surface they may be transmissible by skin-skin contact, as wild-type S. aureus. This 
would leave them vulnerable to the current mechanisms of preventing transfer of
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infection, such as alcohol hand-washes and barrier systems such as gloves. The 
transfer of SCVs should be investigated, along with an assessment of the efficacy of 
procedures such as alcohol hand washes. It remains to be shown whether triclosan 
commercial triclosan formulations, as applied in the clinic, are capable of eliminating 
SCV carriage.
Although triclosan is generally applied topically it is also impregnated into polymers 
such as plastics or silicone for in-dwelling devices. This provides a unique 
environment that is possibly more worrying than selection of SCVs by topical 
preparations. For example, the use of triclosan-impregnated sutures (Rothenburger et 
al., 2002; Edmiston et al., 2004; Edmiston et al., 2006) will provide a selective 
pressure for SCV status in close proximity to a mode of entry into the body. The 
release of triclosan is less controlled so the opportunity that triclosan concentrations 
are closer to those that select for SCVs is greater. Furthermore, during this method of 
triclosan delivery the antimicrobial is not combined with surfactants or other 
ingredients found in topical formulations, hence triclosan will be acting without the 
synergistic effects of these chemicals. A recent paper has reported that silicone discs 
containing triclosan selected for SCVs of 3 MRSA strains (Bayston et al., 2007). 
Hence, there is clear potential for device-related triclosan-induced SCVs. Future work 
should be aimed at assessing the clinical impact of this phenomenon.
8.3.5 Requirement for clinical studies
At present most hypotheses surrounding triclosan resistance are based on the plethora 
of in vitro investigations. Whilst we can speculate on the impact of low-level 
resistance (Goldstein, 2007) clinical studies are required to assess the real-life impact 
of low-level triclosan resistance in staphylococci. Particular attention should be paid 
to assessing formulation effects, assessing the prevalence of resistance and examining 
the efficacy of triclosan treatments against reduced susceptibility organisms. Studies 
should also include CoNS and SCVs as these may represent a little studied reservoir 
of resistance. The effects of triclosan exposure on the development of resistance to 
other antimicrobials requires clarification, and this includes establishing the role of 
gene transfer.
225
8.4 Horizontal gene transfer of triclosan resistance in staphylococci
8.4.1 Transferable triclosan resistance: is their a relationship with mupirocin 
resistance?
An article published by Cookson et a l, (1991) implies that triclosan resistance was 
found on a plasmid alongside mupirocin resistance. This article has attracted much 
attention and is now cited by more than 40 papers that have published in major 
journals. This may have lead to it having become an accepted phenomenon. However, 
no further work has been published regarding the issue and in the light of more recent 
research these findings appear tenuous. We report in chapters 3, 4 and 5 that there is 
no correlation between resistance to triclosan and resistance to mupirocin in our strain 
collection or novel isolates. This has also been reported by Suller & Russell, (2000), 
Brenwald & Fraise, (2003) and Bamber & Neal, (1999). The combined breadth of 
these studies indicates that if triclosan resistance is transferable, in combination with 
mupirocin resistance, then it is a rare event. Indeed, we were unable to transfer low- 
level triclosan resistance amongst S. aureus, either singularly or in association with 
mupirocin resistance.
8.4.2 Gene transfer and the dissemination of low-level triclosan resistance
Our inability to transfer low-level triclosan resistance by three mechanisms of gene 
transfer implies that the evolution of triclosan resistance amongst in situ S. aureus is 
unlikely to be involved this process. These results are encouraging and provide further 
evidence that triclosan resistance is not transferable. Consequently, we hypothesise 
that the main routes for the spread of low-level triclosan resistance are clonal 
expansion and mutation. Indeed, S. aureus is highly clonal, an indication that 
mutation has proved important in the evolution of S. aureus, whereas recombination 
has had negligible impact on the diversification of the core genome of this species 
(Feil et al., 2003).
So the most likely mechanism for the spread of triclosan resistance is development of 
a triclosan-resistant mutation in a successful strain that is able to out compete others. 
This clone would then become dominant, a possibility that is supported by our
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evidence that triclosan resistance is not associated with a significant fitness cost 
(disregarding SCV-associated resistance). However, the lack of such a clone in reports 
to date indicates that this has not happened, even after 30 years of use. This is 
probably due to the high concentration and formulation effects of commercial 
triclosan products and the combinatorial use of other antimicrobials, such as CHX.
8.5 Effects of triclosan on gene transfer
Triclosan did not induce the transfer of resistance and generally caused a reduction in 
transfer frequencies. We found it to be active against bacteriophages, preventing gene 
transfer by transduction. Consequently, we hypothesise that exposure to triclosan does 
not increase the dissemination of resistance traits.
8.6 Gene transfer in SCVs
The discovery that triclosan-induced SCVs did not secrete extracellular DNase led us 
to hypothesise that they may be more amenable for gene transfer, especially by 
transformation. This hypothesis was supported by evidence that S. aureus SCVs were 
more easily transformable than wild-type. So the SCV phenotype appears to confer 
competence, in addition to reduced susceptibility and alterations to virulence and 
growth. Hence, we see that SCVs represent a complex and evolutionarily significant 
stage in S. aureus. Switching between SCV and wild-type phenotypes affords S. 
aureus an inducible and reversible resistance mechanism that circumvents a 
permanent cost to fitness (Massey et al., 2001) and also allows it to better exploit the 
genetic resources of the surrounding environment. If S. aureus is clonal then the SCV 
phenotype offers a process of gene exchange (in this subpopulation) allowing for a 
parasexual cycle to occur in environments where such organisms are normally 
genetically isolated by mechanisms such as conjugation and transduction.
It makes clear evolutionary sense for SCVs to show augmented gene exchange 
properties. They are under a strong environmental pressure from the antimicrobial and 
are restricted in their growth. However, increasing the ability to accept exogenous 
DNA boosts their chances or acquiring other mechanisms of resistance that would 
enable them to revert to wild-type and grow at the significantly faster rate associated
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with this phenotype. Furthermore, SCVs may represent a persistent reservoir of genes 
that is not adversely affected by antimicrobial treatment.
8.7 Conclusions
• The clinically dominant S. aureus capsule polysaccharide serotypes CP5 and 
CP8 do not represent a permeability barrier to antimicrobials, including 
triclosan.
• S. aureus can evolve reduced susceptibility to triclosan through spontaneous 
mutation. MICs of 1-4 mg/L are achieved by mutation of the fab l gene, which 
encodes an enzyme essential for type 2 bacterial fatty acid biosynthesis.
• However, reduced susceptibility has also been observed in non-Fabl mutants, 
implying that other mechanisms of resistance are available (and that triclosan 
has targets other than fabl).
• Furthermore, triclosan is shown to induce the leakage of potassium ions from 
cells, an indication of membrane damage. Hence, there is increasing evidence 
that whilst fabl is a target for triclosan, it is not the sole target.
• Reduced susceptibility to triclosan, as measured by MIC, also confers reduced
susceptibility to the lethal effects of 7.5 mg/L triclosan, but this effect is
ameliorated by higher concentrations of triclosan.
• In-use concentrations of the commercial preparation of triclosan, Irgacide
LP10, are equally active against reduced susceptibility S. aureus and wild-
type.
• Spontaneous mutation to triclosan resistance is not associated with a 
significant fitness cost.
• Evolution of triclosan resistance does not confer co-resistance to other
antimicrobials, including oxacillin, vancomycin, gentamicin, penicillin, CHX
or CPC.
• MRSA and MSSA strains are equally susceptible to triclosan.
• Reduced susceptibility to triclosan is rare amongst the commensal S. aureus
strains of the student population of Cardiff. However, CoNS showed 
consistently higher MICs for triclosan and may represent an amenable 
reservoir of resistance.
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• Familial transfer of MRSA can occur, causing the organism to persist in the 
community setting.
• There is no indication that mupirocin and triclosan resistance have co- 
transferred in the past. Indeed, there appears to be no relationship between 
resistance to either of these compounds in S. aureus.
• Reduced susceptibility to triclosan cannot be disseminated amongst wild-type
S. aureus, or related Gram-positive bacteria by transduction, conjugation or 
transformation.
• There is no bioinformatic evidence to support the historical acquisition offabl 
by horizontal gene transfer in S. aureus.
• Triclosan can select for S. aureus SCVs that are coincidently resistant to 
gentamicin and penicillin. These are slow growing and illustrate the typical 
SCV phenotype. When they revert they are as susceptible as their parent.
• The mechanism of resistance to triclosan in triclosan-induced SCVs has not 
been elucidated, however there are close links between fatty acid biosynthesis 
and cellular ATP production.
• Triclosan-induced SCVs show attenuated production of coagulase, 
haemolysins and DNase.
• Triclosan-induced SCVs show a higher level of competency than wild-type. 
Hence, they were more readily transformable and may represent an enduring 
reservoir of resistance determinants.
8.8 Epilogue
The significance of reduced susceptibility to triclosan in S. aureus is ambiguous. The 
development of resistance has clear repercussions for the efficacy of triclosan 
treatments, however low-level resistant strains remain susceptible to the in-use 
concentrations of triclosan, especially when these are delivered with other ingredients 
such as surfactants. It is also pertinent that most infection control strategies employ a 
selection of control measures, ensuring that efficacy is not reliant upon a single 
procedure.
229
The description of transferable triclosan resistance by Cookson et al., (1991) is a 
unique observation, and the uniqueness is confirmed by the fact that the widespread 
dissemination of triclosan resistance predicted by the authors has not occured. This 
may reflect the poor significance of low-level resistance in S. aureus in the presence 
of the combination of measures that constitute infection control strategies.
The use of triclosan in the home does not seem to have selected for increased 
resistance. However, it remains to be seen whether new antimicrobials directed 
towards bacterial fatty acid biosynthesis, such as platensimycin, will be undermined 
by the increasing use of triclosan-containing products.
Triclosan is highly efficacious against MRSA and forms an important part of current 
and future infection control procedures. However, it is imperative that research is 
continued to fully elucidate the role of triclosan in the formation of SCVs. The level 
of resistance within the environment should be monitored and careful control of the 
types of products that triclosan is incorporated in to is required to reduce the 
possibility of increased resistance.
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Chapter 9 
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9.1 fab l gene sequences
Codons corresponding to 1st amino acid of the Fabl protein and stop codon are 
highlighted in and r e d ,  respectively. Triclosan-resistant mutations are
highlighted in blue (affected codon is in bold).
>9518 fabl
TTAAAATGCAGACGTATTTTAGTACGACGTAAAATTAATGATTTTAAAATGCTAGTATGTATATGATTT 
T GAT AAAT AAAT G C T T T T T AC G T AAAT C AAGT T T GAT AC AGAAAGG AC T AAAT C AAAC AT T TAT C GT T G 
TAATACGTTTAAATAACTTTATTAAAAAGTCATAATAGTGTTAAAATGTATTGACGAATAAAAAGTTAG 
TTAAAACTGGGATTAGATATTCTATCCGTTAAATTAATTATTATAAGGAGTTATCTTACfPfTTAAATC 
TTGAAAACAAAACATATGTCATCATGGGAATCGCTAATAAGCGTAGTATTGCTTTTGGTGTCGCTAAAG 
TTTTAGATCAATTAGGTGCTAAATTAGTATTTACTTACCGTAAAGAACGTAGCCGTAAAGAGCTTGAAA 
AAT TAT T AGAAC AAT T AAAT C AACC AGAAGCGC ACT T AT AT CAAAT TGATGTT C AAAGCGATGAAGAGG 
TTATTAATGGTTTTGAGCAAATTGGTAAAGATGTTGGCAATATTGATGGTGTATATCATTCAATCGCAT 
TTGCTAATATGGAAGACTTACGCGGACGCTTTTCTGAAACTTCACGTGAAGGCTTCTTGTTAGCTCAAG 
AC AT T AGT T CT T AC T CAT T AAC AAT T GT GGC T CAT G AAGC T AAAAAAT T AAT GC C AGAAGGTGG T AGC A 
TTGTTGCAACAACATATTTAGGTGGCGAATTCGCAGTTCAAAATTATAATGTGATGGGTGTTGCTAAAG 
CGAGCTTAGAAGCAAATGTTAAATATTTAGCATTAGACTTAGGTCCTGATAATATTCGCGTTAATGCAA 
TTTCAGCTGGTCCAATCCGTACATTAAGTGCAAAAGGTGTGGGTGGTTTCAATACAATTCTTAAAGAAA 
TCGAAGAGCGTGCACCTTTAAAACGTAACGTTGATCAAGTAGAAGTAGGTAAAACAGCGGCTTACTTAT
t a a g t g a c t t a t c a a g t g g c g t t a c a g g t g a a a a t a t t c a t g t a g a t a g c g g a t t c c a c g c a a t t a a a |
O t a t c a t t c a a c a g c t t t g t t c a c g t t a t c a t a t a t g t g a g c a a a g c t t t t t t g c t t t t a t a a t a a t c
GGACTGATGGAAAATTATTTGATATTTCATCTGACTGATTTTTTTTATGCACAAAAAAATCTCCTCAAA
AGCTGTAGTTTCAAC
>9518T1 fabl
TTAAAATGCAGACGTATTTTAGTACGACGTAAAATTAATGATTTTAAAATGCTAGTATGTATATGATTT 
T GAT AAAT AAAT GC T T T T T ACG T AAAT C AAG T T T G AT AC AG AAAGGAC T AAAT CAAAC AT T TAT C GT T G 
TAATACGTTTAAATAACTTTATTAAAAAGTCATAATAGTGTTAAAATGTATTGACGAATAAAAAGTTAG 
TTAAAACTGGGATTAGATATTCTATCCGTTAAATTAATTATTATAAGGAGTTATCTTAC|®#TTAAATC 
TTGAAAACAAAACATATGTCATCATGGGAATCGCTAATAAGCGTAGTATTGCTTTTGGTGTCGCTAAAG 
TTTTAGATCAATTAGGTGCTAAATTAGTATTTACTTACCGTAAAGAACGTAGCCGTAAAGAGCTTGAAA 
AAT TAT TAG AAC AAT T AAAT C AAC C AG AAGC GCAC T TAT AT CAAAT T GAT G T T CAAAGC GAT GAAGAGG 
TT AT T AAT GGT T T T GAGCAAAT T GGT AAAGATGT T GGCAAT AT T GATGGT GT AT AT CAT TCAAT CG§AT 
TTGCTAATATGGAAGACTTACGCGGACGCTTTTCTGAAACTTCACGTGAAGGCTTCTTGTTAGCTCAAG 
ACATTAGTTCTTACTCATTAACAATTGTGGCTCATGAAGCTAAAAAATTAATGCCAGAAGGTGGTAGCA 
TTGTTGCAACAACATATTTAGGTGGCGAATTCGCAGTTCAAAATTATAATGTGATGGGTGTTGCTAAAG 
CGAGCTTAGAAGCAAATGTTAAATATTTAGCATTAGACTTAGGTCCTGATAATATTCGCGTTAATGCAA
241
TTTCAGCTGGTCCAATCCGTACATTAAGTGCAAAAGGTGTGGGTGGTTTCAATACAATTCTTAAAGAAA
TCGAAGAGCGTGCACCTTTAAAACGTAACGTTGATCAAGTAGAAGTAGGTAAAACAGCGGCTTACTTAT
t a a g t g a c t t a t c a a g t g g c g t t a c a g g t g a a a a t a t t c a t g t a g a t a g c g g a t t c c a c g c a a t t a a a |
^TATCATTCAACAGCTTTGTTCACGTTATCATATATGTGAGCAAAGCTTTTTTGCTTTTATAATAATC
GGACTGATGGAAAATTATTTGATATTTCATCTGACTGATTTTTTTTATGCACAAAAAAATCTCCTCAAA
AGCTGTAGTTTCAAC
>9518T2 fabl
T T AAAAT GC AG AC G TAT T T TAG T AC G AC G T AAAAT T AAT GAT T T T AAAAT GC T AGT AT GT AT AT GAT T T 
TGATAAATAAATGCTTTTTACGTAAATCAAGTTTGATACAGAAAGGACTAAATCAAACATTTATCGTTG
t a a t a c g t t t a a a t a a c t t J a t t a a a a a g t c a t a a t a g t g t t a a a a t g t a t t g a c g a a t a a a a a g t t a g
TTAAAACTGGGATTAGATATTCTATCCGTTAAATTAATTATTATAAGGAGTTATCTTACSf^TTAAATC 
TTGAAAACAAAACATATGTCATCATGGGAATCGCTAATAAGCGTAGTATTGCTTTTGGTGTCGCTAAAG 
TTTTAGATCAATTAGGTGCTAAATTAGTATTTACTTACCGTAAAGAACGTAGCCGTAAAGAGCTTGAAA 
AAT TAT TAG AAC AAT T AAAT C AAC C AG AAGC GC AC T TAT AT CAAAT T G AT GT T CAAAGC GAT GAAG AGG
t t a t t a a t g g t t t t g a g c a a a t t g g t a a a g a t g t t g g c a a t a t t g a t g g t g t a t a t c a t t c a a t c g | a t
TTGCTAATATGGAAGACTTACGCGGACGCTTTTCTGAAACTTCACGTGAAGGCTTCTTGTTAGCTCAAG
ACATTAGTTCTTACTCATTAACAATTGTGGCTCATGAAGCTAAAAAATTAATGCCAGAAGGTGGTAGCA
TTGTTGCAACAACATATTTAGGTGGCGAATTCGCAGTTCAAAATTATAATGTGATGGGTGTTGCTAAAG
CGAGCTTAGAAGCAAATGTTAAATATTTAGCATTAGACTTAGGTCCTGATAATATTCGCGTTAATGCAA
TTTCAGCTGGTCCAATCCGTACATTAAGTGCAAAAGGTGTGGGTGGTTTCAATACAATTCTTAAAGAAA
TCGAAGAGCGTGCACCTTTAAAACGTAACGTTGATCAAGTAGAAGTAGGTAAAACAGCGGCTTACTTAT
t a a g t g a c t t a t c a a g t g g c g t t a c a g g t g a a a a t a t t c a t g t a g a t a g c g g a t t c c a c g c a a t t a a a |
®TATCATTCAACAGCTTTGTTCACGTTATCATATATGTGAGCAAAGCTTTTTTGCTTTTATAATAATC
GGACTGATGGAAAATTATTTGATATTTCATCTGACTGATTTTTTTTATGCACAAAAAAATCTCCTCAAA
AGCTGTAGTTTCAAC
>9518T3 fabl
TTAAAATGCAGACGTATTTTAGTACGACGTAAAATTAATGATTTTAAAATGCTAGTATGTATATGATTT 
T GAT AAAT AAAT GC T T T T T ACG T AAAT C AAGT T T GAT AC AGAAAGG AC T AAAT CAAAC AT T TAT C G T T G
t a a t a c g t t t a a a t a a c t t | a t t a a a a a g t c a t a a t a g t g t t a a a a t g t a t t g a c g a a t a a a a a g t t a g
TTAAAACTGGGATTAGATATTCTATCCGTTAAATTAATTATTATAAGGAGTTATCTTAC®iiTTAAATC
TTGAAAACAAAACATATGTCATCATGGGAATCGCTAATAAGCGTAGTATTGCTTTTGGTGTCGCTAAAG
TTTTAGATCAATTAGGTGCTAAATTAGTATTTACTTACCGTAAAGAACGTAGCCGTAAAGAGCTTGAAA
AATTATTAGAACAATTAAATCAACCAGAAGCGCACTTATATCAAATTGATGTTCAAAGCGATGAAGAGG
t t a t t a a t g g t t t t g a g c a a a t t g g t a a a g a t g t t g g c a a t a t t g a t g g t g t a t a t c a t t c a a t c g | a t
TTGCTAATATGGAAGACTTACGCGGACGCTTTTCTGAAACTTCACGTGAAGGCTTCTTGTTAGCTCAAG
ACATTAGTTCTTACTCATTAACAATTGTGGCTCATGAAGCTAAAAAATTAATGCCAGAAGGTGGTAGCA
TTGTTGCAACAACATATTTAGGTGGCGAATTCGCAGTTCAAAATTATAATGTGATGGGTGTTGCTAAAG
CGAGCTTAGAAGCAAATGTTAAATATTTAGCATTAGACTTAGGTCCTGATAATATTCGCGTTAATGCAA
242
TTTCAGCTGGTCCAATCCGTACATTAAGTGCAAAAGGTGTGGGTGGTTTCAATACAATTCTTAAAGAAA
TCGAAGAGCGTGCACCTTTAAAACGTAACGTTGATCAAGTAGAAGTAGGTAAAACAGCGGCTTACTTAT
t a a g t g a c t t a t c a a g t g g c g t t a c a g g t g a a a a t a t t c a t g t a g a t a g c g g a t t c c a c g c a a t t a a a |
# | t a t c a t t c a a c a g c t t t g t t c a c g t t a t c a t a t a t g t g a g c a a a g c t t t t t t g c t t t t a t a a t a a t c
GGACTGATGGAAAATTATTTGATATTTCATCTGACTGATTTTTTTTATGCACAAAAAAATCTCCTCAAA
AGCTGTAGTTTCAAC
>9518T4 fabl
T T AAAAT GCAGACGT AT T T TAGT AC GACGT AAAAT T AAT GAT T T T AAAAT GCT AGT AT GT AT AT GAT T T 
T GAT AAAT AAAT GC T T T T T AC G T AAAT C AAGT T T GAT AC AGAAAGG AC T AAAT C AAAC AT T TAT C GT T G 
TAATACGTTTAAATAACTTTATTAAAAAGTCATAATAGTGTTAAAATGTATTGACGAATAAAAAGTTAG 
T T AAAAC T GGGAT T AGAT AT T CT AT CCGT T AAAT T AAT TAT T AT AAGGAGT T ATCT T AC|STGT T AAAT C 
TTGAAAACAAAACATATGTCATCATGGGAATCGCTAATAAGCGTAGTATTGCTTTTGGTGTCGCTAAAG 
TTTTAGATCAATTAGGTGCTAAATTAGTATTTACTTACCGTAAAGAACGTAGCCGTAAAGAGCTTGAAA 
AATTATTAGAACAATTAAATCAACCAGAAGCGCACTTATATCAAATTGATGTTCAAAGCGATGAAGAGG 
TTATTAATGGTTTTGAGCAAATTGGTAAAGATGTTGGCAATATTGATGGTGTATATCATTCAATCGCAT 
TTGCTAATATGGAAGACTTACGCGGACGCTTTTCTGAAACTTCACGTGAAGGCTTCTTGTTAGCTCAAG 
ACATTAGTTCTTACTCATTAACAATTGTGGCTCATGAAGCTAAAAAATTAATGCCAGAAGGTGGTAGCA 
TTGTTGCAACAACATATTTAGGTGGCGAATTCGCAGTTCAAAATTATAATGTGATGGGTGTTGCTAAAG 
CGAGCTTAGAAGCAAATGTTAAATATTTAGCATTAGACTTAGGTCCTGATAATATTCGCGTTAATGCAA 
TTTCAGCTGGTCCAATCCGTACATTAAGTGCAAAAGGTGTGGGTGGTTTCAATACAATTCTTAAAGAAA 
TCGAAGAGCGTGCACCTTTAAAACGTAACGTTGATCAAGTAGAAGTAGGTAAAACAGCGGCTTACTTAT
t a a g t g a c t t a t c a a g t g g c g t t a c a g g t g a a a a t a t t c a t g t a g a t a g c g g a t t c c a c g c a a t t a a a |
H t a t c a t t c a a c a g c t t t g t t c a c g t t a t c a t a t a t g t g a g c a a a g c t t t t t t g c t t t t a t a a t a a t c
GGACTGATGGAAAATTATTTGATATTTCATCTGACTGATTTTTTTTATGCACAAAAAAATCTCCTCAAA
AGCTGTGTTTCAAC
>27343 fabl
TTAAAATGCAGACGTATTTTAGTACGACGTAAAATTAATGATTTTAAAATGCTAGTATGTATATGATTT 
T GAT AAAT AAAT GC T T T T T AC GT AAAT C AAGT T T GAT AC AGAAAGG AC T AAAT CAAAC AT T TAT C G T T G 
TAATACGTTTAAATAACTTTATTAAAAAGTCATAATAGTGTTAAAATGTATTGACGAATAAAAAGTTAG 
TTAAAACTGGGATTAGATATTCTATCCGTTAAATTAATTATTATAAGGAGTTATCTTAC^ftgTTAAATC 
TTGAAAACAAAACATATGTCATCATGGGAATCGCTAATAAGCGTAGTATTGCTTTTGGTGTCGCTAAAG 
TTTTAGATCAATTAGGTGCTAAATTAGTATTTACTTACCGTAAAGAACGTAGCCGTAAAGAGCTTGAAA 
AATTATTAGAACAATTAAATCAACCAGAAGCGCACTTATATCAAATTGATGTTCAAAGCGATGAAGAGG 
TTATTAATGGTTTTGAGCAAATTGGTAAAGATGTTGGCAATATTGATGGTGTATATCATTCAATCGCAT 
TTGCTAATATGGAAGACTTACGCGGACGCTTTTCTGAAACTTCACGTGAAGGCTTCTTGTTAGCTCAAG 
AC AT TAG T T C T T AC T CAT T AAC AAT T G T GGC T CAT GAAGC T AAAAAAT T AAT GC C AGAAGGT GG T AGC A 
TTGTTGCAACAACATATTTAGGTGGCGAATTCGCAGTTCAAAATTATAATGTGATGGGTGTTGCTAAAG 
CGAGCTTAGAAGCAAATGTTAAATATTTAGCATTAGACTTAGGTCCTGATAATATTCGCGTTAATGCAA
243
TTTCAGCTGGTCCAATCCGTACATTAAGTGCAAAAGGTGTGGGTGGTTTCAATACAATTCTTAAAGAAA
TCGAAGAGCGTGCACCTTTAAAACGTAACGTTGATCAAGTAGAAGTAGGTAAAACAGCGGCTTACTTAT
t a a g t g a c t t a t c a a g t g g c g t t a c a g g t g a a a a t a t t c a t g t a g a t a g c g g a t t c c a c g c a a t t a a a |
®TATCATTCAACAGCTTTGTTCACGTTATCATATATGTGAGCAAAGCTTTTTTGCTTTTATAATAATC
GGACTGATGGAAAATTATTTGATATTTCATCTGACTGATTTTTTTTATGCACAAAAAAATCTCCTCAAA
AGCTGTGTTTCAAC
>27343T1 fab l
T T AAAAT GC AG AC GT AT T T TAG T AC GACGT AAAAT T AAT GAT T T T AAAAT GC TAG TAT GT AT AT GAT T T 
T GAT AAAT AAAT GC T T T T T AC G T AAAT C AAGT T T GAT AC AGAAAGG AC T AAAT C AAAC AT T T AT CGT T G 
TAATACGTTTAAATAACTTTATTAAAAAGTCATAATAGTGTTAAAATGTATTGACGAATAAAAAGTTAG 
TTAAAACTGGGATTAGATATTCTATCCGTTAAATTAATTATTATAAGGAGTTATCTTAC$£$TTAAATC 
TTGAAAACAAAACATATGTCATCATGGGAATCGCTAATAAGCGTAGTATTGCTTTTGGTGTCGCTAAAG 
TTTTAGATCAATTAGGTGCTAAATTAGTATTTACTTACCGTAAAGAACGTAGCCGTAAAGAGCTTGAAA 
AATTATTAGAACAATTAAATCAACCAGAAGCGCACTTATATCAAATTGATGTTCAAAGCGATGAAGAGG 
TTATTAATGGTTTTGAGCAAATTGGTAAAGATGTTGGCAATATTGATGGTGTATATCATTCAATCG§AT 
TTGCTAATATGGAAGACTTACGCGGACGCTTTTCTGAAACTTCACGTGAAGGCTTCTTGTTAGCTCAAG 
ACATTAGTTCTTACTCATTAACAATTGTGGCTCATGAAGCTAAAAAATTAATGCCAGAAGGTGGTAGCA 
TTGTTGCAACAACATATTTAGGTGGCGAATTCGCAGTTCAAAATTATAATGTGATGGGTGTTGCTAAAG 
CGAGCTTAGAAGCAAATGTTAAATATTTAGCATTAGACTTAGGTCCTGATAATATTCGCGTTAATGCAA 
TTTCAGCTGGTCCAATCCGTACATTAAGTGCAAAAGGTGTGGGTGGTTTCAATACAATTCTTAAAGAAA 
TCGAAGAGCGTGCACCTTTAAAACGTAACGTTGATCAAGTAGAAGTAGGTAAAACAGCGGCTTACTTAT
t a a g t g a c t t a t c a a g t g g c g t t a c a g g t g a a a a t a t t c a t g t a g a t a g c g g a t t c c a c g c a a t t a a a |
B | t a t c a t t c a a c a g c t t t g t t c a c g t t a t c a t a t a t g t g a g c a a a g c t t t t t t g c t t t t a t a a t a a t c
GGACTGATGGAAAATTATTTGATATTTCATCTGACTGATTTTTTTTATGCACAAAAAAATCTCCTCAAA
AGCTGTAGTTTCAAC
>24500fabl
TTAAAATGCAGACGTATTTTAGTACGACGTAAAATTAATGATTTTAAAATGCTAGTATGTATATGATTT 
T GAT AAAT AAAT GC T T T T T ACG T AAAT C AAG T T T G AT AC AGAAAGGAC T AAAT C AAAC AT T T AT CG T T G 
T AAT ACGT T T AAAT AAC T T TAT T AAAAAGTC AT AAT AGT GT T AAAAT GT AT T GACGAAT AAAAAGT T AG 
TTAAAACTGGGATTAGATATTCTATCCGTTAAATTAATTATTATAAGGAGTTATCTTAC&f^TTAAATC 
TTGAAAACAAAACATATGTCATCATGGGAATCGCTAATAAGCGTAGTATTGCTTTTGGTGTCGCTAAAG 
TTTTAGATCAATTAGGTGCTAAATTAGTATTTACTTACCGTAAAGAACGTAGCCGTAAAGAGCTTGAAA 
AAT TAT TAG AAC AAT T AAAT C AAC C AGAAGC GC AC T TAT AT CAAAT T GAT GT T C AAAGC GAT G AAGAGG 
TTATTAATGGTTTTGAGCAAATTGGTAAAGATGTTGGCAATATTGATGGTGTATATCATTCAATCGCAT 
TTGCTAATATGGAAGACTTACGCGGACGCTTTTCTGAAACTTCACGTGAAGGCTTCTTGTTAGCTCAAG 
ACATTAGTTCTTACTCATTAACAATTGTGGCTCATGAAGCTAAAAAATTAATGCCAGAAGGTGGTAGCA 
TTGTTGCAACAACATATTTAGGTGGCGAATTCGCAGTTCAAAATTATAATGTGATGGGTGTTGCTAAAG 
CGAGCTTAGAAGCAAATGTTAAATATTTAGCATTAGACTTAGGTCCTGATAATATTCGCGTTAATGCAA
244
TTTCAGCTGGTCCAATCCGTACATTAAGTGCAAAAGGTGTGGGTGGTTTCAATACAATTCTTAAAGAAA
TCGAAGAGCGTGCACCTTTAAAACGTAACGTTGATCAAGTAGAAGTAGGTAAAACAGCGGCTTACTTAT
t a a g t g a c t t a t c a a g t g g c g t t a c a g g t g a a a a t a t t c a t g t a g a t a g c g g a t t c c a c g c a a t t a a a |
® 4 t a t c a t t c a a c a g c t t t g t t c a c g t t a t c a t a t a t g t g a g c a a a g c t t t t t t g c t t t t a t a a t a a t c
GGACTGATGGAAAATTATTTGATATTTCATCTGACTGATTTTTTTTATGCACAAAAAAATCTCCTCAAA
AGCTGTAGTTTCAAC
>24500T1 fabl
TTAAAATGCAGACGTATTTTAGTACGACGTAAAATTAATGATTTTAAAATGCTAGTATGTATATGATTT 
TGATAAATAAATGCTTTTTACGTAAATCAAGTTTGATACAGAAAGGACTAAATCAAACATTTATCGTTG 
T AAT AC GT T T AAAT AAC T T TAT T AAAAAGT C AT AAT AG T GT T AAAAT G TAT T G AC GAAT AAAAAGT TAG
t t a a a a c t g g g a t t a g a t a t t c t a t c c g t t a a a t t a a t t a t t a t a a g g a g t t a t c t t a c ( H | t t a a a t c
TTGAAAACAAAACATATGTCATCATGGGAATCGCTAATAAGCGTAGTATTGCTTTTGGTGTCGCTAAAG 
TTTTAGATCAATTAGGTGCTAAATTAGTATTTACTTACCGTAAAGAACGTAGCCGTAAAGAGCTTGAAA 
AAT TAT T AGAACAAT T AAAT CAACCAGAAGCGC AC T TAT AT CAAAT T GAT GT T CAAAGCGAT GAAGAGG
t t a t t a a t g g t t t t g a g c a a a t t g g t a a a g a t g t t g g c a a t a t t g a t g g t g t a t a t c a t t c a a t c g | a t
TTGCTAATATGGAAGACTTACGCGGACGCTTTTCTGAAACTTCACGTGAAGGCTTCTTGTTAGCTCAAG
ACATTAGTTCTTACTCATTAACAATTGTGGCTCATGAAGCTAAAAAATTAATGCCAGAAGGTGGTAGCA
TTGTTGCAACAACATATTTAGGTGGCGAATTCGCAGTTCAAAATTATAATGTGATGGGTGTTGCTAAAG
CGAGCTTAGAAGCAAATGTTAAATATTTAGCATTAGACTTAGGTCCTGATAATATTCGCGTTAATGCAA
TTTCAGCTGGTCCAATCCGTACATTAAGTGCAAAAGGTGTGGGTGGTTTCAATACAATTCTTAAAGAAA
TCGAAGAGCGTGCACCTTTAAAACGTAACGTTGATCAAGTAGAAGTAGGTAAAACAGCGGCTTACTTAT
t a a g t g a c t t a t c a a g t g g c g t t a c a g g t g a a a a t a t t c a t g t a g a t a g c g g a t t c c a c g c a a t t a a a |
IjjTATCATTCAACAGCTTTGTTCACGTTATCATATATGTGAGCAAAGCTTTTTTGCTTTTATAATAATC 
G GAC T GAT G GAAAAT TAT T T GATAT T T CAT C T GAC T
>F89 fabl
TTAAAATGCAGACGTATTTTAGTACGACGTAAAATTAATGATTTTAAAATGCTAGTATGTATATGATTT
TGATAAATAAATGCTTTTTACGTAAATCAAGTTTGATACAGAAAGGACTAAATCAAACATTTATCGTTG
TAATACGTTTAAATAACTTTATTAAAAAGTCATAATAGTGTTAAAATGTATTGACGAATAAAAAGTTAG
TTAAAACTGGGATTAGATATTCTATCCGTTAAATTAATTATTATAAGGAGTTATCTTAC(S^|TTAAATC
TTGAAAACAAAACATATGTCATCATGGGAATCGCTAATAAGCGTAGTATTGCTTTTGGTGTCGCTAAAG
TTTTAGATCAATTAGGTGCTAAATTAGTATTTACTTACCGTAAAGAACGTAGCCGTAAAGAGCTTGAAA
AATTATTAGAACAATTAAATCAACCAGAAGCGCACTTATATCAAATTGATGTTCAAAGCGATGAAGAGG
TTATTAATGGTTTTGAGCAAATTGGTAAAGATGTTGGCAATATTGATGGTGTATATCATTCAATCGCAT
TTGCTAATATGGAAGACTTACGCGGACGCTTTTCTGAAACTTCACGTGAAGGCTTCTTGTTAGCTCAAG
ACATTAGTTCTTACTCATTAACAATTGTGGCTCATGAAGCTAAAAAATTAATGCCAGAAGGTGGTAGCA
TTGTTGCAACAACATATTTAGGTGGCGAATTCGCAGTTCAAAACTATAATGTGATGGGTGTTGCTAAAG
CGAGCTTAGAAGCAAATGTTAAATATTTAGCATTAGACTTAGGTCCAGATAATATTCGCGTTAATGCAA
TTTCAGCTGGTCCAATCCGTACATTAAGTGCAAAAGGTGTGGGTGGTTTCAATACAATTCTTAAAGAAA
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TCGAAGAGCGTGCACCTTTAAAACGTAATGTTGATCAAGTAGAAGTAGGTAAAACTGCGGCTTACTTAT
t a a g t g a t t t a t c a a g t g g c g t t a c a g g t g a a a a t a t t c a t g t a g a t a g c g g a t t c c a c g c a a t t a a a |
lifTATCATTCAACAGCTTTGTTCACGTTATTATATATGTGAGCAAAGCTTTTTTGCTTTTATAATAATC
GGACTGATGGAAAATTATTTGATATTTCATTTGACTGATTTTTTAT
>F89T1 fab l
T T AAAAT GC AGAC GT AT T T TAG T AC G AC GT AAAAT T AAT GAT T T T AAAAT GC TAG T AT GT AT AT GAT T T 
T GAT AAAT AAAT GC T T T T T AC GT AAAT C AAGT T T GAT AC AGAAAGG AC T AAAT C AAAC AT T T AT CGT T G 
T AAT ACGT T T AAAT AAC T T TAT T AAAAAGT CAT AAT AGTGT T AAAAT GT AT T GACGAAT AAAAAGT TAG 
TTAAAACTGGGATTAGATATTCTATCCGTTAAATTAATTATTATAAGGAGTTATCTTACjdTTAAATC 
TTGAAAACAAAACATATGTCATCATGGGAATCGCTAATAAGCGTAGTATTGCTTTTGGTGTCGCTAAAG 
TTTTAGATCAATTAGGTGCTAAATTAGTATTTACTTACCGTAAAGAACGTAGCCGTAAAGAGCTTGAAA 
AAT TAT T AGAAC AAT T AAAT C AAC C AGAAGC GC AC T TAT AT CAAAT T GAT GT T CAAAGCGAT GAAGAGG 
TTATTAATGGTTTTGAGCAAATTGGTAAAGATGTTGGCAATATTGATGGTGTATATCATTCAATCGfAT 
TTGCTAATATGGAAGACTTACGCGGACGCTTTTCTGAAACTTCACGTGAAGGCTTCTTGTTAGCTCAAG 
ACATTAGTTCTTACTCATTAACAATTGTGGCTCATGAAGCTAAAAAATTAATGCCAGAAGGTGGTAGCA 
TTGTTGCAACAACATATTTAGGTGGCGAATTCGCAGTTCAAAACTATAATGTGATGGGTGTTGCTAAAG 
CGAGCTTAGAAGCAAATGTTAAATATTTAGCATTAGACTTAGGTCCAGATAATATTCGCGTTAATGCAA 
TTTCAGCTGGTCCAATCCGTACATTAAGTGCAAAAGGTGTGGGTGGTTTCAATACAATTCTTAAAGAAA 
TCGAAGAGCGTGCACCTTTAAAACGTAATGTTGATCAAGTAGAAGTAGGTAAAACTGCGGCTTACTTAT
t a a g t g a t t t a t c a a g t g g c g t t a c a g g t g a a a a t a t t c a t g t a g a t a g c g g a t t c c a c g c a a t t a a a |
U t a t c a t t c a a c a g c t t t g t t c a c g t t a t t a t a t a t g t g a g c a a a g c t t t t t t g c t t t t a t a a t a a t c
GGACT GAT GGAAAAT TAT T T GAT AT T T CAT T T GACT GAT T TT T TAT
Corresponding amino acid sequences for S. aureus strains. Triclosan-resistant 
substitutions are highlighted in blue.
>9518 Fabl
MLNLENKTYVIMGIANKRSIAFGVAKVLDQLGAKLVFTYRKERSRKELEKLLEQLNQPEAHLYQIDVQS
DEEVINGFEQIGKDVGNIDGVYHSIAFANM EDLRGRFSETSREGFLLAQDISSYSLTIVAHEAKKLM PE
GGSIVATTYLGGEFAVQNYNVMGVAKASLEANVKYLALDLGPDNIRVNAISAGPIRTLSAKGVGGFNTI
LKEIEERAPLKRNVDQVEVGKTAAYLLSDLSSGVTGENIHVDSGFHAIK*
>T1 Fabl
MLNLENKTYVIMGIANKRSIAFGVAKVLDQLGAKLVFTYRKERSRKELEKLLEQLNQPEAHLYQIDVQS
d e e v i n g f e q i g k d v g n i d g v y h s i | f a n m e d l r g r f s e t s r e g f l l a q d i s s y s l t i v a h e a k k l m p e
GGSIVATTYLGGEFAVQNYNVMGVAKASLEANVKYLALDLGPDNIRVNAISAGPIRTLSAKGVGGFNTI
LKEIEERAPLKRNVDQVEVGKTAAYLLSDLSSGVTGENIHVDSGFHAIK*
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>T 2
MLNLENKTYVIMGIANKRSIAFGVAKVLDQLGAKLVFTYRKERSRKELEKLLEQLNQPEAHLYQIDVQS
d e e v i n g f e q i g k d v g n i d g v y h s i | f a n m e d l r g r f s e t s r e g f l l a q d i s s y s l t i v a h e a k k l m p e
GGSIVATTYLGGEFAVQNYNVMGVAKASLEANVKYLALDLGPDNIRVNAISAGPIRTLSAKGVGGFNTI 
LKEIEERAPLKRNVDQVEVGKTAAYLLS DLSSGVTGENIHVDSGFHAIK*
>T3 Fabl
M LNLENKTYVIMGIANKRSIAFGVAKVLDQLGAKLVFTYRKERSRKELEKLLEQLNQPEAHLYQIDVQS
d e e v i n g f e q i g k d v g n i d g v y h s i | f a n m e d l r g r f s e t s r e g f l l a q d i s s y s l t i v a h e a k k l m p e
GGSIVATTYLGGEFAVQNYNVMGVAKASLEANVKYLALDLGPDNIRVNAISAGPIRTLSAKGVGGFNTI
LKEIEERAPLKRNVDQVEVGKTAAYLLSDLSSGVTGENIHVDSGFHAIK*
>T4 Fabl
MLNLENKTYVIMGIANKRSIAFGVAKVLDQLGAKLVFTYRKERSRKELEKLLEQLNQPEAHLYQIDVQS
D EEVINGFEQIGKDVGNIDGVYHSIAFANM EDLRGRFSETSREGFLLAQDISSYSLTIVAHEAKKLM PE
GGSIVATTYLGGEFAVQNYNVMGVAKASLEANVKYLALDLGPDNIRVNAISAGPIRTLSAKGVGGFNTI
LKEIEERAPLKRNVDQVEVGKTAAYLLSDLSSGVTGENIHVDSGFHAIK*
>27343 Fabl
MLNLENKTYVIMGIANKRSIAFGVAKVLDQLGAKLVFTYRKERSRKELEKLLEQLNQPEAHLYQIDVQS
DEEVINGFEQIGKDVGNIDGVYHSIAFANM EDLRGRFSETSREGFLLAQDISSYSLTIVAHEAKKLM PE
GGSIVATTYLGGEFAVQNYNVMGVAKASLEANVKYLALDLGPDNIRVNAISAGPIRTLSAKGVGGFNTI
LKEIEERAPLKRNVDQVEVGKTAAYLLSDLSSGVTGENIHVDSGFHAIK*
>27343T1 Fabl
MLNLENKTYVIMGIANKRSIAFGVAKVLDQLGAKLVFTYRKERSRKELEKLLEQLNQPEAHLYQIDVQS
d e e v i n g f e q i g k d v g n i d g v y h s i | f a n m e d l r g r f s e t s r e g f l l a q d i s s y s l t i v a h e a k k l m p e
GGSIVATT YLGGE FAVQNYNVMGVAKAS LEANVKYLALDLGPDNIRVNAISAGPIRTLS AKGVGGFNTI 
LKE I  EERAPLKRNVDQVEVGKTAAYLLS DLS SGVTGENI HVDSGFHAI K*
>24500 Fabl
MLNLENKTYVIMGIANKRSIAFGVAKVLDQLGAKLVFTYRKERSRKELEKLLEQLNQPEAHLYQIDVQS
DEEVINGFEQIGKDVGNIDGVYHSIAFANM EDLRGRFSETSREGFLLAQDISSYSLTIVAHEAKKLM PE
GGSIVATTYLGGEFAVQNYNVMGVAKASLEANVKYLALDLGPDNIRVNAISAGPIRTLSAKGVGGFNTI
LKEIEERAPLKRNVDQVEVGKTAAYLLSDLSSGVTGENIHVDSGFHAIK*
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>24500T1 Fabl
MLNLENKTYVIMGIANKRSIAFGVAKVLDQLGAKLVFTYRKERSRKELEKLLEQLNQPEAHLYQIDVQS
d e e v i n g f e q i g k d v g n i d g v y h s i | f a n m e d l r g r f s e t s r e g f l l a q d i s s y s l t i v a h e a k k l m p e
GGSIVATTYLGGEFAVQNYNVMGVAKASLEANVKYLALDLGPDNIRVNAISAGPIRTLSAKGVGGFNTI
LKEIEERAPLKRNVDQVEVGKTAAYLLSDLSSGVTGENIHVDSGFHAIK*
>F89 Fabl
M LNLENKTYVIMGIANKRSIAFGVAKVLDQLGAKLVFTYRKERSRKELEKLLEQLNQPEAHLYQIDVQS 
D EEV ING FEQIG K DV GNIDGVYHSIAFANM EDLRGRFSETSREGFLLAQDISSYSLTIVAHEAKKLM PE 
G GSIVATT YLGGEFAVQNYNVMGVAKASLEANVKYLALDLGPDNIRVNAISAGPIRTLSAKGVGGFNTI 
LKEIEERAPLKRNVDQVEVGKTAAYLLSDLSSGVTGENIHVDSGFHAIK*
>F89T1 Fabl
MLNLENKTYVIMGIANKRSIAFGVAKVLDQLGAKLVFTYRKERSRKELEKLLEQLNQPEAHLYQIDVQS
d e e v i n g f e q i g k d v g n i d g v y h s i | f a n m e d l r g r f s e t s r e g f l l a q d i s s y s l t i v a h e a k k l m p e
GGS IVATTYLGGEFAVQNYNVMGVAKASLEANVKYLALDLGPDNIRVNAI SA G PI RTLSAKGVGGFNT I  
LKE I  EERAPLKRNVDQVEVGKTAAYLLS DLS SGVTGEN IHV D SGFH AIK *
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9.2 Reply to Bayston et al. published in the Journal of Antimicrobial 
Chemotherapy (Seaman et al. 2007, J  Antimicrob Chemother 60:175-176)
Comment on: Triclosan resistance in methicillin-resistant Staphylococcus aureus 
expressed as small colony variants: a novel mode of evasion of susceptibility to 
antiseptics
Sir,
In their recent article, Bayston et al} provide an interesting report on the occurrence 
of small colony variants (SCV) of Staphylococcus aureus during exposure to silicone 
impregnated with triclosan. In parallel with our prior report2 Bayston et al. describe 
the isolation of SC Vs with low-level resistance to triclosan, reduced coagulase 
production, reduced haemolytic activity and did not detect auxotrophy. They 
recognise, as others have done, the possible clinical importance of SC Vs and the 
potential role of triclosan in their generation. However we would like to urge some 
caution in their interpretation of their data and consequently on the significance of the 
issues raised.
A significant difference between triclosan and other antimicrobials known to select 
for SC Vs (principally aminoglycosides) is that it is used topically. It is thought that 
SC Vs are unlikely to initiate infections, rather, once a wild-type infection has been 
established, antibiotic treatment selects for mutation to give the SCV phenotype/form. 
Hence, selection for SC Vs by systemic antibiotics occurs once the bacteria have 
broached the skin and are at the site of infection, whereas triclosan-induced SC Vs will 
presumably be on the skin surface. So an important question is whether these SC Vs 
would then be capable of ever initiating an infection in healthy individuals.
Extending this logic means the triclosan-induced SCVs formed at the skin surface 
may be transmissible by skin-skin contact, as wild-type S. aureus. This could provide 
a mechanism for them coming into contact with wounds or finding other routes 
through the epidermis. However, it would also leave them vulnerable to the current 
mechanisms of preventing transfer of infection, such as alcohol hand-washes and 
barrier systems such as gloves.
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The association of SCVs with triclosan-impregnated polymers is possibly more 
worrying than selection of SCVs by topical preparations. For example, the use of 
triclosan-impregnated sutures3,4 will provide a selective pressure for SCV status in 
close proximity to a site of entry into the body, and the release of triclosan is less 
controlled, so the opportunity that triclosan concentrations are closer to those that 
select for SCVs is greater. Furthermore, during this method of triclosan delivery the 
antimicrobial is not combined with surfactants or other ingredients found in topical 
formulations, hence triclosan will be acting without the synergistic effects of these 
chemicals.5 It has also been reported that surface-bound SCVs were highly resistant to 
the bactericidal action of oxacillin or vancomycin6, consequently it would be 
interesting to know the susceptibility of these SCVs whilst adhered to the silicone 
discs. However, in contrast to the authors’ comment, we believe that the use of 
materials impregnated with triclosan is not as widely established as some authors 
report. Triclosan is not used as a typical product protectant in plastic articles. Indeed, 
its use in plastic is limited to special articles that represent a niche market. Thus the 
frequency and impact of these events is likely to be very low.
We found previously that the selection of SCVs by triclosan was concentration 
dependent.2 It would be very interesting to know what the triclosan concentration in 
the discs was and at what rate it was released. This is also key to any speculation on 
their clinical impact.
Due to the abnormal characteristics of S. aureus SCVs they are easily confused with 
coagulase negative staphylococci7 and potentially with various other slow growing 
bacterial genera. Additionally, they require extended incubation times and their slow 
growth rate leaves them liable to be ‘overgrown’ by faster growing organisms. For 
these reasons we feel it is necessary to unambiguously confirm that putative SCVs are 
indeed S. aureus and not contaminants. We have found nucleic acid-based methods 
useful for this.
Bayston et al. state that triclosan acts by inhibiting Fabl, an enzyme that executes the 
final step in the elongation cycle o f bacterial fatty acid biosynthesis. It should be noted 
that whilst Fabl is undoubtedly a target for low-levels of triclosan, the antimicrobial
o
also has other targets, such as the cytoplasmic membrane. Thus we feel it would have
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been appropriate to have investigated the possibility that the triclosan resistance found 
in their SCVs was as a result of this phenotype and not through coincidental 
alterations to Fabl or other targets.
Finally, we were concerned to see that the title of the article states that SCVs are ‘a 
novel mode of evasion of susceptibility to antiseptics’, however their results report 
only on susceptibility to triclosan. As the paper presents no evidence that SCVs 
demonstrate resistance to other antiseptics the title of the article is misleading. It 
clearly implies that SCV status, obtained as a result of triclosan exposure, confers 
resistance to multiple antiseptics when there is no evidence to support this hypothesis.
The role of S. aureus SCVs in morbidity and mortality is coming under increasing 
scrutiny. Whilst we welcome all research that aids our understanding of these curious 
infections, there is a danger that too much speculation on the clinical impact of SCVs 
based only on in vitro findings could restrict the use of an antimicrobial that has to 
date performed well during infection management situations. We would also 
recommend that studies unambiguously confirm that putative SCVs are indeed S. 
aureus and investigate alternative mechanisms of resistance in addition to making the 
association with the SCV phenotype.
Transparency declarations
PFS and MJD have nothing to declare. DO is an employee of Ciba 
Spezialitatenchemie Grenzach GmbH, Grenzach-Wyhlen, Germany.
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